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Summary 
Bevacizumab is a complete full-length humanized antibody that binds to all subtypes of 
vascular endothelial growth factor (VEGF) and is used successfully in tumor therapy as a systemic 
drug. Recent studies have demonstrated the usefulness of an intravitreal injection of bevacizumab 
(IVB) in the reduction of macular edema secondary to central retinal vein occlusion, 
and choroidal neovascularization secondary to age-related macular degeneration (AMD). The drug 
is extremely cost-effective compared to similar anti-VEGF drugs on the market, hence the need to 
examine its effect in diabetic eye disease (the ever-growing global health epidemic challenge) for 
application in middle to low income countries.  
The purpose of the current research is to determine if intravitreal bevacizumab (IVB) as anti-VEGF is 
helpful in the management of complications of diabetic retinopathy. We conducted several multicenter 
retrospective studies of eyes with complications from diabetic retinopathy treated with off-label IVB. 
Ten previously published studies (one prospective), and one unpublished prospective study are included 
here on the management of diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). 
We progressively reported over the years our experienced as we followed patients with DME treated 
with IVB at 6 months, 12 months, and 24 months of follow up. In addition, 5 year follow up data was 
added later on. We found that primary IVB at doses of 1.25 to 2.5 mg seem to provide stability or 
improvement in best correct visual acuity (BCVA), optical coherence tomography (OCT), and 
fluorescein angiography (FA) in diffuse DME at 24 months. The results show no evident difference 
between IVB at doses of 1.25 or 2.5 mg. However, the early visual gains due to IVB were not maintained 
5 years after treatment. Later, we provide evidence to support the use of primary IVB with or without 
grid laser photocoagulation (GLP) as treatment of diffuse DME. Primary IVB without GLP seems to be 
superior to GLP alone to provide stability or improvement in best-corrected visual acuity in patients 
with diffuse diabetic macular edema at 24 months. We showed first that IVB resulted in marked 
regression of retinal neovascularization (RN) in patients with PDR and previous pan retinal 
photocoagulation (PRP), and rapid resolution of vitreous hemorrhage in three naive eyes. Six-months 
results of intravitreal bevacizumab at doses of 1.25 or 2.5 mg in patients with PDR did not reveal any 
safety concerns. Later, we published that IVB resulted in marked regression of RN in patients with PDR 
and previous pan-retinal photocoagulation at 2 years. Intravitreal bevacizumab in naive eyes resulted in 
control or regression of 42.1% of eyes without adjunctive laser or vitrectomy during 24 months of 
follow-up. Meaning that a large number of patients (almost 58%) needed PRP or vitrectomy. Another 
one of our studies demonstrated the usefulness of using preoperative IVB during small-gauge 
vitreoretinal surgery in eyes with tractional retinal detachment (TRD) in PDR. This was a prospective 
non-comparative study and patients had significant anatomic and functional success. In addition, we 
reported for the first time ever that TRD may occur or progress shortly following administration of IVB 
in patients with severe PDR (5.2% and 3.2% in two studies). Based on our data, we now believe that 
extreme care must be taken in using a dose of 2.5 mg or more of bevacizumab in patients with PDR. In 




addition, to have more than 15 years with a diagnosis of diabetes can increase the risk of TRD. 
Physicians must be prepared to perform the vitrectomy preferably before 13 days after the application 
of IVB and to perform a vitrectomy immediately on those patients in whom a TRD occurs. We 
recommend less than 5 days after injection as more than 80% of the retinal detachments developed after 
that period of time. Finally, in our prospective randomized clinical trial, pre-operative intravitreal 
bevacizumab therapy as adjuvant to PPV may be helpful and beneficial for patients with TRD secondary 
to severe PDR. Pre-operative IVB seems to reduce intraoperative bleeding, improving surgical visual 
field visualization, and reducing intraoperative and postoperative complications including iatrogenic 
retinal breaks and postoperative hemorrhage. In summary, IVB as anti-VEGF agent is helpful in the 








Opsomming (Summary in Afrikaans)  
 
Bevacizumab is ‘n vaskulêre endoteel groei faktor inhibitor. Dit is primêr geregistreer vir die binne-
aarse gebruik as chemoterapeutiese middel vir verskeie kankers. Onlangs het die ongeregistreerde 
gebruik van die middel vir ouderdomsverwante makulêre degenerasie populêr geword.  Die middel 
is baie koste-effektief vergeleke met soortgelyke anti-vaskulêre endoteel groei faktor inhibitore 
(anti-VEGF) op die mark. Dit het dus nodig geword om die effek van die middel op diabetiese 
oogsiekte, wat ‘n immers toenemende globale gesondheids uitdaging word, te bepaal. Veral middel 
tot lae inkomste lande sal hierby baat. 
Die doel van die huidige navorsing is om te bepaal of intravitreale bevacizumab (IVB) as anti-VEGF 
behulpsaam is in die hantering van komplikasies van diabetiese retinopatie. Ons het verskeie 
multisenter retrospektiewe studies uitgevoer op oë met komplikasies van diabetiese retinopatie wat 
behandel was met IVB.  Tien voorheen publiseerde studies (een prospektief) en een ongepubliseerde 
studie oor die hantering van diabetiese makulêre edeem (DME) en proliferatiewe diabetiese 
retinopatie (PDR) word hier ingesluit.  Soos ons die IVB behandelde pasiente met DME opgevolg 
het oor 6, 12, 24 maande en later 5 jaar het ons progressief ons ervaring publiseer.  Ons het gevind 
dat IVB in dosisse van 1.25 tot 2.5mg stabiliteit of verbetering gebring het in die bes gekorrigeerde 
visie, optiese koherensie tomografie en fluoresien angiografie teen die 24 maande merk. Die 
resultate het geen merkbare verskil getoon tussen die 1.25 en 2.5mg dosisse nie, maar die vroeë 
verbetering in visie kon nie volgehou word oor die 5 jaar periode nie.   Latere studie verskaf bewys 
dat die gesamentlike gebruik van ‘rooster’ laser fototerapie (GLP) met die eerste IVB merkbaar 
beter is in diffuse DME.  Primêre IVB sonder GLP blyk beter te vaar as GLP alleen ten einde 
stabiliteit of verbetering van die bes-gekorrigeerde visie teen 24 maande in pasiente met DME te 
verseker. In drie pasiente met PDR en vorige pan retinale fotokoagulasie (PRP) was ons die eerste 
om te toon dat IVB betekenisvolle regressive van retinale neovaskularisasie induseer sowel as om 
glasvogbloeding op te klaar. Geen veiligheidskwessies was ondervind ses maande na die toediening 
van IVB in dosisse van 1.25 of 2.5mg in pasiente met PDR nie.  Later het ons publiseer dat in 
pasiente met PDR en vorige PRP die toediening van IVB lei tot betekenisvolle regressive van 
retinale neovaskularisasie na 2 jaar. Die toediening van IVB sonder adjuvante laser of vetrektomie 
het in onbehandelde oë gelei tot die beheer van regressive in 42.1% van oë na 24 maande se opvolg. 
Dit beteken dat byna 58% van pasiente wel PRP of vitrektomie benodig het.  In ‘n ander studie het 
ons gewys hoe waardevol pre-operatiewe IVB is tydens klein insisie vitreoretinale chirurgie in oë 
met traksie retinale loslatings in PDR.  Hierdie was ‘n prospektiewe nie-vergelykende studie. 
Pasiente het betekenisvolle anatomiese en funksionele suksesvolle uitkomste.  In twee studies het 
ons voorts vir die eerste keer rapporteer dat traksie retinale loslatings (TRD) mag plaasvind of 
vererger na die toediening van IVB in pasiente met erge PDR (5.2% en 3.2% respektiewelik).  
Gebasseer op ons data, glo ons nou dat ‘n dosis van 2.5mg of meer nadelig kan wees in pasiente met 
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PDR. Voorts wys ons dat as pasiente diabetes het vir meer as 15 jaar is die risiko vir traksie loslatings 
van die retina verhoog.  
Dokters moet bereid wees om vitrektomie chirurgie te doen verkieslik voor dag 13 nadat IVB 
toegedien is. As ‘n TRD vorm, moet onmiddellike chirurgie gedoen word. Omdat meer as 80% van 
die retinale loslatings ontwikkel het na 5 dae post IVB, beveel ons nou aan dat vitrektomie chirurgie 
binne 5 dae na die inspuit van bevacizumab uitgevoer word.   
Laastens, in ons prospektiewe gerandomiseerde kliniese studie, het ons gewys dat IVB as adjuvant 
tot PPV behulpsaam en voordelig is in pasiente met traksie loslatings wat die gevolg is van erge 
PDR. In die studie het pre-operatiewe IVB intraoperatiewe bloeding verminder, chirurgiese 
gesigsveld en visualisasie verbeter en intra- en postoperatiewe kompliksasies soos iatrogene retinale 
gate en post-operatiewe bloedings, verminder. Opsommend is ons gevolgtrekking dat met ‘n middel 
wat geredelik wêreldwyd beskikbaar is in die vorm van IVB voordeel inhou in die hantering van die 
komplikasies van diabetiese retinopatie en so blindheid kan voorkom.  
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Chapter 1: Introduction 
We are currently witnessing a worldwide epidemic in diabetes mellitus (DM). 
Changing dietary habits and an increase in sedentarism are the main culprits of this epidemic. 
In the year 2014, more than 422 million people suffered from DM, this is almost double than 
in 1980. At this rate, by the year 2040 the number of people affected with DM in the world 
may double again, and everyone of them will be at risk of developing diabetic retinopathy 
(DR).1  Vision loss due to diabetes mellitus is primarily caused by 2 mechanisms: diabetic 
macular edema (DME) and proliferative diabetic retinopathy (PDR). Diabetic macular edema 
within 1 disk diameter of the fovea, leading to central vision loss, is present in about 9% of 
the diabetic population.2 Proliferative diabetic retinopathy is present in about 1.5% of adults 
with diabetes,3 and PDR can lead to vision loss by various mechanisms, such as retinal 
neovascularization, vitreous hemorrhage, neovascular glaucoma, and tractional retinal 
detachment (TRD). It has been shown that vision loss secondary to proliferative changes is 
more common in patients with type 1 diabetes, whereas vision loss secondary to DME is 
more common in patients with type 2 diabetes.4 Prior to the advent of pan-retinal 
photocoagulation (PRP), PDR was the main cause of diabetic blindness. Since the 
development of PRP, DME has become the most common cause of visual loss in diabetic 
patients in the developed world.5 Nevertheless, PDR is still a very important cause of 
blindness in diabetic patients. 
More than 60 years ago, Michaelson speculated on the presence of a Factor X that 
was capable of inducing retinal angiogenesis or neovascularization.6 Vascular endothelial 
growth factor (VEGF) appears to be the most likely candidate to be Michaelson’s Factor X 
and the main molecular mediator in diabetic retinopathy. The underlying problem in diabetic 
patients is the progressive retinal ischemia caused by the metabolic disarray of chronic 
hyperglycemia. Hypoxia is a major inducer of VEGF gene transcription.7 VEGF has been 
shown to be an endothelial cell-specific mitogen and an angiogenic inducer in a variety of in 
vitro and in vivo models.7 Furthermore, it has been demonstrated to increase retinal vessel 
permeability by increasing the phosphorylation of tight junction proteins. Recent work has 
found elevated levels of VEGF in ocular fluids of patients with PDR.8-11 In addition, 
intravitreal injection of VEGF into normal primate eyes induces the same pathological 
processes seen in diabetic retinopathy, including microaneurysm formation and increased 
vascular permeability.12-13 Thus it makes sense to consider anti-VEGF treatments in the 
management of DME and PDR.  
Several anti-VEGF agents are currently available in clinical practice. Pegaptanib sodium 
(Macugen®, Eyetech, NY, NY USA) is an aptamer against the VEGF-165 isoform.14 
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Ranibizumab (Lucentis®, Genentech, San Francisco, CA, USA) is a fragment of a humanized 
monoclonal antibody against all VEGF isoforms.15 Bevacizumab (Avastin®, Genentech, San 
Francisco, CA, USA) is a humanized, recombinant monoclonal IgG antibody that binds and 
inhibits all VEGF isoforms.16-18Aflibercept, previously known as VEGF-Trap eye (Eylea®, 
Regeneron Pharmaceutics Inc., Tarrytown, NY) is a recombinant fusion protein that consists 
of portions of human VEGF receptors 1 and 2 that allows it to bind to VEGF-A, VEGF-B 
and placental growth factor.19 All of these agents have been used to diIfeUeQW extents in the 
management of DME and PDR.20-30 
My group has long been interested in studying the effects of intravitreal bevacizumab 
in several vitreoretinal conditions including DME and PDR.23-35 Given the off-label nature of 
intravitreal bevacizumab, its pharmacokinetics and safety have not been as thoroughly studied 
as other approved similar drugs that are more expensive and less accessible to most of the 
population worldwide. We have previously shown in an open label uncontrolled clinical study 
of 1265 patients that were injected with 4303 intravitreal injections of 1.25 mg or 2.5 mg of 
bevacizumab that intravitreal bevacizumab appears to be safe and well tolerated.36 
Purpose of the research 
Central research question: The purpose of the current research is to determine if intravitreal 
bevacizumab as anti-vascular endothelial growth factor is helpful in the management of 
complications of diabetic retinopathy. 
Hypothesis 1: Intravitreal bevacizumab (IVB) may have a beneficial anatomic (Optical 
Coherence Tomography [OCT]), and functional (visual acuity [VA]) effect on eyes with 
diffuse diabetic macular edema at 24 months of follow up. In addition, the lower dose (1.25 
mg) may be as effective or more than the higher dose (2.5 mg) of IVB. 
Hypothesis 2: IVB combined with grid laser photocoagulation may have a beneficial 
anatomic (OCT), and functional (VA) effect on eyes with diffuse diabetic macular edema at 
24 months of follow up as compared to monotherapy. In addition, IVB combined with grid 
laser photocoagulation may decrease the number of injections if IVB necessary at 24 
months. 
Hypothesis 3: IVB may decrease retinal neovascularization in patients with PDR at 6 months 
of follow up. However, the effect may decrease at 24 months of follow up due to 
tachyphylaxis, and pan-retinal photocoagulation and/or vitrectomy will be necessary.  
Hypothesis 4: Preoperative IVB may be beneficial for membrane dissection in 
diabetic tractional retinal detachment with minimally invasive vitreoretinal surgery 
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(23-gauge transconjunctival sutureless vitrectomy [TSV]). In addition, post-operative 
rebleeding may be decreased. 
Hypothesis 5: Tractional retinal detachment (TRD) may occur following IVB as an adjuvant 
to vitrectomy for the management of severe PDR.  
Hypothesis 6: Risk factors for the progression or development of TRD following IVB as an 
adjuvant to vitrectomy in severe PDR may include age, time from diabetes mellitus (DM) 
diagnosis, glycemic control, cholesterol levels, triglycerides levels, hemoglobin A1c 
(HbA1C), dose of bevacizumab, and time from injection to vitrectomy.  
Hypothesis 7 (prospective unpublished study): Intravitreal injection of 1.25 mg of 
bevacizumab as a pre-operative adjunct to PPV in eyes with TRD secondary to PDR will be 
safe and effective. IVB (compared to sham) will decrease intraoperative bleeding, total 
surgical time, post-operative vitreous hemorrhage, and visual acuity at 12 months. 
Methods, and Ethical requirements of the research 
We conducted several multicenter retrospective studies of eyes with complications 
from diabetic retinopathy treated with off-label IVB between September 2005 and July 2015 
at nineteen institutions in 13 countries in Latin America (Venezuela, Colombia, Costa Rica, 
Brazil, Argentina, Peru, and Mexico). In addition, centers in Spain, and Saudi Arabia 
participated. Ten previously published studies (one prospective), and one unpublished 
prospective study are included here. 
Approval was obtained from each participating center’s Institutional Ethics 
Committee, and informed consent was obtained for these studLes. In addition, these studLes 
haYe been performed in accordance with the ethical standards laid down in the 1964 
Declaration of Helsinki. The off-label use of the drug and its potential risks and benefits were 
discussed extensively with all patients.  
The following 11 chapters include the detailed methodology and results from our 
studies on DME and PDR including a prospective randomized clinical trial on Pre-Operative 
Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative 
Diabetic Retinopathy. A final chapter 13 will summarize our conclusions. 
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Chapter 2: Intravitreal Bevacizumab for Diabetic Macular Edema at 6 months of follow up 
Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, Berrocal MH, Solis-
Vivanco A, Farah ME; Pan-American Collaborative Retina Study Group. 
Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-
American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology. 2007 
Apr;114(4):743-50. 
DOI: 10.1016/j.ophtha.2006.12.028 
Hypothesis 1: Intravitreal bevacizumab (IVB) may have a beneficial anatomic (Optical Coherence 
Tomography [OCT]), and functional (visual acuity [VA]) effect on eyes with diffuse diabetic 
macular edema at 24 months of follow up. In addition, the lower dose (1.25 mg) may be as effective 
or more than the higher dose (2.5 mg) of IVB. 
Purpose: To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after 
primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME)Design: 
Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME.  
Participants: We reviewed the clinical records of 88 consecutive patients (110 eyes) with DME. 
Seventy- eight eyes of 64 consecutive patients with a minimum follow-up of 6 months and mean age 
of 59.7±9.3 years were included in this analysis.  
Intervention: Patients were treated with at least one intravitreal injection of 1.25 mg or 2.5 mg of 
bevacizumab and underwent Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA testing, 
ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography 
(FA) at baseline and follow-up visits. Repeated-measures analysis of variance was used to compare 
mean values.  
Main Outcome Measures: Changes in BCVA, OCT, and FA. 
Results: Mean follow-up was 6.31±0.81 months (range, 6–9). Sixteen (20.5%) eyes needed a second 
injection at a mean of 13.8 weeks (range, 4–28), and 6 eyes needed a third injection (7.7%) at a mean 
of 11.5 weeks (range, 5–20). The mean baseline BCVA was 0.87 (logarithm of the minimum angle of 
resolution), and the final mean BCVA was 0.6, a difference that was statistically significant 
(P<0.0001). Final BCVA analysis by subgroups demonstrated that 32 (41.1%) eyes remained stable, 
43 (55.1%) improved ≥2 ETDRS lines of BCVA, and 3 (3.8%) decreased ≥2 ETDRS lines of BCVA. 
Mean central macular thickness at baseline by OCT was 387.0±182.8 µm and decreased to a mean of 
275.7±108.3 at end of follow-up (P<0.0001). No ocular or systemic adverse events were observed.  
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Conclusions: Primary intravitreal bevacizumab at doses of 1.25 to 2.5 mg seem to provide stability or 
improvement in VA, OCT, and FA in DME at 6 months. Follow-up is still short to make any specific 
treatment recommendations; however, the results appear promising. Evaluation in a multicenter 
randomized controlled clinical trial with longer follow-up is needed.  
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Primary Intravitreal Bevacizumab (Avastin)
for Diabetic Macular Edema
Results from the Pan-American Collaborative Retina
Study Group at 6-Month Follow-up
J. Fernando Arevalo, MD, FACS,1 Jans Fromow-Guerra, MD,2 Hugo Quiroz-Mercado, MD,2
Juan G. Sanchez, MD,1 Lihteh Wu, MD,3 Mauricio Maia, MD,4 Maria H. Berrocal, MD,5
Adriana Solis-Vivanco, MD,2 Michel E. Farah, MD,4 for the Pan-American Collaborative Retina Study Group*
Purpose: To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary
intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME).
Design: Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME.
Participants: We reviewed the clinical records of 88 consecutive patients (110 eyes) with DME. Seventy-
eight eyes of 64 consecutive patients with a minimum follow-up of 6 months and mean age of 59.7!9.3 years
were included in this analysis.
Intervention: Patients were treated with at least one intravitreal injection of 1.25 mg or 2.5 mg of bevaci-
zumab and underwent Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA testing, ophthalmoscopic
examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up
visits. Repeated-measures analysis of variance was used to compare mean values.
Main Outcome Measures: Changes in BCVA, OCT, and FA.
Results: Mean follow-up was 6.31!0.81 months (range, 6–9). Sixteen (20.5%) eyes needed a second
injection at a mean of 13.8 weeks (range, 4–28), and 6 eyes needed a third injection (7.7%) at a mean of 11.5
weeks (range, 5–20). The mean baseline BCVA was 0.87 (logarithm of the minimum angle of resolution), and the
final mean BCVA was 0.6, a difference that was statistically significant (P"0.0001). Final BCVA analysis by
subgroups demonstrated that 32 (41.1%) eyes remained stable, 43 (55.1%) improved !2 ETDRS lines of BCVA,
and 3 (3.8%) decreased !2 ETDRS lines of BCVA. Mean central macular thickness at baseline by OCT was
387.0!182.8 "m and decreased to a mean of 275.7!108.3 at end of follow-up (P"0.0001). No ocular or
systemic adverse events were observed.
Conclusions: Primary intravitreal bevacizumab at doses of 1.25 to 2.5 mg seem to provide stability or
improvement in VA, OCT, and FA in DME at 6 months. Follow-up is still short to make any specific treatment
recommendations; however, the results appear promising. Evaluation in a multicenter randomized controlled
clinical trial with longer follow-up is needed. Ophthalmology 2007;114:743–750 © 2007 by the American
Academy of Ophthalmology.
Diabetic retinopathy remains the major threat to sight in the
working age population in the developed world. Further-
more, it is increasing as a major cause of blindness in other
parts of the world, especially developing countries.1 Dia-
betic macular edema (DME) is a manifestation of diabetic
retinopathy that produces loss of central vision. Macular
edema within 1 disc diameter of the fovea is present in 9%
of the diabetic population.2 Although visual loss secondary
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to proliferative changes is more common in patients with
type 1 diabetes, visual loss in patients with type 2 diabetes is
more commonly due to macular edema.3 Diabetic macular
edema is caused by excessive vascular permeability, resulting
in the leakage of fluid and plasma constituents, such as lipopro-
teins, into the retina, leading to its thickening.
Although the Early Treatment Diabetic Retinopathy
Study (ETDRS)4 demonstrated that immediate focal photo-
coagulation reduced moderate visual loss by 50% (from
24% to 12%, 3 years after initiation of treatment), 12% of
treated eyes still lost !15 ETDRS letters at the 3-year
follow-up interval. Approximately 40% of treated eyes that
had retinal thickening involving the center of the macula at
baseline still had thickening involving the center at 12
months, as did 25% of treated eyes at 36 months. Further-
more, only 3% of laser-treated eyes experienced a gain of
!3 lines of vision. This suggests that a distinct subgroup of
eyes exists with DME resistant to conventional laser photoco-
agulation. Other studies have reported a poor prognosis despite
laser photocoagulation in eyes with diffuse DME.4–6
Vascular endothelial growth factor (VEGF) has been
shown to be an endothelial cell-specific mitogen and an
angiogenic inducer in a variety of in vitro and in vivo
models.7 Vascular endothelial growth factor, also known as
vascular permeability factor, has been demonstrated to in-
crease retinal vessel permeability by increasing the phos-
phorylation of tight junction proteins. Also, hypoxia has
been shown to be a major inducer of VEGF gene transcrip-
tion.7 Recent work has found elevated levels of VEGF in
ocular fluids of patients with proliferative diabetic retinop-
athy (PDR).8–10 These studies also found that the growth of
new vessels from the retina or optic nerve was thought to
occur as a result of VEGF release into the vitreous cavity as
a response to ischemia.8–10 Furthermore, injection of VEGF
into normal primate eyes induces the same pathological
processes seen in diabetic retinopathy, including microan-
eurysm formation and increased vascular permeability.11,12
Anti-VEGF treatments have been hypothesized as an alter-
native adjunctive treatment for DME.13
Bevacizumab (Avastin, Genentech Inc., San Francisco,
CA) is a complete full-length humanized antibody that binds to
all subtypes of VEGF and is used successfully in tumor ther-
apy as a systemic drug.14 Recent studies have demonstrated the
usefulness of an intravitreal injection of bevacizumab in the
reduction of macular edema secondary to central retinal vein
occlusion, vascular permeability and fibrovascular prolifera-
tion in retinal neovascularization secondary to PDR, and cho-
roidal neovascularization secondary to age-related macular
degeneration (AMD).15–18 The amount of human retinal pen-
etration for a complete full-length anti-VEGF antibody is not
known at present. However, full-thickness retinal penetration
of intravitreal bevacizumab was observed in an animal
model.19,20 Additionally, intravitreal bevacizumab does not
appear to be toxic to the albino rabbit retina at a concen-
tration of up to 2.5 mg.21
Recently, Pieramici et al22 reported a case of moderate
anterior uveitis after repeated intravitreal injections of bev-
acizumab to treat choroidal neovascularization associated
with AMD. In addition, Meyer et al23 reported 2 patients
who developed an acute retinal pigment epithelial tear after
intravitreal bevacizumab. In an open-label uncontrolled
clinical study of 1804 injections in human eyes with
1.25-mg or 2.5-mg intravitreal bevacizumab, our group
reported 4 (0.3%) cases of endophthalmitis, 3 (0.3%) of
elevation of intraocular pressure (IOP), 3 of tractional reti-
nal detachment, and 1 (0.1%) of uveitis. No systemic ad-
verse events were reported, and bevacizumab appears to be
safe and well tolerated during the first 4 months (Wu et al,
unpublished data).
The purpose of this retrospective study was to report the
6-month anatomic and best-corrected visual acuity (BCVA)
response after primary intravitreal bevacizumab in patients
with DME.
Patients and Methods
We conducted a multicenter retrospective study of eyes with DME
treated with off-label intravitreal bevacizumab (Avastin) between
September 2005 and August 2006 at 6 institutions in Venezuela,
Mexico, Costa Rica, Brazil, Puerto Rico, and Colombia. We re-
viewed the clinical records of 88 consecutive patients (110 eyes)
with DME treated with at least one intravitreal injection of 1.25 mg
or 2.5 mg of bevacizumab. Institutional review board/ethics com-
mittee approval and patients’ informed consent were obtained for
this study at all 6 institutions. The off-label use of the drug and its
potential risks and benefits were discussed extensively with all
patients. Exclusion criteria included patients (eyes) with DME
previously treated with laser photocoagulation or intravitreal tri-
amcinolone, macular ischemia, and the presence of an epiretinal
membrane or vitreomacular traction syndrome. Although not a
formal exclusion criteria, patients with a history of uncontrolled
hypertension and recent thomboembolic events were not usually
injected with bevacizumab, but this decision was at the discretion
of the treating physician.
Each patient underwent BCVA measurement with ETDRS
charts and ophthalmic examination including slit-lamp biomi-
croscopy. Baseline central retinal characteristics were analyzed
by optical coherence tomography (OCT) (Stratus III, Carl Zeiss,
Dublin, CA) utilizing 6 diagonal slow 6-mm radial line scans,
with software versions 3.0 and 4.0, through a dilated pupil
performed by a retina specialist. The retinal thickness of the 1-mm
central retina was obtained using the macular thickness map for
our calculations.
A 0.18-ml aliquot of commercially available bevacizumab was
prepared for each patient and placed in a tuberculin syringe using
aseptic techniques. After the eye had been prepared in a standard
fashion using 5% povidone/iodine, an eyelid speculum was used to
stabilize the eyelids, and the injection of 1.25 mg (0.05 ml) or 2.5
mg (0.1 ml) of bevacizumab was performed 3.5 to 4 mm posterior
to the limbus, through the inferotemporal pars plana with a 30-
gauge needle under topical anesthesia or subconjunctival lido-
caine. After the injection, IOP and retinal artery perfusion were
checked, and patients were instructed to administer topical antibi-
otics for 7 days.
Patients were examined at 1 and 2 weeks and 1 month after the
first injection and monthly thereafter. One, 3, and 6 months after
the initial injection, ophthalmic examination included OCT and
fluorescein angiograhy (FA). However, OCT or FA was performed
earlier (weeks 1 and 2) in some patients according to the investi-
gator’s decision and preference.
Patients were included in this consecutive series only if there
was a minimum of 6 months’ follow-up. Fluorescein angiography
was done at the discretion of the examiner and not at every
postinjection evaluation, usually every 6 weeks. Patients received
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reinjections when there was a recurrence of DME. Recurrence was
defined as a decrease of BCVA associated with an increase of
intraretinal fluid due to macular edema on OCT and/or FA, after
complete or partial resolution in previous follow-up visits.
Patients’ ETDRS BCVAs were transferred from their records
and converted to a logarithm of the minimum angle of resolution
(logMAR) scale for analysis. Repeated-measures analysis of vari-
ance (ANOVA) was used to compare mean values to analyze mean
retinal thickness and logMAR visual acuity (VA) statistically. An
increase or decrease in BCVA was considered to have occurred if
there was a change of !2 ETDRS lines. Main outcome measures
included changes in BCVA, OCT, and FA. Interval data were ana-
lyzed at 1-, 3-, and 6-month follow-up time points. A P value" 0.05
was considered to be significant.
Results
Seventy-eight eyes (64 consecutive patients) with a minimum of 6
months’ follow-up were included for analysis. Fifty-one (79.7%)
patients were Hispanic and 12 (18.7%) were Caucasian. Our
patients had a mean age of 59.7!9.3 years, and 54.7% were male
(35 men, 29 women). Patients had a mean follow-up of 6.31!0.81
months (range, 6–9). Forty-four (56.4%) cases had PDR (Table 1).
All of these 44 cases had had prior scatter photocoagulation at least
6 months before undergoing bevacizumab intravitreal injections.
All eyes had clinically significant macular edema at the baseline
biomicroscopy slit-lamp examination.4
Within 1 month after the initial bevacizumab injection,
improvements in VA and central retinal thickness measure-
ments were observed, and these significant changes continued
throughout the 6-month follow-up. By 1 month, mean BCVA
improved from 0.87 to 0.6, a difference that was statistically
significant (P"0.0001). This BCVA was maintained throughout
6 months (Fig 1). At the 3- and 6-month follow-ups (data available
for all 78 eyes), mean BCVA of 0.6 did not differ statistically (P#
0.775 and P# 0.688 respectively) from BCVA at 1-month follow-
up. Final BCVA analysis by subgroups demonstrated that 32
(41.1%) eyes remained stable, 43 (55.1%) improved !2 ETDRS
lines of BCVA, and 3 (3.8%) decreased !2 ETDRS lines of
BCVA (Table 2, Fig 2).
Optical coherence tomography results were available for all 78
cases at 1-, 3-, and 6-month follow-ups. At 1 month, the mean
1-mm central retinal thickness measurements decreased from
387.0!182.8 "m to 287.9!102.4 "m (P"0.0001), and this over-
all improvement continued throughout the 6-month follow-up. At
3- and 6-month follow-ups, mean central macular thicknesses were
282.8!115.6 "m and 275.7!108.3, respectively, which were not
significantly lower than the 1-month follow-up (P # 0.678 and
P # 0.371, respectively) (Figs 3, 4).
We wished to compare response to treatment between patients
with PDR and previous panretinal photocoagulation and those with
Table 1. Distribution by Grade of Diabetic Retinopathy (DR)
(78 Eyes)
Grade of DR No. of Cases
Mild NDR 2 (2.6%)
Moderate NDR 10 (12.8%)
Severe NDR 20 (25.6%)
PDR 46 (58.9%)
NDR # nonproliferative DR; PDR # proliferative DR.
Figure 1. Changes in best-corrected visual acuity (BCVA) after intravitreal bevacizumab. Best-corrected visual acuity improved at 1 month from 0.87
to 0.6 (logarithm of the minimum angle of resolution), a difference that was statistically significant (P"0.0001); this level of BCVA was maintained
throughout 3 and 6 months. The mean follow-up period was 6.31!0.81 months (range, 6–9). CI # confidence interval.
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nonproliferative diabetic retinopathy and macular edema to see if
there was any difference. However, when we ran the repeated-
measures ANOVA to compare mean values to statistically analyze
mean retinal thickness and logMAR VA adjusting for the grade of
diabetic retinopathy as a covariate, we did not find statistical
significance (P # 0.565 for BCVA and P # 0.446 for OCT retinal
thickness).
All eyes received an intravitreal injection at the initial visit;
however, recurrences were re-treated at the discretion of the
treating physician. Sixty-three (80.8%) cases were treated with
an intravitreal injection of bevacizumab at 2.5 mg, and 15
(19.2%) with a dose of 1.25 mg. Sixteen (20.5%) eyes needed
a second injection at a mean of 13.8 weeks (range, 4 –28), and
6 needed a third injection (7.7%) at a mean of 11.5 weeks
(range, 5–20) (Fig 5). Numbers of eyes that needed reinjections
were 13 of 63 (20.6%) treated with an intravitreal injection of
bevacizumab at 2.5 mg and 3 of 15 (20%) treated with an intrav-
itreal injection of bevacizumab at 1.25 mg. We did not observe
statistically significant differences in changes of BCVA and mac-
ular thickness with OCT between doses of 1.25 and 2.5 mg of
intravitreal bevacizumab.
There were no episodes of inflammation or severe decrease of
vision immediately after an injection. At 6 months, no ocular or
systemic adverse events such as thromboembolic events (cerebro-
vascular accidents, transient ischemic attacks, myocardial infarc-
tions, or peripheral vascular disease) were reported.
Discussion
Diabetic macular edema is a manifestation of diabetic reti-
nopathy that produces loss of central vision. Although sev-
eral treatment modalities are under investigation, the only
demonstrated means to reduce the risk of vision loss from
DME are laser photocoagulation, as demonstrated by the
ETDRS4; intensive glycemic control, as demonstrated by
the Diabetes Control and Complications Trial and the
United Kingdom Prospective Diabetes Study; and blood
pressure control, as demonstrated by the United Kingdom
Prospective Diabetes Study.24,25 Given that most eyes with
DME that are treated with laser photocoagulation do not
have an improvement in VA, there has been an interest in
other treatment modalities such as pharmacologic therapy
with oral protein kinase C inhibitors and the use of intrav-
itreal corticosteroids.26,27 The use of antibodies targeted at
VEGF is another treatment modality that has generated
considerable interest and is being investigated.
Diabetic macular edema is the most frequent cause of
visual impairment in patients with nonproliferative diabetic
retinopathy. However, the breakdown of endothelial tight
junctions and loss of the blood–retina barrier that lead to
DME can be associated with both nonproliferative diabetic
retinopathy and PDR. Our study demonstrates a comparable
population of PDR and nonproliferative diabetic retinopathy
patients with macular edema. Due to the relatively small
number of participants in the study, our series had no
statistical power to determine significative differences in the
treatment with intravitreal bevacizumab between different
stages of diabetic retinopathy.
It was demonstrated recently that retinal hypoxia plays a
role in DME,28 and VEGF, which is upregulated by hyp-
oxia, is likely to contribute to the excessive vascular per-
meability that results in macular edema in people with
diabetes. To the best of our knowledge, there is only a pilot
study in the literature on the intravitreal administration of
antibodies against VEGF for DME as primary therapy.
Chun et al reported that ranibizumab therapy has the poten-
tial to maintain or improve BCVA and reduce retinal thick-
ness in patients with DME.29 In addition, intravitreal injec-
tions of the aptamer pegaptanib sodium in patients with
DME have been shown to improve VA and retinal thicken-
ing.13 The Macugen Diabetic Retinopathy Study Group
reported gains in VA of 10 letters in 34% and 15 letters in
18% of patients with DME after an intravitreal pegaptanib
sodium injection in a randomized, double-masked, multi-
center trial with a follow-up of 36 months.
Figure 2. Number of patients losing, maintaining, or gaining Early Treat-
ment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity
(BCVA) from baseline to final follow-up (mean, 6.31!0.81 months).
Table 2. Best-Corrected Visual Acuity (BCVA) Analysis by Subgroups (78 Eyes)
First Month Third Month Sixth Month
No. of Eyes Percentage No. of Eyes Percentage No. of Eyes Percentage
Decreased !2 ETDRS lines of BCVA 1 1.3 3 3.8 3 3.8
Remained stable 35 44.9 32 41.1 32 41.1
Improved !2 ETDRS lines of BCVA 42 53.8 43 55.1 43 55.1
ETDRS # Early Treatment Diabetic Retinopathy Study.
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The 2 doses of bevacizumab evaluated in this study were
1.25 mg, which is the one that has been used most com-
monly in clinical practice, and 2.5 mg, which also has been
used, though less commonly. Doses lower than 1.25 mg
create difficulties with dilution and the accuracy of injection
of a small volume. The results of our retrospective study
demonstrated the efficacy of 1.25 mg or 2.5 mg of intrav-
itreal bevacizumab as primary treatment of DME, as 55.1%
of eyes showed anatomical and functional improvement. In
addition, our results suggest a reduced risk of VA loss in eyes
with DME treated with intravitreal bevacizumab (96.2% of
eyes). Sixteen (20.5%) eyes needed a second injection at a
mean of 13.8 weeks (range, 4–28), and 6 needed a third
injection (7.7%) at a mean of 11.5 weeks (range, 5–20). We
found that the anatomical and visual benefit of the intravitreal
bevacizumab appears and reaches its maximum value during
the first month and maintains itself over 6 months. Neverthe-
less, we did not find statistically significant differences in
duration or anatomical or functional effectiveness between the
2 doses of bevacizumab evaluated.
The optimum dosing and sequence for intravitreal bev-
acizumab in DME is still undetermined. We elected to defer
reinjections until there was a recurrence. Recurrence was
defined as a decrease of BCVA associated with an increase
of intraretinal fluid due to macular edema on OCT and/or
FA, after complete or partial resolution in previous follow-up
visits. It is possible that a different dosing schedule, such as
a series of injections every 12 weeks for an extended period
followed by retreatment only for recurrences, may be supe-
rior to the method used in this study; however, we chose to
err on the side of undertreatment until further toxicity data
are obtained. It was interesting that, over time, the number
of patients needing reinjections diminished from 20.5% to
7.7%. Probably, bevacizumab has a beneficial cumulative
effect for DME, for which future studies are necessary.
Focal and grid laser photocoagulation are the primary
treatments for DME.4 However, although the ETDRS4 dem-
onstrated that immediate focal photocoagulation reduced
moderate visual loss by 50%, 12% of treated eyes still lost
!15 ETDRS letters at the 3-year follow-up interval, and
24% of immediately treated eyes had thickening involving
the center of the macula at 36 months. In addition, laser
treatment of eyes with diffuse macular edema has been
disappointing.30 Our results indicate that intravitreal bev-
acizumab injections may have a beneficial effect on macular
thickness and VA, independent of the type of macular
edema that is present (focal vs. diffuse). Therefore, in the
future this new treatment modality could replace or com-
plement focal/grid laser photocoagulation. Furthermore,
focal/grid laser photocoagulation could be used to con-
solidate the results obtained with one intravitreal bevaci-
zumab injection and decrease the need for reinjections.
Recently, Chun et al reported the biologic activity and
adverse events of multiple intravitreal injections of ranibi-
Figure 3. Changes in macular thickness with optical coherence tomography (OCT) during follow-up after intravitreal bevacizumab. The foveal thickness
improved after 1 month, mean 1-mm central retinal thickness measurements decreased from 387.0!182.8 "m to 287.9!102.4 "m (P"0.0001), and this
overall improvement continued at the 3- and 6-month time points. At 3- and 6-month follow-ups, mean central macular thicknesses were 282.8!115.6
"m and 275.7!108.3 "m, respectively, which were not significantly lower than the 1-month follow-up (P # 0.678 and P # 0.371, respectively). CI #
confidence interval.
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zumab (0.3 mg or 0.5 mg each injection) in 10 eyes (pa-
tients) with DME.29 Of the 10 patients enrolled, 5 received
0.3-mg and 5 received 0.5-mg ranibizumab. No systemic
adverse events were reported, and 5 occurrences of mild to
moderate ocular inflammation were reported. At month 3, 4
(40%) of 10 eyes gained !3 ETDRS lines of BCVA, and 5
(50%) of 10 gained !2 ETDRS lines of BCVA. At month
3, mean decreases in retinal thickness of the center point of
the central subfield were 45.3!196.3 "m for the low-dose
group and 197.8!85.9 "m for the high-dose group. The
current study showed similar results of improved BCVA
and OCT and no reported episodes of inflammation in a
larger number of patients.
Limitations of our study include that it is short term,
nonrandomized, uncontrolled, and retrospective, which pre-
clude any estimation of the long-term efficacy or safety of
Figure 4. A, A horizontal optical coherence tomography (OCT) scan obtained through the fovea revealed loss of the normal foveal contour, diffuse macular
thickening, and areas of low intraretinal reflectivity consistent with intraretinal cysts and fluid accumulation. The retinal map analysis revealed a foveal thickness
of 670 "m. The patient underwent an intravitreal injection of bevacizumab at a dose of 2.5 mg in this eye. B, One week after the injection, an OCT scan showed
that the foveal thickness had decreased to 479 "m. C, One month after the injection, the cystic spaces had resolved almost completely, and the patient’s visual
acuity (VA) improved to 20/100. Foveal thickness had decreased to 329 "m. D, Optical coherence tomography done 3 months after the injection showed
complete resolution of intraretinal cysts. Visual acuity improved to 20/63 and foveal thickness decreased to 284 "m. E, Six months after the injection, an OCT
scan showed normal macular anatomical architecture. The patient’s VA was 20/63, and foveal thickness decreased to 173 "m.
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intravitreal bevacizumab. In addition, because no control
group is present we cannot rule out the possibility that some
of the improvement in macular edema might be associated
with improvement in systemic health. It is not uncommon
that additional attention is directed towards improving sys-
temic health when patients get involved in a clinical trial or
new treatment. However, the results were very promising
and suggest the need for further investigation. Furthermore,
we can safely assume with a 95% confidence that the true
rate of ocular complications is "3.8%, and that the true rate
of systemic complications is "4.6% in our study.31
In summary, primary intravitreal bevacizumab at doses
of 1.25 mg or 2.5 mg seems to provide stability and im-
provement in VA, OCT, and FA in DME at 6 months.
Follow-up is still too short to make any specific treatment
recommendations; however, the results are promising. Eval-
uation in a multicenter randomized controlled clinical trial
with longer follow-up is needed to evaluate the safety and
efficacy of this new treatment.
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Chapter 3: Intravitreal Bevacizumab for Diabetic Macular Edema at 12 months of follow up 
Arevalo JF, Sanchez JG, Fromow-Guerra J, Wu L, Berrocal MH, Farah ME, Cardillo J, Rodríguez 
FJ; Pan-American Collaborative Retina Study Group (PACORES). Comparison of two doses of 
primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-
American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefes Arch Clin 
Exp Ophthalmol. 2009 Jun;247(6):735-43. doi: 10.1007/s00417-008-1034-x. Epub 2009 Feb 3. 
DOI: 10.1007/s00417-008-1034-x 
Hypothesis 1: Intravitreal bevacizumab (IVB) may have a beneficial anatomic (Optical Coherence 
Tomography [OCT]), and functional (visual acuity [VA]) effect on eyes with diffuse diabetic 
macular edema at 24 months of follow up. In addition, the lower dose (1.25 mg) may be as effective 
or more than the higher dose (2.5 mg) of IVB. 
BACKGROUND: To report the 12-month anatomic and ETDRS best-corrected visual acuity 
(BCVA) response after primary intravitreal bevacizumab (Avastin) (1.25 mg or 2.5 mg) in patients 
with diffuse diabetic macular edema (DDME). In addition, a comparison of the two 
different doses of intravitreal bevacizumab (IVB) utilized was made. 
METHODS: We reviewed the clinical records of 82 consecutive patients (101 eyes) with DDME in 
this interventional retrospective multicenter study. All patients with a minimum follow-up of 12 
months (mean 57.6 +/- 8.4 weeks) were included in this analysis. Patients underwent ETDRS best-
corrected visual acuity (BCVA) testing, ophthalmoscopic examination, optical coherence 
tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits. 
RESULTS: The mean age of our patients was 59.7 +/- 9.3 years. The mean number of IVB 
injections per eye was three (range: one to six injections) at a mean interval of 14.1 +/- 10.5 weeks. 
In the 1.25 mg group at 1 month BCVA improved from 20/190, logMAR = 0.97 to 20/85, logMAR 
0.62, a difference that was statistically significant (p = 0.0001). This improvement was maintained 
throughout the 3-, 6-, and 12-month follow-up. The mean final BCVA at 12 months was 20/76, 
logMAR = 0.58 (p < 0.001), a statistically significant difference from baseline BCVA. Similar 
BCVA changes were observed in the 2.5 mg group. In the 1.25 mg group, the mean central macular 
thickness (CMT) decreased from 419.1 +/- 201.1 microm at baseline to 295.11 +/- 91.5 microm at 1 
month, 302.1 +/- 124.2 microm at 3 months, 313.4.1 +/- 96.3 microm at 6 months, and 268.2 +/- 
95.5 microm at 12 months (p < 0.0001). Similar CMT changes were observed in the 2.5 mg group. 
Adverse events included transient high blood pressure in one patient (1.2%), transient increased 
intraocular pressure in one eye (1%), and tractional retinal detachment in one eye (1%). 
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CONCLUSIONS: Primary IVB at doses of 1.25 to 2.5 mg seem to provide stability or improvement 
in BCVA, OCT, and FA in DDME at 12 months. There seems to be no difference in 
our results between intravitreal bevacizumab at doses of 1.25 mg or 2.5 mg. In addition, 
our results suggest the need for at least three injections a year to maintain the BCVA results. 
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follow-up of 12 months (mean 57.6±8.4 weeks) were
included in this analysis. Patients underwent ETDRS best-
corrected visual acuity (BCVA) testing, ophthalmoscopic
examination, optical coherence tomography (OCT), and
fluorescein angiography (FA) at baseline and follow-up visits.
Results The mean age of our patients was 59.7±9.3 years.
The mean number of IVB injections per eye was three
(range: one to six injections) at a mean interval of 14.1±
10.5 weeks. In the 1.25 mg group at 1 month BCVA
improved from 20/190, logMAR=0.97 to 20/85, logMAR
0.62, a difference that was statistically significant (p=
0.0001). This improvement was maintained throughout the
3-, 6-, and 12-month follow-up. The mean final BCVA at
12 months was 20/76, logMAR=0.58 (p<0.001), a statisti-
cally significant difference from baseline BCVA. Similar
BCVA changes were observed in the 2.5 mg group. In the
1.25 mg group, the mean central macular thickness (CMT)
decreased from 419.1±201.1 µm at baseline to 295.11±
91.5 µm at 1 month, 302.1±124.2 µm at 3 months,
313.4.1±96.3 µm at 6 months, and 268.2±95.5 µm at
12 months (p<0.0001). Similar CMT changes were ob-
served in the 2.5 mg group. Adverse events included
transient high blood pressure in one patient (1.2%), transient
increased intraocular pressure in one eye (1%), and tractional
retinal detachment in one eye (1%).
Conclusions Primary IVB at doses of 1.25 to 2.5 mg seem to
provide stability or improvement in BCVA, OCT, and FA in
DDME at 12 months. There seems to be no difference in our
results between intravitreal bevacizumab at doses of 1.25 mg
or 2.5 mg. In addition, our results suggest the need for at least
three injections a year to maintain the BCVA results.
Keywords Avastin . Bevacizumab . Diffusediabeticmacular
edema . Intravitreal injections . OCT. Primary treatment
Introduction
Diabetic retinopathy remains the major threat to sight in the
working-age population in the developed world. Further-
more, it is increasing as a major cause of blindness in other
parts of the world, especially developing countries [1].
Diabetic macular edema (DME) is a manifestation of
diabetic retinopathy that produces loss of central vision,
and is now the principal cause of vision loss in persons with
diabetes. Macular edema within 1 disc diameter of the
fovea is present in 9% of the diabetic population [2].
Although visual loss secondary to proliferative changes is
more common in patients with type 1 diabetes, visual loss
in patients with type 2 diabetes is more commonly due to
macular edema [3]. However, DME can occur at any stage
of diabetic retinopathy, and it is caused by excessive
vascular permeability, resulting in the leakage of fluid and
plasma constituents, such as lipoproteins, into the retina,
leading to its thickening.
There is good evidence that focal laser treatment preserves
vision in eyes with DME. The Early Treatment Diabetic
Retinopathy Study (ETDRS) [4] randomized 1,490 eyes with
DME to receive focal laser treatment or observation. At
3 years, treatment significantly reduced moderate visual loss
as compared with observation [4], with the greatest benefits
in eyes with clinically significant DME [5]. Although the
ETDRS [1] demonstrated that immediate focal photocoagu-
lation reduced moderate visual loss by 50% (from 24% to
12%, 3 years after initiation of treatment), 12% of treated
eyes still lost >15 ETDRS letters at the 3-year follow-up
interval. Approximately 40% of treated eyes that had retinal
thickening involving the center of the macula at baseline still
had thickening involving the center at 12 months, as did
25% of treated eyes at 36 months. Furthermore, only 3% of
laser-treated eyes experienced a gain of ≥3 lines of vision.
This suggests that a distinct subgroup of eyes exists with
DME resistant to conventional laser photocoagulation. In
addition, some reports have indicated that diffuse diabetic
macular edema (DDME) is refractory to macular photoco-
agulation [4–7]. Lee and Olk [8] demonstrated that with
modified grid laser macular photocoagulation, visual acuity
was stabilized in 60.9%, decreased in 24.6%, and increased
in only 14.5% of eyes with DDME. Therefore, alternative or
adjunct treatments for DME such as intravitreal triamcino-
lone acetonide [9–13], and anti–vascular endothelial growth
factor (VEGF) therapy have been the focus recently [14–17].
Vascular endothelial growth factor (VEGF) has been
demonstrated to increase retinal vessel permeability. Also,
hypoxia has been shown to be a major inducer of VEGF gene
transcription [18, 19]. It has been shown that VEGF-A levels
are considerably higher in DME patients with extensive
leakage in the macular region than in patients with minimal
leakage [20]. Recent work has found elevated levels of
VEGF in ocular fluids of patients with proliferative diabetic
retinopathy (PDR) [21–24]. These studies also found that the
growth of new vessels from the retina or optic nerve was
thought to occur as a result of VEGF release into the vitreous
cavity as a response to ischemia [21, 22].
Currently used anti-VEGF drugs are pegaptanib sodium
(Macugen; OSI Eyetech Pharmaceuticals, Melville, NY,
USA), ranibizumab (Lucentis, Genentech Inc., San Francisco,
CA, USA), and bevacizumab (Avastin; Genentech Inc.).
Bevacizumab is a complete full-length humanized antibody
that binds to all subtypes of VEGF, and is used successfully in
tumor therapy as a systemic drug [25]. Studies have
demonstrated the usefulness of an intravitreal injection of
bevacizumab, with promising effects in the reduction of
macular edema secondary to central retinal vein occlusion,
vascular permeability and fibrovascular proliferation in
retinal neovascularization secondary to PDR, rubeosis iridis,
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retinopathy of prematurity, choroidal neovascularization
secondary to age-related macular degeneration (AMD) and
in the treatment of DME [26–34].
A recetly published multi-center study, funded by the
National Eye Institute and conducted through the Diabetic
Retinopathy Clinical Research Network, studied 840 eyes of
693 subjects with DME involving the fovea and with visual
acuity of 20/40 to 20/320. This 2-year study demonstrated that
focal/grid photocoagulation is more effective and has fewer
side effects than 1-mg or 4-mg doses of preservative-free
intravitreal triamcinolone for most patients with DME who
have characteristics similar to the cohort in this clinical trial.
Though the evidence currently supports focal/grid photoco-
agulation as the most effective treatment, the authors
commented that combining laser therapy with corticosteroids
might prove useful [35]. Therefore, the same may be true for
anti-VEGF therapies, and combination therapies should be
considered. However, some unresolved issues such as the
ideal regimen, duration of treatment, potential of combina-
tion treatments, and safety concerns with long-term VEGF
inhibition deserve further investigation.
The purpose of this retrospective study was to report the
12-month anatomic and ETDRS best-corrected visual acuity
(BCVA) response after primary intravitreal bevacizumab
(1.25 mg or 2.5 mg) in patients with DDME. This report
comprises a series of 101 eyes, including 38 eyes with
DDME from a previously reported series with longer follow
up [34]. In addition, a comparison of the two different doses
of intravitreal bevacizumab (IVB) utilized was made.
Patients and methods
Approval was obtained from each participating center’s
Institutional Ethics Committee, and informed consent was
obtained for this study. In addition, this study has been
performed in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki. This was a
multicenter retrospective study of eyes with DDME treated
with off-label intravitreal bevacizumab (Avastin) between
September 2005 and February 2007 at 8 institutions in
Venezuela, Mexico, Costa Rica, Puerto Rico, Brazil,
Colombia and Argentina. We reviewed the clinical records
of 82 consecutive patients (101 eyes) with DDME treated
with at least one intravitreal injection of 1.25 mg or 2.5 mg of
bevacizumab. The dose of 1.25 mg or a dose of 2.5 mg to be
used to treat a patient was determined at the discretion of the
treating physician. If a patient received one of the doses at
baseline, the same dose was delivered throughout the study.
The off-label use of the drug and its potential risks and
benefits were discussed extensively with all patients.
The DDME had to show evidence of diffuse retinal
thickening involving the center of the macula on biomicro-
scopy, and diffuse fluorescein leakage involving the center of
the macula on fluorescein angiography (FA). In addition, a
significant reduction in the reflectivity of the outer retinal
layers, and/or subretinal fluid collection on by optical
coherence tomography (OCT) (Stratus OCT, Carl Zeiss,
Dublin, CA, USA) should be present. Exclusion criteria
included patients (eyes) with DDME previously treated with
laser photocoagulation or intravitreal triamcinolone, macular
ischemia, intraocular inflammation, uncontrolled intraocular
pressure (IOP), cataract surgery within the past 6 months, or
a prior history of vitreoretinal surgery, and the presence of an
epiretinal membrane or vitreomacular traction syndrome.
Although not a formal exclusion criteria, patients with a
history of uncontrolled hypertension and recent thomboem-
bolic events were not usually injected with bevacizumab, but
this decision was at the discretion of the treating physician.
Each patient underwent best-corrected visual acuity
(BCVA) measurement with ETDRS charts, and ophthalmic
examination including slit-lamp biomicroscopy. Baseline
central retinal characteristics were analyzed by OCT utilizing
six diagonal slow 6-mm radial line scans, with software
version 4.0, through a dilated pupil performed by a retina
specialist. The retinal thickness of the 1-mm central retina was
obtained using the macular thickness map for our calculations.
The scans were reviewed, and manual caliper-assisted
measurements were used in case of delineation errors.
A 0.18-ml aliquot of commercially available bevacizu-
mab was prepared for each patient, and placed in a
tuberculin syringe using aseptic techniques. After the eye
had been prepared in a standard fashion using 5%
povidone/iodine, an eyelid speculum was used to stabilize
the eyelids, and the injection of 1.25 mg (0.05 ml) or
2.5 mg (0.1 ml) of bevacizumab was performed 3.5 to
4 mm posterior to the limbus, through the inferotemporal
pars plana with a 30-gauge needle under topical anesthesia
or subconjunctival lidocaine. After the injection, IOP and
retinal artery perfusion were checked, and patients were
instructed to administer topical antibiotics for 7 days.
Patients were examined at 1 and 2 weeks and 1 month
after the first injection, and monthly thereafter. One, 3, 6 and
12 months after the initial injection, ophthalmic examination
included OCTand FA. However, OCTwas performed earlier
(weeks 1 and 2) in some patients, according to the
investigator’s decision and preference. In addition, FA was
done at the discretion of the examiner and not at every post
injection evaluation, usually every 6 weeks.
Patients were included in this consecutive series only if
there was a minimum follow-up of 12 months. Patients
received reinjections when there was a recurrence of DDME.
Recurrence was defined as a decrease of BCVA associated
with an increase of intraretinal fluid due to macular edema on
OCT (≥ 50 µ in central macular thickness) and/or FA, after
complete or partial resolution in previous follow-up visits.
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Patients’ ETDRS BCVAs were transferred from their
records and converted to a logarithm of the minimum angle
of resolution (logMAR) scale for analysis. Repeated-
measures analysis of variance (ANOVA) was used to
compare mean values to analyze mean retinal thickness
and logMAR visual acuity (VA) statistically. An increase or
decrease in BCVAwas considered to have occurred if there
was a change of 2 ETDRS lines. Main outcome measures
included changes in BCVA, OCT, and FA. Interval data
were analyzed at 1-, 3-, 6 and 12-month follow-up time
points. A p value<0.05 was considered to be significant.
Results
We reviewed the clinical records of 82 consecutive patients
(101 eyes) with DDME. All patients had a minimum
follow-up of 12 months. Sixty-five patients (79.3%) were
Hispanic, and 12 (14.6%) were Caucasian. Our patients had
a mean age of 59.7±9.3 years, and 53.7% were female (38
men, 44 women). Patients had a mean follow-up of 57.6±
8.4 weeks (range: 54–68 weeks). Fifty-three cases (52.4%)
had quiescent PDR. All of these 53 cases had had prior
scatter panretinal photocoagulation (PRP) at least 6 months
before undergoing bevacizumab intravitreal injections. All
the eyes had DDME diagnosed by biomicroscopy slit-lamp
examination, FA, and OCT at baseline.
Within 1 month after the initial bevacizumab injection,
improvements in BCVA and central retinal thickness measure-
ments were observed, and these significant changes continued
throughout the 12-month follow-up. At 1 month, BCVA
improved from logMAR=0.87 to 0.67, a difference that was
statistically significant (p=0.0001). This improvement in
BCVA was maintained throughout the 3-, 6-, and 12-month
follow-up (Fig. 1). At the 6-month follow-up time point, we
noticed a worsening of vision with a mean BCVA of 20/115,
logMAR=0.77, still a difference statistically significant from
BCVA at baseline. In addition, the mean final BCVA at
12 months was 20/96, logMAR=0.68 (p<0.001) a statisti-
cally significant difference from baseline BCVA. Final
BCVA analysis by sub-groups demonstrated that 33 eyes
(32.7%) remained stable, 50 eyes (49.5%) improved 2 or
more ETDRS lines of BCVA, and 18 eyes (17.8%)
decreased 2 or more ETDRS lines of BCVA (Table 1).
Optical coherence tomography results were available for
all 101 eyes at 1-, 3-, 6- and 12-month follow-ups. At
1 month, the mean 1-mm central macular thickness (CMT)
measurements decreased from 401.8 µm±180 µm to
290.2 µm±119.6 µm (p<0.001), and this overall improve-
ment continued throughout the 12-month follow-up
(Fig. 2). At 3-, 6- and 12-month follow-ups, mean CMT
were 309.5.1 µm±147.3 µm, 309.3 µm±123.6 µm, and
281.6 µm±105.0 µm respectively, which were significantly
different from baseline (p<0.001).
We wished to compare the response to treatment
between patients with PDR and previous PRP and those
with nonproliferative diabetic retinopathy and DDME, to
see if there was any difference. However, when we ran the
repeated measures ANOVA to compare mean values to
statistically analyze mean retinal thickness and logMAR
Fig. 1 Changes in best-corrected visual acuity (BCVA) after intra-
vitreal bevacizumab. BCVA improved at 1 month from logMAR=
0.87 to logMAR=0.67, a difference that was statistically significant
(p<0.001); this level of BCVA was maintained throughout 3, 6, and
12 months
Table 1 BCVA analysis by sub-groups (101 eyes)*
Dose 1st month 3rd month 6th month 12 month
1.25 mg 2.5 mg 1.25 mg 2.5 mg 1.25 mg 2.5 mg 1.25 mg 2.5 mg
# eyes (%) # eyes (%) # eyes (%) # eyes (%) # eyes (%) # eyes (%) # eyes (%) # eyes (%)
Decreased 2 or more
ETDRS lines of BCVA
0 (0%) 5 (9.4%) 0(0%) 6 (11.3%) 2 (4.2%) 13 (24.5%) 3 (6.3%) 15 (28.3%)
Remained stable 11 (23%) 21 (39.6%) 15 (31.2%) 19 (35.8%) 16 (33.3%) 15 (28.3%) 17 (35.4%) 16 (30.1%)
Improved 2 or more
ETDRS lines of BCVA
37 (77%) 27 (51%) 33 (68.8%) 28 (52.8%) 30 (62.5%) 25 (47.1%) 28 (58.3%) 22 (41.5%)
* BCVA = best-corrected visual acuity, ETDRS = Early Treatment Diabetic Retinopathy Study.
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VA, adjusting for the grade of diabetic retinopathy as a
covariate, we did not find statistical significance (p=0.565
for BCVA and p=0.446 for CMT).
All eyes received an intravitreal injection at the initial
visit; however, recurrences were re-treated at the discretion
of the treating physician. A total of 244 IVB injections were
performed. The mean number of IVB injections per eye
was three (range: one to six injections) at a mean interval of
14.1±10.5 weeks. Thirty-seven of 101 eyes (36.6%)
received one injection, 16.8% of eyes (17/101) received
two injections, 29.7% of eyes (30/101) received three
injections, 5% of eyes (5/101) received four injections,
8.9% of eyes (9/101) received five injections, and 3% of
eyes (3/101) received six injections (Table 2).
Forty-eight cases (47.5%) were treated with an intra-
vitreal injection of 1.25 mg of bevacizumab and fifty-three
cases (52.5%) with at a dose of 2.5 mg of bevacizumab.
Sixty-four eyes (63.4.%) needed a second injection at a
mean interval of 15.7±11.9 weeks (range: 4 to 64 weeks)
between injections, 47 eyes (46.5%) required a third
injection at a mean interval of 14.8±7.9 weeks (range: 4 to
34 weeks) between injections, 17 eyes (16.8%) required a
fourth injection at a mean interval of 11.2±6.8 weeks (range:
4 to 20 weeks) between injections, 12 eyes (11.9%) required
a fifth injection at a mean interval of 20±10.3 weeks (range:
8 to 26 weeks) between injections, and three eyes (3.0%)
required a sixth injection mean at a mean interval of 8±
6 weeks (range: 4 to 8 weeks) between injections.
Adverse events included transient arterial hypertension
in one patient (1.2%), transient increased intraocular
pressure in one eye (1.0%), and tractional retinal detach-
ment in one eye (1.0%). At 12 months, no systemic adverse
events such as thromboembolic events (cerebrovascular
accidents, transient ischemic attacks, myocardial infarc-
tions, or peripheral vascular disease) were reported.
Analysis of visual acuity and central macular thickness
by doses of 1.25 mg and 2.5 mg
We did not observe statistically significant differences in
changes of BCVA and between doses of 1.25 and 2.5 mg of
intravitreal bevacizumab (Table 3) (Fig. 3). In the 1.25 mg
group, at 1 month BCVA improved from 20/190, logMAR=
0.97 to 20/85, logMAR 0.62, a difference that was
statistically significant (p=0.0001). This improvement was
maintained throughout the 3-, 6-, and 12-month follow-up.
At the 6-month follow-up we noticed worsening of vision,
with a mean BCVA of 20/112, logMAR=0.70 (p<0.001), a
difference that was still statistically significant from BCVA at
baseline. However, BCVA improved again at 12 months
with mean final BCVA of 20/76, logMAR=0.58 (p<0.001),
a statistically significant difference from baseline BCVA
(Fig. 3). Similar BCVA changes were observed in the
2.5 mg group; at 1 month, BCVA improved from 20/120,
logMAR=0.76 to 20/76, logMAR=0.58, a difference that
was statistically significant (p=0.0001). This improve-
ment in BCVA was maintained throughout the 3-, 6-, and
12-month follow-up. At the 6-month follow-up we noticed
worsening of vision with a mean BCVA of 20/106,
Fig. 2 Changes in macular thickness with optical coherence
tomography (OCT) during follow-up after intravitreal bevacizumab.
At 1 month, the mean 1-mm central macular thickness (CMT)
measurements decreased from 401.8 µm±180 µm to 290.2 µm±
119.6 µm (p<0.001), and this overall improvement continued
throughout the 12-month follow-up
Table 2 Injections analysis by sub-groups 1.25 mg (48 eyes) and




Sub-group 1.25 Sub-group 2.5
Frequency Percent Frequency Percent
No re-injection 25 52.1% 12 22.6%
Two injections 5 10.4% 12 22.6%
Three injections 7 14.6% 23 43.4%
Four injections 1 2.1% 4 7.6%
Five injections 7 14.6% 2 3.8%
Six injections 3 6.2% 0 0%
Table 3 BCVA in eyes injected with doses of 1.25 and 2.5 mg of IVB
at 12-month follow-up*
Sub-group 1.25 mg Sub-group 2.5 mg
BCVA LogMar BCVA LogMar
Baseline 20/190 0.97 20/120 0.76
1 month 20/85 0.62 20/76 0.58
3 months 20/90 0.65 20/80 0.6
6 months 20/112 0.74 20/106 0.72
12 months 20/76 0.58 20/85 0.62
* BCVA= best-corrected visual acuity, IVB = intravitreal bevacizumab.
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logMAR=0.72 (p<0.001), a difference still statistically
significant from BCVA at baseline. However, BCVA
improved again at 12 months, with mean final BCVA of
20/85, logMAR=0.62 (p<0.001), a statistically signifi-
cant difference from baseline BCVA (Fig. 3). In addition,
in the 1.25 mg group, at 1 month there was an average
gain of 3.2±2.9 lines of BCVA, at 3 months 2.7±2.6 lines
of BCVA, at 6 months 2.1±3.4 lines of BCVA, and 2.9±
3.6 lines of BCVA at 12 months (p<0.001). In the 2.5 mg
group, at 1 month eyes gained 2.0±4.0 lines of BCVA,
1.9±2.9 lines of BCVA at 3 months, 0.6±5.5 lines of
BCVA at 6 months, and 0.7±5.5 lines of BCVA at
12 months (p<0.01).
We wondered about the reason for a temporary decrease
of BCVA at the 6-month time point, and if the number of
reinjections had any influence on our results. When we
analyzed our data comparing eyes that had one or two
injections against those eyes that had three or more
injections, there was a significant drop in BCVA at 6 months
in the “one or two injections” group, and not in the “three
or more injections” group (Fig. 4).
We did not observe statistically significant differences in
macular thickness with OCT between doses of 1.25 and
2.5 mg of intravitreal bevacizumab (Fig. 5). In the 1.25 mg
group, the mean CMT decreased from 419.1±201.1 µm at
baseline to 295.11±91.5 µm at 1 month, 302.1±124.2 µm
at 3 months, 313.4.1±96.3 µm at 6 months, and 268.2±
95.5 µm at 12 months (p<0.001). In the 2.5 mg group, the
mean CMT decreased from 387.7±162 µm at baseline to
287±136 µm at 1 month, 316.9±169.8 µm at 3 months,
306.7±139.6 µm at 6 months, and 295.5±113.9 µm at
12 months (p<0.001).
Fig. 3 Changes in best-corrected visual acuity (BCVA) between
doses of 1.25 and 2.5 mg of intravitreal bevacizumab. In the 1.25 mg
group at 1 month, BCVA improved from logMAR=0.97 to logMAR
0.58, a difference that was statistically significant (p=0.0001). This
improvement in BCVA was maintained throughout the 3-, 6-, and
12-month follow. At the 6-month follow-up a worsening of vision was
noted, with a mean logMAR = 0.74 (p<0.001), a difference
statistically significant from BCVA at baseline. Similar BCVA
changes was observed in the 2.5 mg group; at 1 month BCVA
improved from logMAR=0.76 to logMAR=0.62, a difference that
was statistically significant (p=0.0001). This improvement in BCVA
was maintained throughout the 3-, 6-, and 12-month follow-up. At the
6-month follow-up a worsening of vision was noted, with a mean
logMAR=0.72 (p<0.001), a difference statistically significant from
BCVA at baseline
Fig. 4 When we analyzed our data comparing eyes that had one or
two injections against those eyes that had three or more injections,
there was a significant drop in best-corrected visual acuity (BCVA) at
6 months in the “one or two injections” group, and not in the “three or
more injections” group. This suggests the need for at least three
injections a year to maintain the BCVA results
Fig. 5 Changes in macular thickness with optical coherence tomog-
raphy (OCT) during follow-up between doses of 1.25 and 2.5 mg of
intravitreal bevacizumab. In the 1.25 mg group, the mean central
macular thickness (CMT) decreased from 419.1 µm to 295.11±
91.5 µm at 1 month, 302.1 µm at 3 months, 313.4 µm at 6 months,
and 268.2 µm at 12 months (p<0.001). In the 2.5 mg group, the mean
CMT decreased from 387.7 µm at baseline to 287 µm at 1 month,
316.9 µm at 3 months, 306.7 µm at 6 months, and 295.5 µm at
12 months (p<0.001)
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Discussion
Diabetic macular edema is a manifestation of diabetic
retinopathy that produces loss of central vision. Although
several treatment modalities are under investigation, the
only demonstrated means to reduce the risk of vision loss
from DME are: (1) laser photocoagulation, as demonstrated
by the ETDRS [4], (2) intensive glycemic control, as
demonstrated by the Diabetes Control and Complications
Trial and the United Kingdom Prospective Diabetes Study,
and (3) blood pressure control, as demonstrated by the
United Kingdom Prospective Diabetes Study [36, 37].
Taking into account that most eyes with DDME that are
treated with laser photocoagulation do not have an
improvement in VA [8], there has been an interest in other
treatment modalities such as pharmacologic therapy with
oral protein kinase C inhibitors and the use of intravitreal
corticosteroids [38, 39]. The use of antibodies targeted at
VEGF is another treatment modality that has generated
considerable interest and is being investigated [9–17].
We report on 101 consecutive eyes with DDME treated
with intravitreal bevacizumab, which resulted in both
anatomic and functional improvement. Interestingly, the
reduction of retinal thickness and improvement of BCVA
were detected within the first 4 weeks after the injection in
most of the patients. In addition, both doses (1.25 and
2.5 mg) were associated with improvement of BCVA and a
greater reduction in CMT, and no differences between the
groups were found. Ocular tolerance of the two different
doses of IVB was demonstrated, and no serious systemic
adverse events were noticed during the study.
There are several studies in the literature on the
intravitreal administration of antibodies against VEGF for
DDME. However, none of them deal with anti-VEGF as a
primary treatment with a 12-month follow-up. Haritoglou et
al. reported that intravitreal ranibizumab has the potential to
maintain or improve BCVA and reduce retinal thickness in
patients with DDME not responding to previous treatments
such as photocoagulation, intravitreal injection of triamcin-
olone, or vitrectomy. Their follow-up period was too short
(6 weeks) to provide specific treatment recommendations
[16]. Kumar and Sinha reported results of 20 eyes with
DDME treated with IVB at dose of 1.25 mg that had not
responded to previous photocoagulation. Their follow-up
period was 6 months. They concluded that IVB resulted in
a significant decrease in macular thickness and improve-
ment in VA at 3 months, but the effect was somewhat
blunted, though still statistically significant, at the end of
6 months [40]. Our study compares favorably with these
reports, and confirms their findings with longer follow-up,
and a larger number of patients. Furthermore, at the 6-
month follow-up time point we noticed a small worsening
of vision, as described by Kumar and Sinha [40]. When we
analyzed our data comparing eyes that had one or two
injections against those eyes that had three or more
injections, there was a significant drop in BCVA at 6 months
in the “one or two injections” group, and not in the “three
or more injections” group. This suggests the need for at
least three injections a year to maintain the BCVA results.
Sixty-four eyes (63.4.%) needed at least a second injection
at a mean of 15.7±11.9 weeks (range: 4 to 64 weeks).
A recent study has suggested that repeated intravitreal
injections of bevacizumab in exudative AMD may be
associated with decreased bioefficacy. This phenomenon
has been termed tachyphylaxis [41]. Our study was not
designed to investigate whether repeated intravitreal injec-
tion of bevacizumab can induce a decrease in biological
response in DDME. However, we found no statiscally
significant difference in OCT CMT after each IVT
bevacizumab injection.
The two doses of bevacizumab evaluated in this study
were 1.25 mg (which is the one that has been used most
commonly in clinical practice) and 2.5 mg, which also has
been used, though less commonly. The results of our
retrospective study demonstrated the efficacy of 1.25 mg or
2.5 mg of IVB as primary treatment of DDME, as 49.5% of
eyes showed anatomical and functional improvement. In
addition, our results suggest a reduced risk of VA loss in
eyes with DDME treated with IVB (82.2% of eyes). We
found that the anatomical and visual benefit of intravitreal
bevacizumab appears and reaches its maximum value
during the first month, and maintains itself over 12 months.
Nevertheless, we did not find statistically significant
differences in duration or anatomical or functional effec-
tiveness between the two doses of bevacizumab evaluated.
Our results indicate that IVB injections may have a
beneficial effect on macular thickness and BCVA in
DDME. Therefore, in the future this new treatment
modality could complement focal/grid laser photocoagula-
tion. Furthermore, focal/grid laser photocoagulation could
be used to consolidate the results obtained with one IVB
injection and decrease the need for reinjections.
Limitations of our study include that it is nonrandom-
ized, uncontrolled, and retrospective, which precludes any
estimation of the long-term efficacy or safety of IVB. In
addition, because no control group is present we cannot rule
out the possibility that some of the improvement in macular
edema might be associated with improvement in systemic
health. It is not uncommon that additional attention is
directed towards improving systemic health when patients
get involved in a clinical trial or new treatment. However,
the results were very promising and suggest the need for
further investigation. Furthermore, we can safely assume
with a 95% confidence that the true rate of ocular
complications in our study was <2.9%, and that the true
rate of systemic complications was <3.6% [42].
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In summary, primary intravitreal bevacizumab at doses
of 1.25 mg or 2.5 mg seems to provide stability and
improvement in BCVA, OCT, and FA in DDME at
12 months. Follow-up is still short; however, the results
are promising. There seems to be no difference in our
results between IVB at doses of 1.25 mg or 2.5 mg.
Therefore, lower doses than 2.5 mg should be preferred. In
addition, our results suggest the need for at least three
injections a year to maintain the BCVA results. Evaluation
in a multicenter randomized controlled clinical trial with
longer follow-up is needed to evaluate the safety and
efficacy of this treatment modality.
Appendix
The following investigators belong to the Pan-American
Collaborative Retina Study Group (PACORES):
The Pan-American Collaborative Retina Study Group
(PACORES): L. Wu (PI), T. Evans, Instituto de Cirugia
Ocular, San Jose, Costa Rica; J.F. Arevalo (PI), J.G. Sanchez,
R.A. Garcia-Amaris, D.G. Zeballos, J.V. Espinoza, Clinica
Oftalmologica Centro Caracas and the Arevalo-Coutinho
Foundation for Research in Ophthalmology, Caracas,
Venezuela; M. Farah (PI), M. Maia, F.B. Aggio, Universidade
Federal de São Paulo - Departamento de Oftalmologia -
Instituto da Visão - Sao Paulo, Brazil; H. Quiroz-Mercado
(PI), J. Fromow-Guerra, V. Morales-Canton, J.L. Guerrero-
Naranjo, Asociación para Evitar la Ceguera en México,
Mexico City, Mexico; F.J. Rodriguez (PI), R. Infante, S.
Flores, D. Medina, Fundacion Oftalmologica Nacional,
Universidad del Rosario, Bogota, Colombia; M.H.
Berrocal (PI), V. Cruz-Villegas, University of Puerto Rico,
San Juan, Puerto Rico; F. Graue-Wiechers (PI), D. Lozano-
Rechy, V. Robledo, J.L. Rodriguez-Loaiza, Fundacion
Conde Valenciana, Mexico City, Mexico; J.A. Roca (PI), G.
Reategui, Clínica Ricardo Palma, Lima, Peru; M. J. Saravia
(PI), M. Martinez-Cartier, Hospital Universitario Austral,
Buenos Aires, Argentina; M. Avila (PI), Universidade Federal
de Goiás- Departamento de Oftalmologia - Goiânia, Brazil;
RA Costa (PI), J. Cardillo, Hospital de Olhos de Araraquara,
and the Universidade de São Paulo, Sao Paulo, Brazil; J.
Verdaguer T. (PI), C. Carpentier, J.I. Verdaguer D., L.
Filsecker, G. Sepúlveda, Fundacion Oftalmologica Los
Andes, Santiago de Chile, Chile.
PI = principal investigator.
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Chapter 4: Intravitreal Bevacizumab for Diabetic Macular Edema at 24 months of follow up 
Arevalo JF, Sanchez JG, Wu L, Maia M, Alezzandrini AA, Brito M, Bonafonte S, Lujan S, Diaz-
Llopis M, Restrepo N, Rodríguez FJ, Udaondo-Mirete P; Pan-American Collaborative Retina Study 
Group. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American 
Collaborative Retina Study Group at 24 months. Ophthalmology. 2009 Aug;116(8):1488-97, 1497.e1. 
doi: 10.1016/j.ophtha.2009.03.016. Epub 2009 Jul 9. 
DOI: 10.1016/j.ophtha.2009.03.016 
Hypothesis 1: Intravitreal bevacizumab (IVB) may have a beneficial anatomic (Optical Coherence 
Tomography [OCT]), and functional (visual acuity [VA]) effect on eyes with diffuse diabetic 
macular edema at 24 months of follow up. In addition, the lower dose (1.25 mg) may be as effective 
or more than the higher dose (2.5 mg) of IVB. 
PURPOSE: To report the 24-month anatomic and Early 
Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) response 
after primary intravitreal bevacizumab (Avastin; Genentech, Inc., San Francisco, CA; 1.25 or 2.5 
mg) in patients with diffuse diabetic macular edema (DDME). In addition, a comparison of the 2 
different doses of intravitreal bevacizumab (IVB) used is presented. 
DESIGN: Retrospective, multicenter, interventional, comparative case series. 
PARTICIPANTS: The clinical records of 115 consecutive patients (139 eyes) with DDME at 11 
centers from 8 countries were reviewed. 
METHODS: Patients were treated with at least 1 intravitreal injection of 1.25 or 2.5 mg 
of bevacizumab. All patients were followed up for 24 months. Patients underwent ETDRS BCVA 
testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein 
angiography (FA) at the baseline, 1-, 3-, 6-, 12-, and 24-month visits. 
MAIN OUTCOME MEASURES: Changes in BCVA and OCT results. 
RESULTS: The mean age of the patients was 59.4+/-11.1 years. The mean number of IVB 
injections per eye was 5.8 (range, 1-15 injections). In the 1.25-mg group at 1 month, BCVA 
improved from 20/150 (0.88 logarithm of the minimum angle of resolution [logMAR] units) to 
20/107, 0.76 logMAR units (P<0.0001). The mean BCVA at 24 months was 20/75 (0.57 logMAR 
units; P<0.0001). Similar BCVA changes were observed in the 2.5-mg group: at 1 month, BCVA 
improved from 20/168 (0.92 logMAR units) to 20/118 (0.78 logMAR units; P = 0.02). The mean 
BCVA at 24 months was 20/114 (0.76 logMAR units; P<0.0001). In the 1.25-mg group, the mean 
central macular thickness (CMT) decreased from 466.5+/-145.2 microm at baseline to 332.2+/-
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129.6 microm at 1 month and 286.6+/-81.5 microm at 24 months (P<0.0001). Similar results were 
obtained in the 2.5-mg group. 
CONCLUSIONS: Primary IVB at doses of 1.25 to 2.5 mg seem to provide stability or improvement 
in BCVA, OCT, and FA in DDME at 24months. The results show no evident difference between IVB 
at doses of 1.25 or 2.5 mg. 
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Primary Intravitreal Bevacizumab for
Diffuse Diabetic Macular Edema
The Pan-American Collaborative Retina Study Group
at 24 Months
J. Fernando Arevalo, MD, FACS,1 Juan G. Sanchez, MD,2 Lihteh Wu, MD,3 Mauricio Maia, MD,4
Arturo A. Alezzandrini, MD,5 Miguel Brito, MD,6 Sergio Bonafonte, MD,7 Silvio Lujan, MD,8
Manuel Diaz-Llopis, MD,9 Natalia Restrepo, MD,2 Francisco J. Rodríguez, MD,10
Patricia Udaondo-Mirete, MD,9 for the Pan-American Collaborative Retina Study Group (PACORES)
Purpose: To report the 24-month anatomic and Early Treatment Diabetic Retinopathy Study (ETDRS)
best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin; Genentech, Inc.,
San Francisco, CA; 1.25 or 2.5 mg) in patients with diffuse diabetic macular edema (DDME). In addition, a
comparison of the 2 different doses of intravitreal bevacizumab (IVB) used is presented.
Design: Retrospective, multicenter, interventional, comparative case series.
Participants: The clinical records of 115 consecutive patients (139 eyes) with DDME at 11 centers from 8
countries were reviewed.
Methods: Patients were treated with at least 1 intravitreal injection of 1.25 or 2.5 mg of bevacizumab. All
patients were followed up for 24 months. Patients underwent ETDRS BCVA testing, ophthalmoscopic exami-
nation, optical coherence tomography (OCT), and fluorescein angiography (FA) at the baseline, 1-, 3-, 6-, 12-, and
24-month visits.
Main Outcome Measures: Changes in BCVA and OCT results.
Results: The mean age of the patients was 59.4!11.1 years. The mean number of IVB injections per eye was
5.8 (range, 1–15 injections). In the 1.25-mg group at 1 month, BCVA improved from 20/150 (0.88 logarithm of the
minimum angle of resolution [logMAR] units) to 20/107, 0.76 logMAR units (P"0.0001). The mean BCVA at 24
months was 20/75 (0.57 logMAR units; P"0.0001). Similar BCVA changes were observed in the 2.5-mg group:
at 1 month, BCVA improved from 20/168 (0.92 logMAR units) to 20/118 (0.78 logMAR units; P# 0.02). The mean
BCVA at 24 months was 20/114 (0.76 logMAR units; P"0.0001). In the 1.25-mg group, the mean central macular
thickness (CMT) decreased from 466.5!145.2 !m at baseline to 332.2!129.6 !m at 1 month and 286.6!
81.5 !m at 24 months (P"0.0001). Similar results were obtained in the 2.5-mg group.
Conclusions: Primary IVB at doses of 1.25 to 2.5 mg seem to provide stability or improvement in BCVA, OCT,
and FA in DDME at 24 months. The results show no evident difference between IVB at doses of 1.25 or 2.5 mg.
Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed
in this article. Ophthalmology 2009;116:1488–1497 © 2009 by the American Academy of Ophthalmology.
Group members of PACORES listed in Appendix 1 (available at http://aaojournal.org).
Diabetic retinopathy remains the major threat to sight in the
working-age population in the developed world. Further-
more, it is increasing as a major cause of blindness in other
parts of the world, especially developing countries.1 Dia-
betic macular edema (DME) is a manifestation of diabetic
retinopathy that produces loss of central vision and is now
the most common cause of moderate vision loss in persons
with diabetes.2 Macular edema within 1 disc diameter of the
fovea is present in 9% of the diabetic population.3 Although
visual loss secondary to proliferative changes is more com-
mon in patients with type 1 diabetes, visual loss in patients
with type 2 diabetes more commonly is the result of macular
edema.4 Diabetic macular edema can occur at any stage of
diabetic retinopathy and is caused by excessive vascular
permeability resulting in the leakage of fluid and plasma
constituents, such as lipoproteins, and a secondary thicken-
ing and distortion of the central retina, together with stretch-
ing of neurons and an initial reversible loss of vision.
Because in the course of time these disturbed neurons can
die off, permanent sight reduction also can result.2
There is good evidence that focal laser treatment pre-
serves vision in eyes with DME. The Early Treatment
Diabetic Retinopathy Study (ETDRS)5 randomized 1490
eyes with DME to receive focal laser treatment or observa-
1488 © 2009 by the American Academy of Ophthalmology ISSN 0161-6420/09/$–see front matter
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tion. At 3 years, treatment significantly reduced moderate
visual loss as compared with observation,5 with the greatest
benefits in eyes with clinically significant DME.6 Although
the ETDRS5 demonstrated that immediate focal photocoag-
ulation reduced moderate visual loss by 50% (from 24% to
12%, 3 years after initiation of treatment), 12% of treated
eyes still lost 15 ETDRS letters or more at the 3-year
follow-up. Approximately 40% of treated eyes that had
retinal thickening involving the center of the macula at
baseline still had thickening involving the center at 12
months, as did 25% of treated eyes at 36 months. Further-
more, only 3% of laser-treated eyes experienced a gain of 3
lines of vision or more. This suggests that a distinct sub-
group of eyes exists with DME resistant to conventional
laser photocoagulation. In addition, some reports have in-
dicated that diffuse diabetic macular edema (DDME) is
refractory to macular photocoagulation.6–8 Lee and Olk9
demonstrated that with modified grid laser macular photo-
coagulation, visual acuity was stabilized in 60.9%, de-
creased in 24.6%, and increased in only 14.5% of eyes with
DDME. The low frequency of improvement, gain of signif-
icant vision ("3 lines), or both, after focal laser photoco-
agulation for DME has prompted interest in alternative or
adjunct treatments, such as intravitreal triamcinolone ace-
tonide,10–14 pars plana vitrectomy,15 and antibodies directed
against vascular endothelial growth factor (VEGF).16–19
Vascular endothelial growth factor has been shown to be
an endothelial cell-specific mitogen and an angiogenic in-
ducer in a variety of in vitro and in vivo models.20 Vascular
endothelial growth factor, also known as vascular perme-
ability factor, has been demonstrated to increase retinal
vessel permeability by increasing the phosphorylation of
tight junction proteins. Also, hypoxia has been shown to be
a major inducer of VEGF gene transcription.20 All variants
of VEGF (particularly VEGF-A) have been implicated in
the occurrence of increased vascular permeability by affect-
ing endothelial tight-junction proteins in ocular vascular
diseases such as DME.21 It has been shown that VEGF-A
levels are considerably higher in DME patients with exten-
sive leakage in the macular region than in patients with
minimal leakage.22,23 Recent work has found elevated
levels of VEGF in the ocular fluids of patients with pro-
liferative diabetic retinopathy (PDR).24 –26 These studies
also found that the growth of new vessels from the retina
or optic nerve occurred as a result of VEGF release into
the vitreous cavity as a response to ischemia.24 –26 Fur-
thermore, injection of VEGF into normal primate eyes
induces the same pathologic processes seen in diabetic
retinopathy, including microaneurysm formation and in-
creased vascular permeability.27,28
Human VEGF-A is found in at least 9 isoforms. Cur-
rently used anti-VEGF drugs are pegaptanib sodium
(Macugen; OSI Eyetech Pharmaceuticals, Melville, NY),
ranibizumab (Lucentis; Genentech, Inc., San Francisco,
CA), and bevacizumab (Avastin; Genentech, Inc.). Bev-
acizumab is a complete full-length humanized antibody
that binds to all subtypes of VEGF and is used success-
fully in tumor therapy as a systemic drug.29 Studies have
demonstrated the usefulness of intravitreal bevacizumab
(IVB) with promising effects in the reduction of macular
edema secondary to central retinal vein occlusion, vascular
permeability, fibrovascular proliferation in retinal neovascular-
ization secondary to PDR, rubeosis iridis, retinopathy of
prematurity, choroidal neovascularization secondary to
age-related macular degeneration and in the treatment of
DME.30–43 The amount of human retinal penetration for a
complete full-length anti-VEGF antibody is not known at
present. However, full-thickness retinal penetration of IVB
was observed in an animal model.44,45 Additionally, IVB
does not seem to be toxic to the albino rabbit retina at a
concentration of up to 2.5 mg.46 The use of anti-VEGF
drugs is becoming increasingly prevalent; however, some
unresolved issues such as the ideal regimen or dose, dura-
tion of treatment, potential of combination treatments, and
safety concerns with long-term VEGF inhibition deserve
further investigations.
The purpose of this retrospective study was to report the
24-month anatomic and ETDRS best-corrected visual acuity
(BCVA) response after primary IVB (1.25 or 2.5 mg) in
patients with DDME. This report comprises a series of 139
eyes, including 38 eyes with DDME from a previously
reported series43 with longer follow-up. In addition, a com-
parison of the 2 different doses of IVB used was carried out.
Patients and Methods
A multicenter, retrospective study was conducted of eyes with
DDME treated with off-label IVB between September 2005 and
July 2006 at 11 institutions in Venezuela, Colombia, Costa Rica,
Brazil, Argentina, Spain, Peru, and Mexico. The clinical records
were reviewed of 115 consecutive patients (139 eyes) with DDME
treated with at least 1 intravitreal injection of 1.25 or 2.5 mg
bevacizumab. All patients were followed up for 24 months.
Whether a dose of either 1.25 or 2.5 mg was to be used to treat a
patient was determined at the discretion of the treating physician.
If a patient received one of the doses at baseline, the same dose
was delivered throughout the study. Approval was obtained from
each participating center’s institutional ethics committee, and in-
formed consent was obtained for this study. In addition, this study
Figure 1. Graph showing changes in best-corrected visual acuity (BCVA)
after intravitreal bevacizumab. The BCVA improved at 1 month from 0.90
to 0.76 logarithm of the minimum angle of resolution (logMAR) units, a
difference that was statistically significant (P"0.001). This level of BCVA
was maintained throughout 3, 6, 12, and 24 months of follow-up. CI #
confidence interval.
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has been performed in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki. The off-label use of the
drug and its potential risks and benefits were discussed extensively
with all patients.
The definition of DDME required evidence of diffuse retinal
thickening, hard exudates (without a circinate ring pattern) involv-
ing the center of the macula (clinically significant DME as defined
by the ETDRS on slit-lamp biomicroscopic examination), or both,
and diffuse fluorescein leakage involving the center of the macula
on fluorescein angiography (FA) with less than 33% of leakage
associated with microaneurysms.47 In addition, a significant reduc-
tion in the reflectivity (cysts) of the outer retinal layers, subretinal
fluid collection by optical coherence tomography (OCT; Stratus
OCT; Carl Zeiss, Dublin, CA), or both, should be present.48
Exclusion criteria included patients (eyes) with DDME previously
treated with laser photocoagulation or intravitreal triamcinolone,
macular ischemia, intraocular inflammation, uncontrolled intraoc-
ular pressure, cataract surgery within the past 6 months or a prior
history of vitreoretinal surgery, and the presence of an epiretinal
membrane or vitreomacular traction syndrome. Although not a
formal exclusion criterion, patients with a history of uncontrolled
hypertension and recent thromboembolic events usually were not
injected with bevacizumab, but this decision was left at the dis-
cretion of the treating physician.
Each patient underwent BCVA measurement with ETDRS
charts and ophthalmic examination, including slit-lamp biomicros-
copy. Baseline central retinal characteristics were analyzed by
OCT using 6 diagonal slow 6-mm radial line scans, with software
version 4.0, through a dilated pupil performed by a retina special-
ist. The retinal thickness of the 1-mm central retina was obtained
using the macular thickness map for the calculations. The scans
were reviewed and manual caliper-assisted measurements were
used in case of delineation errors.
A 0.18-ml aliquot of commercially available bevacizumab was
prepared for each patient and placed in a tuberculin syringe using
aseptic techniques. After the eye had been prepared in a standard
fashion using 5% povidone–iodine, an eyelid speculum was used
to stabilize the eyelids, and the injection of 1.25 mg (0.05 ml) or
2.5 mg (0.1 ml) bevacizumab was performed 3.5 to 4 mm posterior
to the limbus through the inferotemporal pars plana with a 30-
gauge needle under topical anesthesia or subconjunctival lido-
caine. After the injection, retinal artery perfusion was checked
with the indirect ophthalmoscope (no anterior chamber paracente-
sis was necessary), and patients were instructed to administer
topical antibiotics for 7 days.
Patients were examined at 1 and 2 weeks and 1 month after the
first injection, and monthly thereafter. One, 3, 6, 12, and 24 months
after the initial injection, the ophthalmic examination included
OCT and FA. However, OCT was performed earlier (weeks 1 and
2) in some patients according to the investigator’s decision and
preference. In addition, FA was performed at the discretion of the
examiner and not at every postinjection evaluation, rather, usually
every 6 weeks.
Patients received reinjections whenever there was a recurrence
of DDME. Recurrence was defined as a decrease of BCVA asso-
ciated with an increase of intraretinal fluid because of macular
edema on OCT ("50 !m in central macular thickness [CMT]),
FA, or both, after complete or partial resolution in previous
follow-up visits.
All data were collected in a Microsoft Excel 2003 spreadsheet
(Microsoft Corporation, Unterschleissheim, Germany) and were
analyzed using SPSS software version 13.0 for Windows (SPSS,
Inc., Chicago, IL). For statistical analysis, the Friedman test was
performed and P"0.05 was considered significant. Interval data
were analyzed at the 1-, 3-, 6-, 12-, and 24-month follow-up time
points. Patients’ ETDRS BCVAs were transferred from their
records and were converted to a logarithm of the minimum angle
of resolution (logMAR) scale for analysis. Repeated measures of
the analysis of variance were used to compare mean values to
analyze mean retinal thickness and logMAR visual acuity (VA)
statistically. An increase or decrease in BCVA was considered to
have occurred if there was a change of 2 or more ETDRS lines.
Main outcome measures included changes in BCVA and CMT
measured by OCT.
Results
The clinical records of 115 consecutive patients (139 eyes) with
DDME were reviewed. All patients had a minimum follow-up
of 24 months. Seventy-six (66.1%) patients were Hispanic, 37
Figure 2. Bar graph showing the number of patients losing, maintaining,
or gaining Early Treatment Diabetic Retinopathy Study (ETDRS) best-
corrected visual acuity (BCVA) from baseline to the 24-month follow-up.












1.25 mg 2.5 mg 1.25 mg 2.5 mg 1.25 mg 2.5 mg 1.25 mg 2.5 mg 1.25 mg 2.5 mg
Decreased 2 or more ETDRS
lines of BCVA
6 (8.1) 5 (6.8) 5 (6.8) 4 (6.2) 9 (12.2) 11 (16.9) 3 (4.0) 8 (12.3) 2 (2.7%) 3 (4.6)
Remained stable 29 (39.2) 40 (54.1) 31 (41.9) 36 (55.4) 19 (25.7) 32 (49.2) 21 (28.4) 31 (47.7) 25 (33.8) 37 (56.9)
Improved 2 or more ETDRS
lines of BCVA
39 (52.7) 20 (27.0) 38 (51.3) 25 (38.4) 46 (62.1) 22 (33.8) 50 (67.6) 26 (40.0) 47 (63.5) 25 (38.5)
BCVA # best-corrected visual acuity; ETDRS # Early Treatment Diabetic Retinopathy Study.
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(32.2%) were white, and 2 (1.7%) were black. The patients had a
mean age of 59.4!11.1 years, and 51.3% were male (59 men, 56
women). In the current study, patients had a glycosylated hemo-
globin mean of 9.1!1.86%. Regarding the severity of diabetic
retinopathy (DR), 17 (12.2%) eyes had mild DR, 25 (18%) eyes
had moderate DR, 39 (28.1%) eyes had severe DR, and 58 (41.7%)
eyes had PDR. All these 58 cases with PDR had undergone prior
scatter panretinal photocoagulation at least 6 months before un-
dergoing IVB. All eyes had DDME diagnosed by biomicroscopic
slit-lamp examination, FA, and OCT at baseline.
Within 1 month after the initial bevacizumab injection,
improvements in BCVA and CMT measurements were ob-
served, and these significant changes continued throughout the
24-month follow-up. At 1 month, BCVA improved from 0.90 to
0.76 logMAR units, a difference that was statistically significant
(P # 0.0001). This improvement in BCVA was maintained
throughout the 3-, 6-, 12-, and 24-month follow-up (Fig 1). In
addition, the mean BCVA at 24 months was 20/100 (0.70 logMAR
units; P"0.001), a statistically significant difference from baseline
BCVA. Twenty-four–month BCVA analysis by subgroups dem-
onstrated that 62 (44.6%) eyes remained stable, 72 (51.8%) eyes
Figure 3. Graph showing the changes in macular thickness with optical
coherence tomography (OCT) during follow-up after intravitreal bevaci-
zumab. The foveal thickness improved after 1 month, mean 1-mm central
macular thickness (CMT) measurement decreased from 446.4!154.4 !m
to 333.75!117 !m (P"0.001), and this overall improvement continued
throughout the 24-month follow-up. At 3-, 6-, 12-, and 24-month follow-
up, CMT measurements were 344.7!115.3 !m, 321.7!102.7 !m,
303!89.1 !m, and 279.7!80 !m, respectively, which were significantly
lower than baseline (P"0.001). CI # confidence interval.
™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™3
Figure 4. Sequential optical coherence tomography (OCT) of a 32-year-
old diabetic man with a 3-month history of loss of vision to counting
fingers (CF) in his right eye, in which diabetic macular edema (DME) had
developed. A, Horizontal OCT scan obtained through the fovea revealing
loss of the normal foveal contour, diffuse macular thickening, areas of low
intraretinal reflectivity consistent with intraretinal cysts, and subretinal
fluid (SRF). The retinal map analysis revealed a foveal thickness of 943
!m. The patient underwent an intravitreal injection of bevacizumab at a
dose of 2.5 mg in this eye. B, Optical coherence tomography image
revealing decrease of macular edema and SRF at 1 month after bevaci-
zumab injection. The retinal map analysis indicates a central foveal
thickness of 421 !m. Visual acuity (VA) improved to 10/200. C, Three
months after the injection, OCT scan showing improvement in foveal
thickness (354 !m) and almost complete resolution of the SRF. The VA
improved to 20/200. D, Four months after the first injection, VA dimin-
ished to 20/400 and OCT scan demonstrated the reappearance of macular
edema associated with an increase of intraretinal cysts and SRF. Central
foveal thickness increased to 861 !m. He received a second injection of
intravitreal bevacizumab at a dose of 2.5 mg at this point. E–G, Optical
coherence tomography scans obtained at (E) 5, (F) 6, and (G) 9 months
showing a progressive decrease in macular edema, intraretinal cysts, and
SRF, which were confirmed with decrease of central foveal thickness (723
!m, 436 !m, and 397 !m, respectively). The VA also improved progres-
sively (20/200, 20/160, and 20/125, respectively). H, Twelve months after
the first injection, OCT scan showed resolution of DME, with complete
reabsorption of SRF and restoration of foveal anatomy. Central foveal
thickness decreased to 200 !m, and visual acuity was 20/80. I, Optical
coherence tomography scan obtained at 24 months showing a marked
resolution of DME, with complete reabsorption of SRF and restoration of
foveal anatomic features. Central foveal thickness was 157 !m, and the
visual acuity improved to 20/50.
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improved 2 or more ETDRS lines of BCVA, and 5 (3.6%) eyes
decreased 2 or more ETDRS lines of BCVA (Fig 2 and Table 1).
Optical coherence tomography results were available for all
139 eyes at the 1-, 3-, 6-, 12-, and 24-month follow-up examina-
tions. At 1 month, the mean 1-mm CMT measurements decreased
from 446.4!154.4 !m to 333.75!117 !m (P"0.001), and this
overall improvement continued throughout the 24-month follow-up
(Figs 3–5). At the 3-, 6-, 12-, and 24-month follow-up examina-
tions, mean CMTs were 344.7!115.3 !m, 321.7!102.7 !m,
303!89.1 !m, and 279.7!80 !m, respectively, which were sig-
nificantly different from baseline (P"0.001).
The response to treatment between patients with PDR and
previous panretinal photocoagulation were compared with that of
patients with nonproliferative diabetic retinopathy and DDME to
see if there was any difference. However, when the repeated-
measures analysis of variance was carried out to compare mean
values to analyze statistically the mean retinal thickness and log-
MAR VA adjusting for the grade of diabetic retinopathy as a
covariate, no statistical significance (P # 0.511 for BCVA and
P # 0.483 for CMT) was found.
All eyes received an intravitreal injection at the initial visit;
however, recurrences were retreated at the discretion of the treat-
Figure 5. Sequential optical coherence tomography (OCT) imaging of a 69-year-old diabetic woman with a 6-month history of loss of vision to counting
fingers (CF) in her left eye, in which diabetic macular edema (DME) had developed. A, Horizontal OCT scan obtained through the fovea revealing loss
of the normal foveal contour, diffuse macular thickening, areas of low intraretinal reflectivity consistent with intraretinal cysts, and subretinal fluid (SRF).
The retinal map analysis revealed a foveal thickness of 619 !m. The patient underwent an intravitreal injection of bevacizumab at a dose of 2.5 mg in
this eye. B, Optical coherence tomography image revealing partial resolution of intraretinal macular edema and complete reabsorption of SRF at 1 month
after bevacizumab injection. The retinal map analysis indicates a central foveal thickness of 479 !m. Visual acuity (VA) improved to 20/400. C, Three
months after the injection, OCT scan showing improvement in foveal thickness (306 !m). The VA improved to 20/200. D, Four months after the first
injection, VA diminished to CF, and OCT scan showed the reappearance of macular edema associated to increase of intraretinal cysts. Central foveal
thickness increased to 715 !m. She received a second injection of intravitreal bevacizumab at a dose of 2.5 mg at this point. E–G, At month 6, she received
a third injection of intravitreal bevacizumab at dose of 2.5 mg. The OCT scans at (E) 5, (F) 6, and (G) 9 months showed a progressive resolution in
macular edema and intraretinal cysts, which were confirmed with decrease of central foveal thickness (400 !m, 318 !m, and 173 !m, respectively). Her
VA also improves progressively (20/200, 20/200, and 20/125, respectively). H, Twelve months after the first injection, the OCT scan showed resolution
of DME, with complete reabsorption of SRF and restoration of foveal anatomic features. Foveal thickness decreased to 148 !m, and visual acuity was
20/125. I, Sixteen months after the first injection, VA diminished to 20/400, and the OCT scan showed a reappearance of macular edema associated to
increase of intraretinal cysts. Central foveal thickness increased to 557 !m. She received a fourth injection of intravitreal bevacizumab at dose of 2.5 mg.
J, Optical coherence tomography scan obtained at 17 months showing a resolution in macular edema and intraretinal cysts. Central foveal thickness
decreased to 245 !m and VA was 20/160. K, Eighteen months after the first injection (2 months after the previous injection), OCT scan showing
improvement in foveal thickness (200 !m). The VA improved to 20/125. L, Nineteen months after the first injection, her visual acuity diminished to
20/400. Optical coherence tomography scan showing the reappearance of macular edema. The retinal map analysis indicates a central foveal thickness
of 599 !m. She received a fifth injection of intravitreal bevacizumab at a dose of 2.5 mg at this point. M, Optical coherence tomography scan obtained
at 20 months showing resolution in macular edema and intraretinal cysts. Central foveal thickness decreased to 316 !m. The VA improved to 20/200.
N, Twenty-four months after the first injection, OCT showing a marked resolution in macular edema and restoration of foveal anatomic features. Central
foveal thickness was 125 !m, and VA improved to 20/160.
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ing physician. There were a total of 807 IVB injections performed.
The mean number of IVB injections per eye was 5.8 (range, 1–15
injections) at a mean interval of 12.2!10.4 weeks (Tables 2 and 3).
Seventy-four (53.2%) cases were treated with an intravitreal in-
jection of 1.25 mg bevacizumab and 65 (46.8%) cases were treated
with a 2.5-mg dose of IVB.
Adverse events included transient high blood pressure in 1
(0.9%) patient, cerebrovascular accident in 1 (0.9%) patient, heart
attack in 1 (0.9%) patient, transient increased intraocular pressure
in 7 (5%) eyes, cataract in 5 (3.6%) eyes, and tractional retinal
detachment in 1 (0.7%) eye.
Analysis of Visual Acuity and Central Macular
Thickness by Doses of 1.25 and 2.5 mg
No statistically significant differences in changes of BCVA be-
tween doses of 1.25 and 2.5 mg of IVB were observed (Table 4
and Fig 6). In the 1.25-mg group at 1 month, BCVA improved
from 20/150 (0.88 logMAR units) to 20/107 (0.73 logMAR units),
a difference that was statistically significant (P"0.0001). This
improvement was maintained throughout the 3-, 6-, 12-, and 24-
month follow-up. The mean BCVA at 24 months was 20/75 (0.57
logMAR units; P"0.0001), a statistically significant difference
from baseline BCVA (Fig 6). Similar BCVA changes were ob-
served in the 2.5-mg group: at 1 month, BCVA improved from
20/168 (0.92 logMAR units) to 20/118 (0.78 logMAR units), a
difference that was statistically significant (P # 0.02). This im-
provement in BCVA was maintained throughout the 3-, 6-, 12-,
and 24-month follow-up. The mean BCVA at 24 months was
20/114 (0.76 logMAR units; P"0.0001), a statistically significant
difference from baseline BCVA (Fig 6). In addition, in the
1.25-mg group, at 1 month there was an average gain of 3.1!2.1
lines of BCVA, at 3 months there was an average gain of 3.2!2.5
lines of BCVA, at 6 months there was an average gain of
2.4!1.8 lines of BCVA, at 12 months there was an average of
3.8!2.6 lines of BCVA, and at 24 months there was an average
gain of 2.4!1.6 lines of BCVA (P"0.001). In the 2.5-mg group,
at 1 month eyes gained 4.2!3.3 lines of BCVA, 1.8!1.3 lines of
BCVA at 3 months, 3.0!2.1 lines of BCVA at 6 months, 2.6!2.3
lines of BCVA at 12 months, and 2.4!2.2 lines of BCVA at 24
months (P"0.01).
No statistically significant differences in macular thickness
with OCT were observed between doses of 1.25 and 2.5 mg of IVB
(Fig 7). In the 1.25-mg group, the mean CMT decreased from
466.5!145.2 !m at baseline to 332.2!129.6 !m at 1 month,
358.8!111.8 !m at 3 months, 317.6!87.7 !m at 6 months,
299.1!79.4 !m at 12 months, and 286.6!81.5 !m at 24 months
(P"0.0001). In the 2.5-mg group, the mean CMT decreased from
423.4!163.5 !m at baseline to 335.5!102.8 !m at 1 month,
328.7!118.8 !m at 3 months, 326.3!118.7 !m at 6 months,
307.5!99.9 !m at 12 months, and 271.8!78.8 !m at 24 months
(P"0.0001).
Discussion
Diabetic macular edema is a manifestation of DR that
produces loss of central vision. Although several treatment
methods are under investigation, the only demonstrated
means to reduce the risk of vision loss from DME are laser
photocoagulation, as shown by the ETDRS5; intensive gly-
cemic control, as reported by the Diabetes Control and
Complications Trial and the United Kingdom Prospective
Diabetes Study; and blood pressure control, as demon-
strated by the United Kingdom Prospective Diabetes
Study.49,50 Taking into account that most eyes with DDME
treated with laser photocoagulation show no improvement
in VA,9 there has been an interest in other treatment meth-
ods such as pharmacologic therapy with oral protein kinase











2 Injections 132 10.9!11.5 1–52 94.9
3 Injections 109 13.3!4.8 4–75 78.4
4 Injections 99 15.2!13.7 4–83 71.2
5 Injections 76 16.1!10.9 3–83 54.7
6 Injections 50 18.4!12.3 4–86 36
7 Injections 37 13.3!5.1 4–24 26.6
8 Injections 28 18.4!12.3 4–86 20
9 Injections or more 16 15.7!4.8 4–40 11.5
*Total percentage is more than 100% because 132 eyes needed 2 or more
injections.
Table 2. Analysis of the Frequency of Injections by Subgroups 1.25 mg (74 Eyes) and 2.5 mg
(65 Eyes)
Injections Required by Eye
during 24 Months
1.25 mg 2.5 mg Both Groups
Frequency Percentage Frequency Percentage Frequency Percentage
No reinjection 7 9.5 0 0 7 5
2 Injections 17 23 6 9.2 23 16.5
3 Injections 3 4.1 7 10.8 10 7.2
4 Injections 9 12.2 14 21.5 23 16.5
5 Injections 20 27.1 6 9.2 26 18.7
6 Injections 5 6.7 8 12.3 13 9.3
7 Injections 4 5.4 5 7.7 9 6.4
8 Injections 6 8.1 5 7.7 11 7.9
9 Injections 1 1.3 7 10.8 8 5.7
10 Injections 0 0 1 1.5 1 0.7
11 Injections 2 2.7 2 3.1 4 2.8
12 Injections 0 0 1 1.5 1 0.7
14 Injections 0 0 1 1.5 1 0.7
15 Injections 0 0 1 1.5 1 0.7
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C inhibitors and the use of intravitreal corticosteroids.51,52
The use of antibodies targeted at VEGF is another treatment
method that has generated considerable interest and is being
investigated.10–19
Retinal hypoxia and various rheological disturbances
play a role in DME. Several medical articles point to leu-
kocyte dynamics as one of the causes of diabetic retinopa-
thy.53–54 Leukocytes have decreased deformability,55 in-
creased activation,44 and increased adhesiveness to vascular
endothelium in diabetes.54 The levels of intercellular adhe-
sion molecule 1 immunoreactivity were reported to be ele-
vated in the retina of diabetic patients.54 A previous study
demonstrated that the vitreous levels of intercellular adhe-
sion molecule 1 and VEGF were significantly higher in
DME patients than in control patients.23 Leukocyte entrap-
ment, which is promoted by intercellular adhesion molecule
1 expression, is considered the critical early event in the
pathogenesis of diabetic retinopathy. The trapped leuko-
cytes cause transient or permanent microcirculatory distur-
bances and release cytotoxic products, such as cytokines,
oxygen-free radicals, or proteolytic enzymes, and result in
vascular endothelial cell damage and promote vascular per-
meability.53,54 Long-term circulatory disturbance may lead
to functional vascular obstruction, relative retinal ischemia,
and release of cytokines such as VEGF. In 2 studies, Fu-
natsu et al22,23 reported that the levels of VEGF were
elevated in the vitreous fluid of subjects with DME. Vas-
cular endothelial growth factor causes conformational
changes in the tight junctions of retinal endothelial cells56,57
and plays a major role in increasing vascular permeability
and in the progression of DME.58
This study reports on 139 consecutive eyes with DDME
treated with intravitreal bevacizumab, which resulted in
both anatomic and functional improvement. In most of the
patients, the reduction of retinal thickness and improvement
of BCVA were detected within the first 4 weeks after the
injection. In addition, both doses (1.25 and 2.5 mg) were
associated with improvement of BCVA and a greater reduc-
tion in CMT, and no differences in between were found.
Ocular tolerance of the 2 different doses of IVB was dem-
Table 4. Best-Corrected Visual Acuity in Eyes Injected with Doses of 1.25 and 2.5 mg Intravitreal
Bevacizumab at 24 Months of Follow-up
1.25 mg 2.5 mg
Best-Corrected
Visual Acuity
Logarithm of the Minimum
Angle of Resolution Units
Best-Corrected
Visual Acuity
Logarithm of the Minimum
Angle of Resolution Units
Baseline 20/150 0.88 20/168 0.92
1 month 20/107 0.73 20/118 0.78
Third month 20/100 0.70 20/114 0.76
Sixth month 20/94 0.67 20/118 0.78
Twelfth month 20/80 0.60 20/114 0.76
Twenty-fourth month 20/75 0.57 20/114 0.76
Figure 6. Graph showing changes in best-corrected visual acuity (BCVA)
between doses of 1.25 and 2.5 mg of intravitreal bevacizumab. In the
1.25-mg group (solid line), BCVA at 1 month improved from 0.88 to 0.73
logarithm of the minimum angle of resolution (logMAR) units, a differ-
ence that was statistically significant (P"0.0001). This improvement was
maintained throughout the 3-, 6-, 12-, and 24-month follow-up examina-
tions. The mean BCVA at 24 months was 0.57 logMAR units (P"
0.0001), a statistically significant difference from baseline BCVA. Similar
BCVA changes were observed in the 2.5-mg group (doted line): at 1
month, BCVA improved from 0.92 to 0.78 logMAR units, a difference
that was statistically significant (P # 0.02). This improvement in BCVA
was maintained throughout the 3-, 6-, 12-, and 24-month follow-up
examinations. The mean BCVA at 24 months was 0.76 logMAR units
(P"0.0001), a statistically significant difference from baseline BCVA.
CI # confidence interval; — # 1.25 mg; # 2.5 mg.
Figure 7. Graph showing changes in macular thickness with optical
coherence tomography (OCT) during follow-up between doses of 1.25 and
2.5 mg intravitreal bevacizumab. In the 1.25-mg group (solid line), the
mean central macular thickness (CMT) decreased from 466.5!145.2 !m
at baseline to 332.2!129.6 !m at 1 month, 358.8!111.8 !m at 3 months,
317.6!87.7 !m at 6 months, 299.1!79.4 !m at 12 months, and
286.6!81.5 !m at 24 months (P"0.0001). In the 2.5-mg group (dotted
line), the mean CMT decreased from 423.4!163.5 !m at baseline to
335.5!102.8 !m at 1 month, 328.7!118.8 !m at 3 months, 326.3!118.7
!m at 6 months, 307.5!99.9 !m at 12 months, and 271.8!78.8 !m at 24
months (P"0.0001). CI # confidence interval;— # 1.25 mg; # 2.5 mg.
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onstrated, and no seriously adverse systemic events were
noted during the study.
There are several studies in the literature on the intravitreal
administration of antibodies against VEGF for DDME. Two
studies previously reported IVB as a primary treatment for
DME, including a previously reported series at 6 months43
and a study by Soheilian et al59 that reported 103 eyes with
12 weeks follow-up comparing IVB alone or combined with
intravitreal triamcinolone versus macular focal or grid laser
photocoagulation. They reported better results with IVB
regarding visual outcome than with laser photocoagulation,
although it was not associated with a significant decrease in
CMT. No further beneficial effect of intravitreal triamcino-
lone could be demonstrated in their study.59 Haritoglou et
al18 reported that intravitreal ranibizumab has the potential
to maintain or improve BCVA and to reduce retinal thick-
ness in patients with DDME not responding to previous
treatments such as photocoagulation, intravitreal injection
of triamcinolone, or vitrectomy. Their follow-up period was
too short (6 weeks) to provide specific treatment recommen-
dations. Kumar and Sinha60 reported results of 20 eyes with
DDME treated with IVB at a dose of 1.25 mg that had not
responded to previous photocoagulation. Their follow-up
period was 6 months. They concluded that IVB resulted in
a significant decrease in macular thickness and improve-
ment in VA at 3 months, but that the effect was somewhat
blunted, although still statistically significant, at the end of
6 months. The results of the current study compare favor-
ably with those of these reports and confirm their findings
with longer follow-up and a larger number of patients.
The 2 doses of bevacizumab evaluated in this study were
1.25 mg, which is the one that has been used most com-
monly in clinical practice, and 2.5 mg, which also has been
used, although less commonly. The results of this retrospec-
tive study demonstrated the efficacy of 1.25 or 2.5 mg of
IVB as primary treatment of DDME, because 51.8% of eyes
showed anatomic and functional improvement. In addition,
the results suggest a reduced risk of VA loss in eyes with
DDME treated with IVB (97.1% of eyes). The anatomic and
visual benefit of intravitreal bevacizumab appears and
reaches its maximum value during the first month and is
maintained over 24 months. This study had an 80% power
with an # of 5% to detect a 25% difference between the
1.25-mg and the 2.5-mg groups with respect to BCVA and
CMT variations. No statistically significant differences in
duration or anatomic or functional effectiveness were found
between the 2 doses of bevacizumab evaluated.
These results indicate that IVB injections may have a
beneficial effect on macular thickness and BCVA in
DDME. Therefore, in the future, this new treatment method
may replace or complement focal or grid laser photocoag-
ulation. Furthermore, focal or grid laser photocoagulation
may be used to consolidate the results obtained with 1 IVB
injection and may decrease the need for reinjections. A
recently published multicenter study, funded by the Na-
tional Eye Institute and conducted through the Diabetic
Retinopathy Clinical Research Network, studied 840 eyes
of 693 subjects with DME involving the fovea and with VA
of 20/40 to 20/320. This 2-year study demonstrated that
focal or grid photocoagulation is more effective and has
fewer side effects than 1-mg or 4-mg doses of preservative-
free intravitreal triamcinolone for most patients with DME
who have characteristics similar to the cohort in this clinical
trial.61 This study showed that at 2 years, focal or grid
photocoagulation is more effective than expected. Scha-
chat62 recently pointed out 2 main reasons for these find-
ings: longer-term follow-up than in previous intravitreal
triamcinolone studies and the fact that in the ETDRS, sub-
jects mainly had good vision at baseline. If the subject starts
out with VA better than 20/40, it is harder to gain 5, 10, or
15 letters or 1 to 3 ETDRS lines than if the patient has worse
vision at baseline. Therefore, we should all consider laser
therapy for patients with DME while we await advances and
better outcomes from new therapies still under investiga-
tion. Although the evidence currently supports focal or grid
photocoagulation as the most effective treatment, the au-
thors from the Diabetic Retinopathy Clinical Research Net-
work study commented that combining laser therapy with
corticosteroids may prove useful.61 The same may be true
for anti-VEGF therapies, and combination therapies should
be considered.
Limitations of this study include that it is nonrandom-
ized, uncontrolled, and retrospective, that is, features that
preclude any estimation of the long-term efficacy or safety
of IVB. In addition, because no control group is present, the
possibility that some of the improvement in macular edema
may be associated with improvement in systemic health
cannot be ruled out. It is not uncommon that additional
attention is directed toward improving systemic health when
patients become involved in a clinical trial or new treatment.
Furthermore, there was no standardized adverse event form
to collect the safety data. However, the results are very
promising and suggest the need for further investigation. In
addition, it can be safely assumed (with 95% confidence)
that the true rate of ocular complications in this study was
less than 4.3% and that the true rate of systemic complica-
tions was less than 2.6%.56,63
In summary, primary IVB at doses of 1.25 or 2.5 mg
seem to provide stability and improvement in BCVA, OCT,
and FA results in DDME at 24 months. No difference in
outcomes between IVB at doses of 1.25 or 2.5 mg was
identified. Therefore, doses lower than 2.5 mg should be
preferred. Evaluation in a multicenter, randomized, con-
trolled clinical trial comparing IVB and focal or grid pho-
tocoagulation is needed to evaluate the safety and efficacy
of this treatment method.
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Chapter 5: Intravitreal Bevacizumab plus Grid Laser Photocoagulation for Diabetic Macular 
Edema at 24 months of follow up 
 
Arevalo JF, Lasave AF, Wu L, Diaz-Llopis M, Gallego-Pinazo R, Alezzandrini AA, Berrocal MH; 
Pan-American Collaborative Retina Study Group (PACORES). Intravitreal bevacizumab plus grid 
laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for 
diffuse diabetic macular edema: results of the Pan-american Collaborative Retina Study Group at 24 




Hypothesis 2: IVB combined with grid laser photocoagulation may have a beneficial anatomic 
(OCT), and functional (VA) effect on eyes with diffuse diabetic macular edema at 24 months of 
follow up as compared to monotherapy. In addition, IVB combined with grid laser photocoagulation 
may decrease the number of injections if IVB necessary at 24 months. 
 
PURPOSE: To evaluate the anatomical and functional outcomes at 24 months in patients 
with diffuse diabetic macular edema treated with 
primary intravitreal bevacizumab (IVB) plus grid laser photocoagulation (GLP) or primary IVB alone 
or GLP alone. 
 
METHODS: Retrospective, interventional, comparative, multicenter study. We included in this 
analysis 141 eyes of 120 patients with diffuse diabetic macular edema treated with primary IVB alone 
(Group A), 120 eyes of 94 patients with GLP therapy (Group B), and 157 eyes of 104 patients treated 
with IVB plus GLP (Group C). 
 
RESULTS: In all 3 groups, the authors observed improvement of Early 
Treatment Diabetic Retinopathy Study best-corrected visual acuity from baseline to 24-month follow-
up (P < 0.0001). The improvement rate in Group A was statistically significantly better than in Group 
B (analysis of variance, P = 0.013). The authors also found a decrease in central macular thickness in 
all groups from baseline to the 24-month follow-up (P < 0.0001). The comparison among 3 groups 
showed higher central macular thickness decrease in Group A than in Groups B and C (analysis of 
variance, P < 0.001). 
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 CONCLUSION: The study provides evidence to support the use of primary IVB with or without GLP 
as treatment of diffuse diabetic macular edema. Primary IVB without GLP seems to be superior to 
GLP alone to provide stability or improvement in best-corrected visual acuity in patients 
with diffuse diabetic macular edema at 24 months. 
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INTRAVITREAL BEVACIZUMAB PLUS
GRID LASER PHOTOCOAGULATION OR
INTRAVITREAL BEVACIZUMAB OR GRID
LASER PHOTOCOAGULATION FOR
DIFFUSE DIABETIC MACULAR EDEMA
Results of the Pan-American Collaborative Retina
Study Group at 24 Months
J. FERNANDO AREVALO, MD, FACS,*†‡ ANDRES F. LASAVE, MD,§ LIHTEH WU, MD,¶
MANUEL DIAZ-LLOPIS, MD,** ROBERTO GALLEGO-PINAZO, MD,**
ARTURO A. ALEZZANDRINI, MD,†† MARIA H. BERROCAL, MD,‡‡ FOR THE PAN-AMERICAN
COLLABORATIVE RETINA STUDY GROUP (PACORES)
Purpose: To evaluate the anatomical and functional outcomes at 24 months in patients
with diffuse diabetic macular edema treated with primary intravitreal bevacizumab (IVB)
plus grid laser photocoagulation (GLP) or primary IVB alone or GLP alone.
Methods: Retrospective, interventional, comparative, multicenter study. We included in
this analysis 141 eyes of 120 patients with diffuse diabetic macular edema treated with
primary IVB alone (Group A), 120 eyes of 94 patients with GLP therapy (Group B), and
157 eyes of 104 patients treated with IVB plus GLP (Group C).
Results: In all 3 groups, the authors observed improvement of Early Treatment Diabetic
Retinopathy Study best-corrected visual acuity from baseline to 24-month follow-up (P ,
0.0001). The improvement rate in Group A was statistically signiﬁcantly better than in Group
B (analysis of variance, P = 0.013). The authors also found a decrease in central macular
thickness in all groups from baseline to the 24-month follow-up (P , 0.0001). The com-
parison among 3 groups showed higher central macular thickness decrease in Group
A than in Groups B and C (analysis of variance, P , 0.001).
Conclusion: The study provides evidence to support the use of primary IVB with or
without GLP as treatment of diffuse diabetic macular edema. Primary IVB without GLP
seems to be superior to GLP alone to provide stability or improvement in best-corrected
visual acuity in patients with diffuse diabetic macular edema at 24 months.
RETINA 33:403–413, 2013
Diabetic retinopathy is the leading cause of blind-ness among the working population in industrially
developed countries.1,2 Diabetic macular edema
(DME) is a common manifestation of diabetic retinop-
athy that can occur at any stage of the disease and
produce loss of central vision. The Wisconsin Epide-
miologic Study of Diabetic Retinopathy3 estimated
that in people whose age at the time of diagnosis of
diabetes was 30 years or older, the prevalence rate of
DME was approximately 28% in both Type 1 and
Type 2 diabetes if they had more than 20 years of
known diabetes.3
Although several treatment modalities are currently
under investigation, until recently, the only demon-
strated means to reduce the risk of vision loss from
DME were laser photocoagulation, as demonstrated by
the Early Treatment Diabetic Retinopathy Study
(ETDRS)4; intensive glycemic control, as demonstrated
by the Diabetes Control and Complications Trial and
the U.K. Prospective Diabetes Study; and blood
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pressure control, as demonstrated by the U.K. Prospec-
tive Diabetes Study.5–7
Although the ETDRS4 demonstrated that immediate
focal photocoagulation reduced moderate visual loss
by 50% (from 24 to 12%, 3 years after initiation of
treatment), 12% of treated eyes still lost 15 or more
ETDRS letters at the 3-year follow-up interval.
Approximately 40% of treated eyes that had retinal
thickening involving the center of the macula at base-
line still had thickening involving the center at
12 months, as did 25% of treated eyes at 36 months.
Furthermore, only 3% of laser-treated eyes experi-
enced a gain of 3 or more lines of vision. This suggests
that a distinct subgroup of eyes exists with DME resis-
tant to conventional laser photocoagulation. As well
as, some studies have reported a poor prognosis
despite laser photocoagulation in eyes with diffuse
diabetic macular edema (DDME).4,8,9 The Diabetic
Retinopathy Clinical Research Network (DRCR.net)
showed that focal/grid photocoagulation in eyes with
center-involved DME and visual acuity # 20/40 pro-
duces gradual visual acuity improvement of $2 lines
in approximately one third of eyes after 2 years of
follow-up, although approximately 20% of laser-trea-
ted eyes worsen by $2 lines.10 Thus, different addi-
tional therapies have been proposed for the treatment
of DME.11,12
It has been suggested that DME is caused by
excessive vascular permeability, resulting in the leakage
of ﬂuid and plasma constituents, such as lipoproteins
into the retinal layers, leading to thickening of the retina.
It was recently demonstrated that retinal hypoxia plays
a role in DME,13 and vascular endothelial growth factor
(VEGF), which is upregulated by hypoxia, is likely to
contribute to the excessive vascular permeability that
results in macular edema in people with diabetes. Several
studies have demonstrated not only a correlation of
VEGF levels with the severity of diabetic retinopathy14
but also a reduction in levels after successful laser treat-
ment of proliferative diabetic retinopathy.15 If VEGF has
a role in the development or exacerbation of DME,14,16
a rational approach to treat macular edema in these
patients would include the use of anti-VEGF agents.
Chun et al17 reported that ranibizumab (RBZ)
(Lucentis; Genentech, Inc, San Francisco, CA) therapy
has the potential to maintain or improve best-corrected
visual acuity (BCVA) and reduce retinal thickness in
patients with DME. In addition, intravitreal injections
of the aptamer pegaptanib sodium (Macugen; OSI
Eyetech Pharmaceuticals, Melville, NY) in patients
with DME have been shown to improve visual acuity
and retinal thickening. Cunningham et al18 reported
gains in visual acuity of 10 letters in 34% and 15 letters
in 18% of patients with DME after an intravitreal
pegaptanib sodium injection in a randomized, double-
masked, multicenter trial with a follow-up of
36 months. Our group has also reported the 24-month
anatomical and BCVA response after primary intravi-
treal bevacizumab (IVB) in patients with DME. These
results demonstrated the efﬁcacy of 1.25 mg or 2.5 mg
of IVB as primary treatment of DME as 51.8% of eyes
showed anatomical as well as functional improve-
ment.19 Recently, the Diabetic Retinopathy Clinical
Research Network20 showed that intravitreal RBZ with
prompt or deferred laser is more effective through at
least 2 years compared with prompt laser alone for the
treatment of DME involving the central macula.
Solaiman et al21 published that combined therapy with
IVB and sequential grid laser photocoagulation (GLP) 3
weeks later appeared to be superior to GLP or IVB alone
in reducing macular thickening and improving visual
acuity. However, at 6 months of follow-up, there was
no signiﬁcant improvement of BCVA. The RESTORE
Study22 demonstrated recently that RBZ monotherapy
and combined with laser provided superior visual acuity
gain over standard laser in patients with visual impair-
ment because of DME. At 1 year, no differences were
detected between the RBZ and RBZ plus laser arms.
They concluded that RBZ monotherapy and combined
with laser had a safety proﬁle in DME similar to that in
age-related macular degeneration.
Because IVB and GLP achieve their effect on
different pathways, a combination therapy may yield
more favorable results than either therapy alone. We
wished to know whether intravitreal therapy of
bevacizumab has a synergistic effect when combined
with GLP to produce better visual outcomes or greater
decrease in central macular thickness (CMT) in
patients with DDME and to compare this combination
with primary IVB therapy or GLP alone.
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The purpose of this retrospective study was to
evaluate the anatomical and functional outcomes in
patients with DDME treated with primary IVB (1.25
or 2.5 mg) plus GLP or primary IVB alone or GLP
alone at 24 months of follow-up.
Patients and Methods
This is a retrospective, comparative, multicentric,
and interventional study performed at 5 centers from
Venezuela, Costa Rica, Argentina, Spain, and Puerto
Rico between May 2006 and May 2009. All patients
with DDME treated with primary IVB (1.25 or 2.5 mg)
plus GLP or primary IVB alone or GLP alone were
included in this study. We reviewed the clinical records
of 318 consecutive patients (418 eyes) with DDME
treated with primary IVB alone (1.25 or 2.5 mg), GLP,
or combined IVB plus GLP. Each pattern of treatment
was separated into different groups. One hundred and
forty-one (141) eyes of 120 patients with DDME were
treated with at least 1 intravitreal injection of 1.25 mg
or 2.5 mg of bevacizumab alone (Group A). The dose
of 1.25 mg or a dose of 2.5 mg to be used to treat
a patient was determined at the discretion of the
treating physician. If a patient received one of the
doses at baseline, then the same dose was delivered
throughout the study. One hundred and twenty (120)
eyes of 94 patients were treated with GLP therapy
(Group B), and 157 eyes of 104 patients were treated
with IVB plus GLP (Group C). In Group A, 75 eyes
(53.2%) were treated with an intravitreal injection of
1.25 mg of bevacizumab and 66 eyes (46.8%) with
a dose of 2.5 mg of bevacizumab. In Group C, 96 eyes
(61.1%) were treated with an intravitreal injection of
1.25 mg of bevacizumab and 61 eyes (38.9%) with
a dose of 2.5 mg of bevacizumab.
Approval was obtained from each participating
center’s Institutional Ethics Committee, and informed
consent was obtained for this study. In addition, this
study has been performed in accordance with the eth-
ical standards laid down in the 1964 Declaration of
Helsinki. The off-label use of the drug and its potential
risks and beneﬁts were discussed extensively with all
patients.
Our deﬁnition of DDME required evidence of
diffuse retinal thickening and/or hard exudates (with-
out a circinate ring pattern) involving the center of the
macula (clinically signiﬁcant DME as deﬁned by the
ETDRS on slit-lamp biomicroscopic examination) and
diffuse ﬂuorescein leakage involving the center of the
macula on ﬂuorescein angiography (FA) with ,33%
of leakage associated with microaneurysms.23 In addi-
tion, a signiﬁcant reduction in the reﬂectivity (cysts) of
the outer retinal layers and/or subretinal ﬂuid collec-
tion by optical coherence tomography (OCT) should
be present.24
All cases with proliferative diabetic retinopathy had
had previous scatter panretinal photocoagulation at
least 6 months before undergoing IVB or GLP. All
eyes had DDME diagnosed by biomicroscopic slit-
lamp examination, FA, and OCT (Stratus OCT; Carl
Zeiss, Dublin, CA) at baseline.
Patients were excluded if they had other conditions
known to cause macular edema, such as branch retinal
vein occlusion, central retinal vein occlusion, exuda-
tive macular degeneration, or previous radiation. In
addition, patients (eyes) with DDME previously
treated with intravitreal triamcinolone, macular ische-
mia, intraocular inﬂammation, uncontrolled intraocular
pressure, cataract surgery within the past 6 months, or
a history of vitreoretinal surgery were excluded.
Although not a formal exclusion criterion, patients
with a history of uncontrolled hypertension and recent
thromboembolic events were not usually injected with
bevacizumab but this decision was left at the discretion
of the treating physician.
Each patient underwent BCVA measurement with
ETDRS charts and ophthalmic examination including
slit-lamp biomicroscopy. Baseline central retinal char-
acteristics were analyzed by OCT using 6 diagonal
slow 6-mm radial line scans, with software version
4.0, through a dilated pupil performed by a retina
specialist. The retinal thickness of the 1-mm central
retina was obtained using the macular thickness map
for our calculations. The scans were reviewed, and
manual caliper-assisted measurements were used in
case of delineation errors.
A 0.18-mL aliquot of commercially available bev-
acizumab was prepared for each patient included in
Group A or Group C. Bevacizumab was placed in
a tuberculin syringe using aseptic techniques. After the
eye had been prepared in a standard fashion using 5%
povidone/iodine, an sterile eyelid speculum was used
to stabilize the eyelids and the injection of 1.25 mg
(0.05 mL) or 2.5 mg (0.1 mL) of bevacizumab was
performed 3.5 mm to 4 mm posterior to the limbus,
through the inferotemporal pars plana with a 30-gauge
needle under topical anesthesia or subconjunctival
lidocaine. After withdrawal of the needle, sterile
cotton-tipped applicator was used to apply pressure
over the injection site for 1 minute and then retinal
artery perfusion was checked with the indirect oph-
thalmoscope (no anterior chamber paracentesis was
necessary). All patients were instructed to administer
topical antibiotics for 7 days.
In patients treated with laser therapy (Groups B and
C), GLP was performed with an argon or green laser
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delivering 2 to 3 rows of 75 mm spots and 100 mm
apart in the parafoveal region guided by FA and OCT.
Then, 150 mm to 200 mm spots were applied 200 mm
apart to the remaining areas of retinal thickening and
capillary nonperfusion. Focal leaks outside or within
the zones of diffuse leakage were treated with 100 mm
to 150 mm spots to achieve a mild whitening of the
microaneurysms. Treatment was placed up to 500 mm
from the foveal center.
Patients were examined 1 month after the initial
therapy and monthly thereafter. At each visit, patients
underwent a complete ophthalmic examination using
the same procedures performed at baseline except FA
that was done at the discretion of the examiner.
Patients’ ETDRS BCVAs were transferred from
their records and converted to a logarithm of the mini-
mal angle of resolution (logMAR) scale for analysis.
An increase or decrease in BCVA was considered to
have occurred if there was a change of two or more
ETDRS lines. Main outcome measures included
changes in BCVA and CMT measured by OCT.
Patients received retreatment whenever there was
a recurrence of DDME. Recurrence was deﬁned as
a decrease of BCVA associated with an increase of
intraretinal ﬂuid because of macular edema on OCT
($50 mm in CMT) and/or an increase of diffuse ﬂuo-
rescein leakage involving the center of the macula on
FA, after complete or partial resolution in previous
follow-up visits. Retreatment in Group B was GLP
even if full laser was already in place. Retreatment
in Group C was IVB.
All data were collected in a Microsoft Ofﬁce
Excel 2007 spreadsheet (Microsoft Corporation,
Unterschleissheim, Germany) and statistically ana-
lyzed by MedCalc Software for Windows 8.2.0.3
(MedCalc, Mariakerke, Belgium). The paired sam-
ple t-test was performed to compare the CMT and
the BCVA with baseline values within each treat-
ment group. Correlation was considered signiﬁcant
with a P value , 0.05. Repeated measures analysis
of variance (ANOVA method) were used to compare
mean values to statistically analyze mean retinal
thickness and logMAR visual acuity among the three
treatment groups.
Results
We reviewed the clinical records of 318 consecutive
patients (418 eyes) with DDME. All patients had 24
months of follow-up. One hundred and forty-one (141)
eyes of 120 patients with DDME were treated with
primary IVB alone (Group A), 120 eyes of 94 patients
with GLP therapy (Group B), and 157 eyes of 104
patients with IVB plus GLP (Group C). The baseline
ocular and systemic characteristics of all three groups
were comparable. Baseline characteristics of patients
in each treatment group are presented in Table 1.
The total number of injections was 5.8 ± 3.2 in
Group A and 6.2 ± 4.9 in Group C. The interval
between the ﬁrst and second injection was 11.2 ± 9.4
weeks in Group A and 12.4 ± 18.8 weeks in Group C.
The number of macular GLP sessions was 2.2 ± 1.4,
and the interval between the ﬁrst and second laser
application was 20.2 ± 14.1 weeks in Group B. In
Group C, the time of laser application was prompt
(within 1 week) in 75 eyes (47.8%), intermediate
(1 week # 24 weeks) in 55 eyes (35%), and deferred
(.24 weeks) in 27 eyes (17.2%).
In all 3 groups, we observed improvement of
BCVA from baseline to 24 months of follow-up
(Figures 1 and 2). In the Group A (IVB therapy), at
1 month after intravitreal injection of bevacizumab,
BCVA improved signiﬁcantly and these changes were
maintained throughout 24 months of follow-up. In this
group, the mean BCVA improved from baseline
20/160, logMAR 0.87 ± 0.4 (range, 0.1–1.8), to
20/100, logMAR 0.72 ± 0.5 (range, 0.1–1.8; P ,
0.0001) at 1 month of follow-up. At 3 months and
6 months, the mean BCVA were 20/100, logMAR
0.70 ± 0.5 (range, 0.1–1.8; P, 0.0001). At 12 months
and 24 months of follow-up, the mean BCVAs were
20/100, logMAR 0.65 ± 0.5 (range, 0.1–1.8) at both
time points (P , 0.0001). Twenty-four months of
BCVA analysis by subgroups demonstrated that
62 eyes (44.6%) remained stable, 74 (52.5%) eyes
improved 2 or more ETDRS lines of BCVA, and
5 eyes (3.6%) decreased 2 or more ETDRS lines of
BCVA. Mean BCVA letter score from baseline to
Month 1 was 7.48 ± 14.49 (range, −35 to +60) and
8.55 ± 16.48 (−30 to +65) at 3 months of follow-up.
At 6, 12, and 24 months of follow-up, the mean
BCVA letter scores were 8.16 ± 17.37 (range, −40
to +60), 11.13 ± 17.65 (range, −50 to +65), and
11.84 ± 17.18 (range, −20 to +30), respectively.
In Group B (GLP therapy), there was no statistically
signiﬁcant difference from baseline BCVA until the
ﬁrst 6 months of treatment. In this group, the mean
BCVA slightly improved from baseline 20/125,
logMAR 0.77 ± 0.34 (range, 0.3–1.4), to 20/100,
logMAR 0.75 ± 0.32 (range, 0.2–1.5; P = 0.1257),
and 0.73 ± 0.32 (range, 0.2–1.8) (P = 0.1162) at 1
month and 3 months of follow-up. However, we found
that 6 months after GLP, BCVA improved signiﬁcantly
(P,0.05) from baseline, and these changes were main-
tained throughout the 24 months of follow-up. At 6, 12,
and 24 months of follow-up, the mean BCVA was
20/100, logMAR 0.72 ± 0.4 (P = 0.0258), logMAR
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0.71 ± 0.4 (range, 0.1–3; P = 0.0107), and logMAR
0.65 ± 0.4 (range, 0.2–4; P = 0.0020), respectively.
Twenty-four months of BCVA analysis by subgroups
demonstrated that 59 eyes (49.2%) remained stable,
36 eyes (30.0%) improved 2 or more ETDRS lines of
BCVA, and 25 eyes (20.8%) decreased 2 or more
ETDRS lines of BCVA. Mean BCVA letter scores from
baseline to Month 1 were 1.25 ± 7.2 (range, −15 to
+25) and 3.29 ± 9.8 (range, −15 to +35) at 3 months
of follow-up. At 6, 12, and 24 months of follow-up, the
mean BCVA letter scores were 4.1 ± 11.3 (range, −15
to +30), 4.41 ± 11.7 (range, −35 to +40), and 4.82 ±
12.9 (range, −30 to +45), respectively.
In Group C (IVB plus GLP), the mean BCVA
improved from baseline 20/125, logMAR 0.76 ± 0.44
(range, 0.1–1.8), to 20/100, logMAR 0.70 ± 0.43
(range, 0.1–1.8; P , 0.0001) at 1 month of follow-
up. At 3, 6, 12, and 24 months of follow-up, the mean
BCVAs were 20/100, logMAR 0.69 ± 0.39 (P =
0.0150); 20/80, logMAR 0.67 ± 0.4 (P = 0.0002);
20/80, logMAR 0.65 ± 0.44 (P = 0.0001); and
20/80, logMAR 0.60 ± 0.43 (P , 0.0001), respec-
tively. Twenty-four months of BCVA analysis by sub-
groups demonstrated that 78 eyes (49.7%) remained
stable, 58 eyes (36.9%) improved 2 or more ETDRS
lines of BCVA, and 21 eyes (13.4%) decreased 2 or
more ETDRS lines of BCVA. Mean BCVA letter
scores from baseline to Month 1 were 3.44 ± 9.07
(range, −15 to +30) and 3.66 ± 12.27 (range, −35 to
+30) at 3 months of follow-up. At 6, 12, and 24
months of follow-up, the mean BCVA letter scores
were 4.9 ± 16.37 (range, −30 to +30), 7.44 ± 16.73
(range, −25 to +30), and 8.18 ± 16.96 (range, −25
to +30), respectively. Best-corrected visual acuity
analysis by subgroups of all eyes included in this study
is shown in Table 2.
In Groups A and C, there were statistically signiﬁcant
differences from baseline BCVA at all time points of
follow-up (P , 0.0001). The improvement rate in
Group A was statistically signiﬁcantly better than in
Group B (ANOVA, P = 0.013). However, the improve-
ment rate was not statistically signiﬁcantly different
between Groups A and C (ANOVA, P = 0.167) or
between Groups B and C (ANOVA, P = 0.092).
Optical coherence tomography results were avail-
able for all 418 eyes at 1-, 3-, 6-, 12-, and 24-month
follow-ups. We also found a decrease in CMT in all
groups from baseline to the 24-month follow-up
(Figure 3). In Group A (IVB therapy), there was
a decrease from 446.2 ± 155.8 mm (range, 222–1082
mm) to 330.2 ± 115.6 mm (range, 198–841 mm; P ,
0.0001) at the ﬁrst month after IVB. At 3 months and 6
Table 1. Baseline Characteristics of Patients with DDME Included in Each Treatment Group
Group A (IVB Therapy) Group B (GLP Therapy) Group C (IVB plus GLP) P
Number of patients 120 94 104 —
Number of eyes 141 120 157 —
Sex (%)
Male 63 (52.5) 46 (48.9) 43 (41.3) 0.379
Female 57 (47.5) 48 (51.1) 61 (58.7) 0.982
Age (mean ± SD), years 59.4 ± 10.8 64.3 ± 9.0 62.2 ± 8.7 0.229
Mean BCVA: baseline 20/160 20/125 20/125 0.061
Mean OCT baseline scores, mm 446.2 ± 155.8 379.1 ± 91 415.5 ± 144.8 0.001*
Hypertension (%) 69 (57.5) 52 (55.3) 59 (57) 0.898
Systemic glycemic control, n (%)
Insulin 71 (59.1) 49 (52.1) 79 (75.9) 0.0127†
Oral hypoglycemic 59 (49.1) 65 (69.1) 42 (40.3) 0.1573
Combined therapy 0% 0% 34 (21.7%) —
None, n (%) 11 (7.8) 6 (5) 0 (0) 0.158
HbA1c, % 8.9 ± 1.6 9.7 ± 1.7 9.1 ± 1.6 0.064‡
Grade of DR, n (%)
Mild NPDR 17 (12.1) 10 (8.3) 10 (6.4) 0.283
Moderate NPDR 27 (19.1) 27 (22.5) 49 (31.2) 0.155
Severe NPDR 38 (27) 27 (22.5) 44 (28) 0.707
PDR 59 (41.8) 30 (25) 54 (34.4) 0.130
Values represent number and percentages.
*Optical coherence tomography baseline score comparison among 3 groups showed a greater basal central macular thickening in
Groups A and C than in Group B (ANOVA, P , 0.001).
†Chi-square test. The differences in the comparison of proportions of insulin treatment between Group A and Group C, P = 0.010 and
between Group B and Group C, P = 0.0007, were observed.
‡In Groups A, B, and C, glycosylated hemoglobin data were obtained in 72% (86/120), 41% (39/94), and only in 56% (58/104) of
patients, respectively. Chi-square test P = 0.066.
DR, diabetic retinopathy; HbA1c, glycosylated hemoglobin; n, number of patients; NPDR, no proliferative diabetic retinopathy; PDR,
proliferative diabetic proliferative.
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months, the mean CMT measurements were 341.5 ±
114.9 mm (range, 174–715 mm; P , 0.0001) and
356.1 ± 103.9 mm (range, 175–705 mm; P ,
0.0001), respectively. At 12 months and 24 months
of follow-up, the mean CMT measurements were
302.8 ± 89.6 mm (range, 150–524 mm; P , 0.0001)
and 273.8 ± 79.5 mm (range, 135–583 mm; P ,
0.0001), respectively.
In Group B (GLP therapy), there was a decrease
from 379.1 ± 91 mm (range, 220–763 mm) to 368.9 ±
84.4 mm (range, 230–689 mm; P = 0.1370) at the ﬁrst
month after grid laser therapy. At 3 months and 6
months, the mean CMT measurements were 351.7 ±
86.2 mm (range, 216–640 mm; P = 0.0010) and
333.7 ± 103.9 mm (range, 202–581 mm; P ,
0.0001), respectively. At 12 months and 24 months
of follow-up, the mean CMT measurements were
303.5 ± 89.6 mm (range, 169–531 mm; P , 0.0001)
and 271.2 ± 78.6 mm (range, 156–579 mm; P ,
0.0001), respectively.
In the Group C (IVB plus GLP), there was a decrease
from 415.5 ± 144.8 mm (range, 222–1,076 mm) to
377 ± 118.6 mm (range, 155–900 mm; P , 0.0001)
at the ﬁrst month after combined therapy. At 3 months
and 6 months, the mean CMT measurements were
314.9 ± 135.9 mm (range, 150–1055 mm; P ,
0.0001) and 364.4 ± 140.1 mm (range, 144–1,465
mm; P , 0.0001), respectively. At 12 months and 24
months of follow-up, the mean CMT measurements
were 345.1 ± 118.5 mm (range, 142–1,033 mm; P ,
0.0001) and 333 ± 138.5 mm (range, 132–608 mm; P,
0.0001), respectively (Figures 4 and 5). The comparison
among 3 groups showed higher CMT decrease in Group
A than in Groups B and C (ANOVA, P , 0.001).
In the IVB groups, we did not ﬁnd any differences
in the effectiveness between the doses of 1.25 mg and
2.5 mg in terms of BCVA or CMT. In Groups A and
C, there were no complications related to the intra-
vitreal injection during the 24 months of follow-up.
No ocular or systemic adverse events were observed in
all groups.
Discussion
This is a retrospective, comparative, multicentric,
and interventional study that evaluates the anatomical
and functional outcomes at 24 months of follow-up in
patients with DDME treated with primary IVB alone
(Group A), GLP (Group B), or primary IVB plus GLP
(Group C).
Fig. 1. Changes in BCVA after IVB alone (Group A), GLP (Group B),
and IVB plus GLP (Group C) in patients with DDME at 24 months of
follow-up. In Group A, the mean BCVA improved from baseline log-
MAR 0.87 ± 0.4 to logMAR 0.72 ± 0.5 (P , 0.0001) at 1 month of
follow-up. At 3 months and 6 months, the mean BCVAs were logMAR
0.70 ± 0.5 (P, 0.0001). At 12 months and 24 months of follow-up, the
mean BCVAs were logMAR 0.65 ± 0.5 (P , 0.0001). In Group B, the
mean BCVA slightly improved from baseline logMAR 0.77 ± 0.34 to
logMAR 0.75 ± 0.32 (P = 0.1257) and 0.73 ± 0.32 (P = 0.1162) at 1
month and 3 months of follow-up. At 6, 12, and 24 months of follow-
up, the mean BCVAs were logMAR 0.72 ± 0.4 (P = 0.0258), logMAR
0.71 ± 0.4 (P = 0.0107), and logMAR 0.65 ± 0.4 (P = 0.0020),
respectively. In Group C, the mean BCVA improved from baseline
logMAR 0.76 ± 0.44 to 0.70 ± 0.43 (P , 0.0001) at 1 month of follow-
up. Best-corrected visual acuity improved signiﬁcantly (,0.05) from
baseline, and these changes were maintained throughout the 24 months
of follow-up. At 3, 6, 12, and 24 months of follow-up, the mean BCVAs
were logMAR 0.69 ± 0.39 (P = 0.0150), logMAR 0.67 ± 0.4 (P =
0.0002), logMAR 0.65 ± 0.44 (P = 0.0001), and logMAR 0.60 ± 0.43
(P , 0.0001), respectively.
Fig. 2. Mean gain in BCVA letter score from baseline to 24 months of
follow-up in all groups of treatment. In Group A (IVB therapy), mean
BCVA letter score from baseline to Month 1 was 7.48 ± 14.49
(range, −35 to +60) and 8.55 ± 16.48 (−30 to +65) at 3 months of
follow-up. At 6, 12, and 24 months of follow-up, the mean BCVA letter
scores were 8.16 ± 17.37 (range, −40 to +60), 11.13 ± 17.65 (range, −50
to +65), and 11.84 ± 17.18 (range, −20 to +30), respectively. In Group
B (GLP therapy), mean BCVA letter scores from baseline to Month 1
were 1.25 ± 7.2 (range, −15 to +25) and 3.29 ± 9.8 (range, −15 to +35)
at 3 months of follow-up. At 6, 12, and 24 months of follow-up, the
mean BCVA letter scores were 4.1 ± 11.3 (range, −15 to +), 4.41 ± 11.7
(range, −35 to +40), and 4.82 ± 12.9 (range, −30 to +45), respectively.
In Group C (IVB plus GLP), mean BCVA letter scores from baseline to
Month 1 were 3.44 ± 9.07 (range, −15 to +30) and 3.66 ± 12.27
(range, −35 to +30) at 3 months of follow-up. At 6, 12, and 24 months
of follow-up, the mean BCVA letter scores were 4.9 ± 16.37
(range, −30 to +30), 7.44 ± 16.73 (range, −25 to +30), and 8.18 ± 16.96
(range, −25 to +30), respectively.
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It is known that focal/grid photocoagulation has
potential side effects, including laser scar expansion,
paracentral scotoma, elevation of central visual ﬁeld
thresholds, and secondary choroidal neovasculariza-
tion and subretinal ﬁbrosis.25–27 In addition, given that
most eyes with DME that are treated with laser pho-
tocoagulation do not have an improvement in visual
acuity, there has been an interest in other treatment
modalities, and thus, newer approaches continue to
be studied. Recent studies showed that adding anti-
VEGF to laser therapy for DME achieved a visual
acuity better than laser-alone therapy at 1 year to 2
years of follow-up.28–30
The DRCR.net study compared RBZ plus prompt or
deferred laser with Early Treatment Diabetic Study
type laser alone. At 1 year, the mean change in visual
acuity letter score compared with baseline was signif-
icantly greater in the RBZ plus prompt laser group (8
letters) and RBZ plus deferred laser group (9 letters)
but only 3 letters in the laser-alone group. At 2 years,
the data were stable and similar with 7, 9, and 3 letters,
respectively.20,28
The READ-2 study29,30 analyzed RBZ alone, laser
alone, and RBZ plus laser. The mean improvement in
BCVA was about 7, 0.5, and 4 letters at the 6-month
primary end point compared with 8, 5, and 7 letters at
Month 24, for the RBZ alone, combined, and laser-
only groups, respectively.
Recently, results of the randomized controlled
RESOLVE study have been published. RESOLVE
had about 50 subjects in a sham arm and about 100 in
RBZ arms. Ranibizumab subjects had three initial
monthly injections, and rescue laser was permitted in
each group. For 1-year primary outcome, RBZ sub-
jects improved about 10 letters and sham subjects had
lost about 1 letter.31
The results from the RESTORE Study22 also dem-
onstrated that treatment with RBZ as monotherapy and
combined with laser treatment provided superior
visual acuity gain over standard laser in patients with
visual impairment because of DME at 12 months of
follow-up.
Solaiman et al21 showed that combined therapy with
IVB and sequential GLP 3 weeks later appeared to be
superior to GLP or IVB alone in reducing macular
thickening and improving visual acuity at 6 months
of follow-up. However, no signiﬁcant improvement
in BCVA occurs 6 months after treatment. The authors
showed that a combination of IVB and sequential GLP
could be used as an initial treatment of DDME.
A prospective randomized trial of IVB or laser
therapy in the management of DME (BOLT study 2)
showed that IVB group gained a median of 8 ETDRS
letters, whereas the laser group lost a median of 0.5
ETDRS letters (P = 0.0002) at 12 months of follow-
up. At 12 months, CMT decreased from 507 ± 145 mm
Table 2. Variation of BCVA at 24 Months after IVB, GLP, and IVB plus GLP Therapy for the Treatment of DDME
BCVA (logMAR) Results Group A (IVB Therapy) Group B (GLP Therapy) Group C (IVB plus GLP)
Improved 2 or more lines, n (%) 74 (52.5) 36 (30) 58 (36.9)
Remained stable, n (%) 62 (44.6) 59 (49.2) 78 (49.7)
Decreased 2 or more lines, n (%) 5 (3.6) 25 (20.8) 21 (13.4)
Mean gain letter score +11.84 +4.82 +8.18
Values represent number and percentages.
n, number of patients.
Fig. 3. Changes in macular thickness with OCT after IVB alone (Group
A), GLP (Group B), and IVB plus GLP (Group C) in patients with
DDME at 24 months of follow-up. In Group A, there was a decrease
from 446.2 ± 155.8 mm to 330.2 ± 115.6 mm (P , 0.0001) at the ﬁrst
month after intravitreal therapy of bevacizumab. At 3 months and
6 months, the mean CMT measurements were 341.5 ± 114.9 mm (P ,
0.0001) and 356.1 ± 103.9 mm (P , 0.0001), respectively. At 12
months and 24 months, the mean CMT measurements were 302.8 ±
89.6 mm (P, 0.0001) and 273.8 ± 79.5 mm (P, 0.0001), respectively.
In Group B, there was a decrease from 379.1 ± 91 mm to 368.9 ±
84.4 mm (P = 0.1370) at the ﬁrst month after grid laser therapy. At 3
months and 6 months, the mean CMT measurements were 351.7 ±
86.2 mm (P = 0.0010) and 333.7 ± 103.9 mm (P , 0.0001), respec-
tively. At 12 months and 24 months of follow-up, the mean CMT
measurements were 303.5 ± 89.6 mm (P , 0.0001) and 271.2 ±
78.6 mm (P , 0.0001), respectively. In Group C, there was a decrease
from 415.5 ± 144.8 mm to 377 ± 118.6 mm (P , 0.0001) at the ﬁrst
month after combined therapy. At 3 months and 6 months, the mean
CMT measurements were 314.9 ± 135.9 mm (P , 0.0001) and 364.4 ±
140.1 mm (P , 0.0001), respectively. At 12 months and 24 months of
follow-up, the mean CMT measurements were 345.1 ± 118.5 mm (P ,
0.0001) and 333 ± 138.5 mm (P , 0.0001), respectively.
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at baseline to 378 ± 134 mm (P , 0.001) in the IVB
group, whereas it decreased to a lesser extent in the
laser group from 481 ± 121 mm to 413 ± 135 mm (P =
0.02).32
The present study compares favorably with previous
studies. Our results indicate that primary IVB at doses
of 1.25 mg or 2.5 mg with or without GLP seems to
provide fast stability and improvement in BCVA at 24
months. Groups A and C had a statistically signiﬁcant
difference from baseline BCVA at all time points of
follow-up (P , 0.0001). Conversely, in Group B,
there was no statistically signiﬁcant difference from
baseline BCVA until the ﬁrst 6 months of treatment.
We found that 6 months after GLP, BCVA improved
signiﬁcantly (,0.05) from baseline and these changes
were maintained throughout the 24 months of follow-
up. The improvement rate in Group A was statistically
signiﬁcantly better than in Group B (ANOVA, P =
0.013). However, the improvement rate was not statis-
tically signiﬁcantly different between Groups A and C
(ANOVA, P = 0.167) or between Groups B and C
(ANOVA, P = 0.092).
In addition, we observed that CMT improved in all
treatment groups at 24 months of follow-up, although
primary IVB alone produced greater decrease in CMT
than treatments in Groups B and C. The comparison
among 3 groups showed higher CMT decrease in
Group A than in Groups B and C (ANOVA, P ,
0.001). In addition, the number of eyes that experi-
enced a signiﬁcant improvement of visual acuity
(2 ETDRS lines or more) was higher (52.5%) in Group
A (IVB therapy).
About the rate of visual improvement and the
absence of a statistically signiﬁcant difference between
Group B (GLP) and Group C (primary IVB plus GLP)
at the end of follow-up, we observed that both our
results and those obtained in the READ-2 study29,30
differ surprisingly with the results obtained by the
DRCR.net.20 We believe that as ours is a retrospective
study, selection of patients for combined treatment
(Group C) might have happened because of increased
metabolic, functional, and anatomical impairment.
Table 1 demonstrates that 75% of patients in Group
C were insulin dependent (with a statistically signiﬁ-
cant difference with the other groups; ANOVA, P =
0.012), which generally denotes a poor glycemic con-
trol at some point in therapy. In addition, in Group A,
baseline BCVA was worse and CMT was higher that
gives primary IVB alone more room for improvement
to better functional and anatomical outcomes during
Fig. 4. A 56-year-old man was
diagnosed with Type 2 diabetes
11 years before presentation.
He had excellent metabolic
control with oral hypo-
glycemiants and was pre-
viously treated with panretinal
photocoagulation and macular
focal laser 1 year ago. From
left to right, color-coded OCT
map, color fundus photograph,
and horizontal and vertical
OCT scans over the fovea. A.
At baseline visit, there was
a diffuse macular edema with
relative foveal sparing. His
BCVA was 20/25. Intravitreal
bevacizumab (1.25 mg/0.5 mL)
was injected at baseline and at
Month 2 (BCVA 20/25) and
Month 4 (combined with mac-
ular grid photocoagulation). B.
At 6 months, there was a sig-
niﬁcant decrease of macular
thickening (BCVA 20/32). In-
travitreal bevacizumab was
repeated at Month 6. C. At 12
months, there was a focal
macular edema with foveal
involvement (BCVA 20/25).
Intravitreal bevacizumab was
repeated at Month 12 and
Month 18 (BCVA 20/32). D.
At Month 24, there was
a decrease in macular thickness
with a marked regression of the lipid exudation (BCVA 20/25).
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follow-up. Other important limitation of our retrospec-
tive study is the lack of HbA1c data on nearly half of
the patients in all groups. This fact prevents us from
knowing the real metabolic status of each group. These
baseline characteristics could bias our results and
could explain why the combination of anti-VEGF ther-
apy and GLP did not result in fewer injections in
our cohort.
Additional limitations of our study include that it is
nonrandomized and retrospective in nature, that there
is lack of a control group, and that there was no
independent grading for OCT and FA. Finally, as in
the READ-2 study,29 our sample size may have been
insufﬁcient to determine whether combined treatment
is superior to GLP or to anti-VEGF injections alone.
In summary, our study provides evidence to support
the use of primary IVB with or without GLP as
treatment for DDME. These results indicate that
primary IVB had a statistically signiﬁcant difference
from baseline BCVA at all time points of 24 months of
follow-up, and we observed that primary IVB alone
produced greater decrease in CMT than GLP therapy or
IVB plus GLP in patients with DDME. The effect of
primary IVB with or without GLP was faster than GLP
alone. Primary IVB without GLP seems to be superior
to GLP alone to provide stability or improvement in
BCVA in patients with DDME at 24 months. In
addition, the number of eyes that experienced a signif-
icant improvement of visual acuity was higher in the
IVB group.
Key words: Avastin, diffuse diabetic macular
edema, grid laser photocoagulation, intravitreal beva-
cizumab, intravitreal injections, OCT.
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BACKGROUND/AIMS: To report the long-term anatomical and functional outcomes of patients 
with centre-involved diabetic macular oedema (DME) treated with intravitreal bevacizumab (IVB). 
 
METHODS: Retrospective case series. Patients diagnosed with centre-involved DME that were 
treated with at least one injection of 1.25 mg IVB and had a minimum follow-up of 60 months. 
Patients underwent measurement of best-corrected visual acuity (BCVA), ophthalmoscopy, optical 
coherence tomography and fluorescein angiography at baseline, 6-month, 12-month, 24-month, 36-
month, 48-month and 60-month visits. The paired samples t test was used to compare the 
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Background/aims To report the long-term anatomical
and functional outcomes of patients with centre-involved
diabetic macular oedema (DME) treated with intravitreal
bevacizumab (IVB).
Methods Retrospective case series. Patients diagnosed
with centre-involved DME that were treated with at least
one injection of 1.25 mg IVB and had a minimum
follow-up of 60 months. Patients underwent
measurement of best-corrected visual acuity (BCVA),
ophthalmoscopy, optical coherence tomography and
ﬂuorescein angiography at baseline, 6-month, 12-month,
24-month, 36-month, 48-month and 60-month visits.
The paired samples t test was used to compare the
central macular thickness (CMT) and BCVA with baseline
values. Statistical signiﬁcance was indicated by p<0.05.
Results Two hundred and one consecutive patients
(296 eyes) were included. The mean number of IVB
injections per eye was 8.4±7.1 (range: 1–47 injections).
At 5 years, the BCVA remained stable at 20/100
(logarithm of the minimum angle of resolution=0.7
±0.4). Eighty-six (29%) eyes improved ≥2 lines of
BCVA, 129 (43.6%) eyes remained stable and 81
(27.4%) eyes lost ≥2 lines of BCVA at 60 months. Mean
CMT decreased from 403.5±142.2 μm at baseline to
313.7±117.7 μm over 5 years follow-up (p≤0.0001).
Conclusions The early visual gains due to IVB were
not maintained 5 years after treatment.
INTRODUCTION
Diabetic retinopathy (DR) is a major cause of blind-
ness in low-income and middle-income countries.1
Diabetic macular oedema (DME) is the most
common cause of visual loss from DR.1 Up to 26%
of patients with DR present with DME.2 Vascular
endothelial growth factor (VEGF) plays a key role
in the pathogenesis of DME.3
Ranibizumab and aﬂibercept for the treatment of
DME are approved by several regulatory agencies.
However, intravitreal bevacizumab (IVB) has been
widely used off-label despite approved therapies.
The lower cost of bevacizumab, perceived effective-
ness and relative safety makes it a popular choice
particularly in the developing world.4 5 Numerous
reports have presented beneﬁcial visual and ana-
tomical results.6–8 To the best of our knowledge,
none of these studies have reported long-term
outcomes.
This study reports the 5-year anatomical and
functional outcomes after primary IVB (1.25 mg)
in patients with centre-involved DME. This report
comprises a series of 296 eyes, including 58 eyes
from a previously reported series with shorter
follow-up.8
METHODS
This multi-centre retrospective study evaluated eyes
with centre-involved DME that had received an
initial injection of off-label IVB between September
2006 and July 2009 at 12 institutions in Latin
America and Spain. Clinical records were reviewed
of 201 consecutive patients (296 eyes) with
centre-involved DME treated with at least one
injection of 1.25 mg IVB. Each participating
centre’s institutional ethics committee approved
this study. Informed consent was obtained for this
study. This study adheres to the tenets of the
Declaration of Helsinki. The off-label use of the
drug and potential risks and beneﬁts were discussed
with all patients.
Patient eligibility
Patients (18 years or older) with type 1 or 2 dia-
betes mellitus and DME were included if they had
decreased visual acuity and met the following cri-
teria: (1) no other possible causes of decreased
vision; (2) no prior treatment for DME such as
macular laser photocoagulation, intravitreal triamci-
nolone, micropulse laser or pars plana vitrectomy;
(3) no evidence of vitreomacular traction on optical
coherence tomography (OCT); (4) no evidence of
macular ischaemia on ﬂuorescein angiography (FA);
(5) at least 5 years follow-up and (6) no evidence of
intraocular inﬂammation, uncontrolled intraocular
pressure or cataract surgery within the previous
6 months.
Examination and treatment procedures
At baseline, ophthalmic examination included, best-
corrected visual acuity (BCVA) with Snellen charts
expressed as the number of lines read, and slit lamp
biomicroscopy. Baseline central retinal character-
istics were analysed with time domain OCT
(TD-OCT) using six diagonal slow 6 mm radial line
scans through a dilated pupil. The retinal thickness
of the 1 mm central retina was obtained using the
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macular thickness map for calculations in all cases. Once spectral
domain OCT (SD-OCT) was available, a volume scan centred on
the fovea was performed. The scans were reviewed and manual
measurements were used in cases of segmentation errors.
A 0.10 mL aliquot of commercially available bevacizumab was
prepared for each patient and placed in a tuberculin syringe
using aseptic techniques. Topical anaesthetic was instilled in the
eye. The eye was prepared in a standard fashion using 5% povi-
done/iodine. An eyelid speculum was inserted. An injection of
1.25 mg (0.05 mL) bevacizumab was performed 3.5–4 mm pos-
terior to the limbus, through the pars plana with a 30-gauge
needle. After the injection, retinal artery perfusion was assessed
with indirect ophthalmoscopy.
Patients were examined and treated on an as-needed regimen
based on BCVA and OCT at the discretion of the treating phys-
ician. Therapy was initiated at the diagnosis of DME. Patients
were examined and treated monthly until the oedema stabilised.
Subsequently, patients returned every 3–4 months at the treating
physician’s discretion. All return visits included OCT. FA was
performed at the examiners discretion.
Statistical analysis
Data were collected in an Excel 2007 spreadsheet (Microsoft,
Redmond, Washington, USA). Statistical analysis was performed
using MedCalc Software for Windows V.8.2.0.3 (MedCalc,
Mariakerke, Belgium). The paired samples t test was performed
to compare the central macular thickness (CMT) and BCVA
with baseline values. Correlation was considered signiﬁcant
when p<0.05.
Data were analysed at 1-month, 6-month, 12-month,
24-month, 36-month, 48-month and 60-month follow-up visits.
Snellen BCVA was converted to the logarithm of the minimum
angle of resolution (logMAR) for statistical analysis. An increase
or decrease in BCVA was deﬁned as a change of ≥2 lines of
Snellen vision prior to logMAR conversion. The main outcome
measures included changes in BCVA and CMT at the 60-month
follow-up visit.
RESULTS
Charts of 201 consecutive patients (296 eyes) were reviewed
who ﬁt the inclusion criteria. The mean follow-up was 66.7
±12.1 months (range, 60 to 114 months). The mean age was
62.3±9.6 years. There were 101 (50.2%) females. The mean
duration of diabetes was 15.8±8.1 years. The mean glycosylated
haemoglobin was 8.6±2.4%. In this cohort, 220 (74.4%) eyes
were phakic, and 76 (25.6%) were pseudophakic. Eleven
(3.7%) eyes had mild DR, 80 (27.1%) had moderate DR, 92
(31.1%) had severe DR and 113 (38.1%) had proliferative dia-
betic retinopathy (PDR). All eyes with PDR had undergone
prior scatter panretinal photocoagulation (PRP) at least
6 months prior to receiving IVB. Baseline characteristics are
summarised in table 1.
Figure 1 presents the BCVA at baseline, and each follow-up
visit after IVB. The mean BCVA was 0.7±0.4 logMAR (range,
0.2 to 1.6 logMAR; Snellen equivalent 20/100) at baseline, 0.5
±0.4 logMAR (range, 0.1 to 1.4 logMAR; Snellen equivalent
20/60) (p=0.002) at 1 month and 0.4±0.5 logMAR (range 0 to
1.3 logMAR; Snellen equivalent 20/50) (p=0.003) at 6 months.
At the 12-month, 24-month, 36-month, 48-month and
60-month follow-up visits the respective BCVAs were, 0.4±0.5
logMAR (range 0 to 1.3 logMAR; Snellen equivalent 20/50)
(p=0.0032), 0.5±0.5 logMAR (range, 0.1 to 1.6 logMAR;
Snellen equivalent 20/60) (p=0.006), 0.5±0.5 logMAR (range,
0.1 to 1.4 logMAR; Snellen equivalent 20/60) (p=0.03), 0.6
±0.3 logMAR (range, 0 to 2 logMAR; Snellen equivalent 20/
80) (p=0.10) and 0.7±0.3 logMAR (range, 0 to 2 logMAR;
Snellen equivalent 20/100) (p=0.387).
Subgroup analysis of the 60-month BCVA indicated that 86
(29%) eyes improved two or more lines of BCVA, and BCVA
remained stable in 129 (43.6%) eyes at 60 months. BCVA
Table 1 Baseline characteristics of patients with diabetic macular
oedema*
Demographic Number
Number of patients (n) 201




Age (mean±SD) (years) 62.3±9.6
Baseline Snellen chart BCVA (mean±SD) 20/100
Baseline logMAR (mean±SD) 0.7±0.3
Baseline OCT (μm) (mean±SD) 403.5±142.2
Hypertension, n (%) 104 (51.7)
Systemic glycaemic control, n (%)
Insulin 18 (9.1)
Oral hypoglycaemic 70 (34.7)
Combined therapy 108 (53.7)
None, n (%) 5 (2.5)
Baseline HbA1c, % 8.6±2.4
Grade of DR, n (%)
Mild NPDR 11 (3.7)
Moderate NPDR 80 (27.1)
Severe NPDR 92 (31.1)
PDR
*Values represent number and percentages.
BCVA, best-corrected visual acuity; DME, diffuse diabetic macular oedema; DR,
diabetic retinopathy; HbA1c, glycosylated haemoglobin; logMAR, logarithm of the
minimum angle of resolution; n, number of patients; NPDR, no proliferative diabetic
retinopathy; OCT, optical coherence tomography; PDR, proliferative diabetic
retinopathy.
Figure 1 Graph showing changes in best-corrected visual acuity
(BCVA) after intravitreal bevacizumab over 60 months of follow-up. The
BCVA mean improved at 1 month from baseline BCVA 20/100,
logMAR=0.7±0.4 to 20/60, logMAR=0.5±0.4 (p=0.002). At 6 months,
the mean of BCVA was 20/50, logMAR= 0.4±0.5 (p=0.003). At
12 months, the BCVA mean was 20/50, logMAR=0.4±0.5 (p=0.0032).
Mean 24-month BCVA was 20/60, logMAR=0.5±0.5 (p=0.006). At
36 months, the mean of BCVA was 20/60, logMAR= 0.5±0.5 (p=0.03).
At 48 months, the mean of BCVA decreased to 20/80, logMAR=0.6
±0.3 (p=0.10). At 60 months, the mean of BCVA was 20/100,
logMAR=0.7±0.3 (p=0.387). * denotes statistically signiﬁcant change
(p<0.05) compared with baseline. logMAR, logarithm of the minimum
angle of resolution.
1606 Arevalo JF, et al. Br J Ophthalmol 2016;100:1605–1610. doi:10.1136/bjophthalmol-2015-307950
Clinical science





ol: first published as 10.1136/bjophthalm
ol-2015-307950 on 24 February 2016. Downloaded from
 
Stellenbosch University  https://scholar.sun.ac.za
decreased by two or more lines in 81 (27.4%) eyes at the end of
follow-up (table 2).
The mean CMT decreased statistically signiﬁcantly from
403.5±142.2 μm at baseline to 336.8±147 mm (p<0.001) at
6 months follow-up, and this overall improvement continued
during the 60-month follow-up. At 12-month, 24-month,
36-month, 48-month and 60-month follow-up visits, the mean
CMT was 297.7±82.9 mm, 314.7±118.7 mm, 315±146.1 mm,
295.7±97.8 mm and 313.7±117.7 mm, respectively, which
were all signiﬁcantly lower than baseline (p≤0.0001, all com-
parisons) (ﬁgures 2–4).
Five years after IVB, 29.4% (87/296) of eyes had a
CMT≤260 mm, 21.6% (64/296) of eyes had a CMT between
261 and 300 mm, 19.9% (59/296) of eyes had a CMT between
300 and 400 mm and 13.9% (41/296) of eyes had a
CMT≥401 mm. Five-year OCT data were not available for
15.2% (45/296) of eyes.
A subgroup comparison was performed of the response to
IVB treatment for DME between patients with PDR and previ-
ous PRP and those with non-proliferative DR. A total of 113
(38.1%) eyes had been diagnosed with PDR and treated with
PRP at least 6 months before undergoing IVB for DME. In this
subgroup of eyes the mean BCVA improved from 0.83 logMAR
at baseline to 0.75 logMAR at 5 years after IVB (p=0.114). In
eyes with non-proliferative DR and DME treated with IVB, the
mean BCVA improved statistically signiﬁcantly from 0.69
logMAR at baseline to 0.58 logMAR at the end of follow-up
(p=0.004). In eyes with PDR, the mean CMT decreased statis-
tically signiﬁcantly from 411.1±140.6 μm at baseline to 328.8
±120.6 μm at 5 years (p=0.0002). In non-PDR eyes, the mean
CMT decreased statistically signiﬁcantly from 399.1±145.1 μm
at baseline to 309.4±104.1 μm (p<0.0001) at 5 years. The
repeated measures analysis of variance to compare the mean
retinal thickness and the logMAR BCVA, adjusting for the grade
of DR as a covariate, indicated that there was no statistical sig-
niﬁcance (p=0.718 for BCVA and p=0.164 for CMT).
A total of 2390 injections of IVB were performed during
60 months of follow-up. In the ﬁrst year of follow-up a mean of
3.3±2.1 (range, 1–10) IVB injections per eye were performed.
A mean of 2.1±2 (range, 1–9) IVB injections were administered
during the second year. During the third, fourth and ﬁfth year
of follow-up, a mean of 1.5±2 (range, 1–10), 1.3±1.9 (range,
1–10) and 1.2±2.1 (range, 1–9) IVB was administered, respect-
ively. The mean number of IVB injections per eye was 8.1±7.1
(range, 1–47 injections) at 5 years. Table 3 presents an analysis
of injections per year of follow-up. Table 4 presents the total
number of injections during 60 months of follow-up.
Ocular complications included tractional retinal detachment
(TRD) in eight (2.7%) eyes, glaucoma in six (2%) eyes, uveitis
in four (1.4%) eyes, rhegmatogenous retinal detachment (RRD)
in three (1%) eyes, vitreous haemorrhage in two (0.7%) eyes
and endophthalmitis in one (0.3%) eye. Systemic adverse events
included 10 (3.4%) patients who developed a stroke, nine (3%)
patients died and myocardial infarction (MI) occurred in ﬁve
(1.7%) patients.
The TRD incidence rate (IR) was 0.005 cases per person-year
equivalent to an annual incidence of ﬁve cases per 1000 persons
with DME who underwent IVB observed during 1 year of
follow-up. For glaucoma the IR was 0.004 cases per person-
year, and the IR for uveitis was 0.003 cases per person-year.
The IR for RRD was 0.002 cases per person-year, the IR for vit-
reous haemorrhage was 0.001 cases per person-year and the IR
for endophthalmitis was 0.0007 cases per person-year. The IR
for stroke was 0.006 cases per person-year. The annual IR for
death was 0.006 cases per person-year and the IR for MI was
0.003 cases per person-year (table 5).
DISCUSSION
This 5-year study shows that IVB treatment ‘as needed’
improves the BCVA of eyes with centre-involved DME for the
ﬁrst 3 years. However, these gains were not maintained over
time. Several recent randomised studies have shown that
anti-VEGF agents outperform macular laser photocoagulation
and have become ﬁrst line agents in the treatment of
centre-involved DME.9–13
Despite the availability of approved medications for DME
such as ranibizumab and aﬂibercept, off-label use of IVB is wide-
spread worldwide. The lower cost of bevacizumab, perceived
effectiveness and relative safety make it a popular choice par-
ticularly in low-income and middle-income countries.4 5
Previous studies have shown that IVB at doses up to 2.5 mg
improves BCVA and CMT in eyes with DME.8 9 14–25 The beva-
cizumab or laser therapy (BOLT) study prospectively compared
the outcomes of eyes randomly assigned to IVB or macular laser
photocoagulation. At 2 years follow-up, IVB-treated eyes had a
mean gain of 8.6 letters compared with a mean loss of 0.5
letters for the laser-treated eyes. Furthermore, 32% of the
IVB-treated eyes gained at least three lines of BCVA compared
with only 4% of laser-treated eyes.9 These results concur with
our previous studies of clinical outcomes at 24 months of 139
eyes with centre-involved DME treated with IVB.8
To the best of our knowledge, there are no studies that report
the 5-year results of IVB for centre-involved DME. Figure 1
Table 2 Variation of best-corrected visual acuity at 60 months of
intravitreal bevacizumab therapy for diabetic macular oedema in
296 eyes*
BCVA (logMAR) results Number of eyes Per cent
Improved two or more lines 86 29.0
Remained stable 129 43.6
Decreased two or more lines 81 27.4
*Values represent number and percentages.
BCVA, best-corrected visual acuity; logMAR, logarithm of the minimal angle of
resolution.
Figure 2 Changes in central macular thickness (CMT) with optical
coherence tomography after intravitreal bevacizumab over 60 months of
follow-up. Mean CMT decreased from 403.5±142.2 μm at baseline to
336.8±147 mm (p<0.001) at 6 months of follow-up. At 12-month,
24-month, 36-month, 48-month and 60-month follow-ups, mean CMT
was 297.7±82.9 mm, 314.7±118.7 mm, 315±146.1 mm, 295.7
±97.8 mm and 313.7±117.7 mm, respectively (p≤0.0001). * denotes
statistically signiﬁcant change (p<0.05) compared with baseline.
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illustrates that the response to IVB was rapid and by 6 months
the mean maximum gain was obtained. However by the fourth
year of follow-up, these gains started to disappear. BCVA at the
ﬁfth year of follow-up was the same as the mean baseline BCVA.
IVB treatment rapidly reduced CMT achieving maximal
reduction by 6. However, the mean decrease in CMTwas main-
tained throughout the 5 years. It should be noted that at
5 years, CMT≥300 mm remained in approximately one-third of
eyes which indicates persistent DME.
We can only speculate on why our patients did not maintain
visual gains. One possibility is that the eyes developed tachy-
phylaxis to bevacizumab.18 19 In tachyphylaxis, there is a dimin-
ished therapeutic response over time after repeated
administration of a drug. This does not seem to be the case in
our study as the number of injections was low, at a mean of 8.4
IVB injections per eye over 5 years.
Another possibility is that as the DME became more chronic
in nature, the intravitreal cytokine proﬁle changed. Several
proinﬂammatory cytokines are present in the vitreous of eyes
with DME.20 Inhibition of VEGF by anti-VEGF drugs such as
bevacizumab will not have an effect on other inﬂammatory cyto-
kines.21 Initially, VEGF may have played an important central
role in the pathogenesis of DME. However, once VEGF is
inhibited by bevacizumab, perhaps other inﬂammatory cytokines
started to play a more prominent role. Others have suggested
that chronic DME may exacerbate inﬂammation in diabetic
retinas leading to a vicious cycle of persistent DME.22 Of note
at the 5-year follow-up, about a third of the eyes in the current
study had persistent DME.
It is very likely that our patients were undertreated. In the
current study, the average number of injections was 8.4 over
5 years. In contrast, patients in RIDE (A Study of Ranibizumab
Injection in Subjects With Clinically Signiﬁcant Macular Edema
With Center Involvement Secondary to Diabetes Mellitus) and
RISE (A Study of Ranibizumab Injection in Subjects With
Clinically Signiﬁcant Macular Edema With Center Involvement
Secondary to Diabetes Mellitus) were injected monthly over
3 years.10 In the DRCR.net protocol I study, the average
number of injections over 5 years was 13 and 17 in the ranibizu-
mab plus prompt and deferred laser groups, respectively. In the
BOLT study, eyes received an average of 13 injections in
2 years.9 This is considerably higher than our study. A key
aspect in the management of patients with exudative DME is
the follow-up protocol. Currently, there is no consensus on a
particular follow-up protocol. In general, the best visual out-
comes were obtained through ﬁxed monthly injections followed
by treatment-as-needed therapy. However, this approach does
not seem to be sustainable in the medium or long term due to
many barriers that differ in each country. Our data reﬂect the
‘real world’ use of anti-VEGF in Latin America and Spain, and
not clinical trial data. Several studies have reported that in
exudative age-related macular degeneration (AMD), there is also
Figure 3 Illustrative case of diabetic
macular oedema. A 32-year-old female
with proliferative diabetic retinopathy,
cystoid macular oedema and foveal
detachment. Her baseline
best-corrected visual acuity (BCVA) was
20/50 OD (A) and 20/30 OS (B). Initial
treatment with intravitreal
bevacizumab (IVB) combined with
panretinal photocoagulation was
performed. After 6 months of
follow-up there was persistent oedema
in her OD (C) with BCVA of 20/60
(after 4 IVB), and a better anatomical
response in the OS (D) with BCVA of
20/40 (after 3 IVB). After 12 months of
follow-up and 7 IVB the BCVA
improved to 20/100 OD (E) and to 20/
100 OS after 5 IVB (F) and the fovea
OU showed no signiﬁcant ﬂuid.
Macular grid photocoagulation was
performed OU. After 24 months of
follow-up and 8 IVB (G) the BCVA was
20/50 OD and 20/30 OS after 6 IVB (H)
with no signiﬁcant recurrence of ﬂuid
involving the fovea. After 36 months of
follow-up and 10 IVB the BCVA was
20/60 OD (I) and 20/25 OS after 7 IVB
( J). After 48 months of follow-up and
12 IVB the BCVA was 20/60 OD (K)
and 20/25 OS after 9 IVB (L). Although
OS evidenced recurrence of the
oedema with foveal cysts the
functional improvement was
signiﬁcant. After 60 months of
follow-up and 13 IVB BCVA was 20/30
OD (M) and 20/30 OS after 11 IVB (N).
OD, right eye; OS, left eye; OU, both
eyes.
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under treatment in a ‘real world’ scenario.23–25 These results
call into question the sustainability of long-term anti-VEGF
treatment in eyes with chronic conditions such as DME and
exudative AMD. It appears that applying clinical trial protocols
to daily clinical practice may not be feasible.
Ocular adverse events in the current study included TRD,
glaucoma, uveitis, RRD, vitreous haemorrhage and endophthal-
mitis. Systemic adverse events observed included cerebrovascular
accidents, MI and death. Ocular and systemic adverse events
presented in this study were consistent with the literature.17–19
There is increasing evidence of a beneﬁcial effect of VEGF
inhibition on the severity score of DR.10 11 Due to the retro-
spective nature of our study we cannot determine the change in
severity of DR.
Limitations of this study are that it is non-randomised, uncon-
trolled and retrospective in nature. In addition, we had no
standard treatment regimen, or a standard regimen for retreat-
ment. Furthermore, the possibility that change in BCVA or
CMT may be secondary to a change in systemic health cannot
Figure 4 A case of diabetic macular
oedema. A 57-year-old male with
moderate-severe non-proliferative
diabetic retinopathy, cystoid macular
oedema and foveal detachment. His
baseline best-corrected visual acuity
(BCVA) was 20/60 OD (A) and 20/40
OS (B). After 6 months of follow-up
and after 3 intravitreal bevacizumab
(IVB) (C) there was a signiﬁcant
response in OD with BCVA of 20/100,
and an increase of retinal thickness in
the OS with BCVA of 20/400 after 1
IVB (D). After 12 months of follow-up
and 5 IVB the BCVA was 20/40 OD (E)
and 20/400 OS after 3 IVB (F). After
24 months of follow-up and 5 IVB the
BCVA was 20/50 OD (G) and 20/400
OS after 6 IVB (H). After 36 months of
follow-up and 7 IVB the BCVA was 20/
30 OD (I) and 20/400 OS after 7 IVB
( J). After 48 months of follow-up the
BCVA was 20/30 OD after 8 IVB (L)
and 20/400 OS (after 9 IVB). A severe
recurrence of the oedema was
observed in his OD (K). After
60 months of follow-up BCVA was 20/
30 OD after 11 IVB (M) and 20/400 OS
after 10 IVB (N). OD, right eye; OS, left
eye.









*Values represent number and percentages.n, number of eyes.
Table 3 Analysis of number of intravitreal bevacizumab injection













1 32 (12.1) 64 (30.8) 49 (37.9) 36 (36) 34 (40.7)
2 58 (21.9) 55 (26.4) 29 (22.5) 24 (24) 11 (13.1)
3 55 (20.8) 37 (17.8) 16 (12.4) 15 (15) 10 (11.9)
4 48 (18.2) 21 (10.1) 19 (14.7) 10 (10) 9 (10.7)
5 23 (8.7) 5 (2.4) 3 (2.3) 5 (5) 3 (3.6)
6 27 (10.2) 12 (5.8) 6 (4.7) 3 (3) 8 (9.5)
7 10 (3.8) 5 (2.4) 1 (0.8) 3 (3) 3 (3.6)
8 10 (3.8) 8 (3.8) 4 (3.1) 2 (2) 3 (3.6)
9 1 (0.4) 1 (0.5) 1 (0.8) 1 (1) 3 (3.6)
10 1 (0.4) 0 (0) 1 (0.8) 1 (1) 0 (0)
Total
(n1 per year)
264 208 129 100 84
Total
(n2 per IVB)
951 574 340 268 257
*Values represent number and percentages.
IVB, intravitreal bevacizumab; n, number of eyes; n1, number of eyes per year; n2,
number of intravitreal injection of bevacizumab per year.
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be ruled out. Despite these limitations, the authors believe that
the results of this retrospective multi-centre study may be clinic-
ally useful and can offer some valuable insight.
To the best of our knowledge, this is the ﬁrst study that
reports the long-term anatomical and functional results of IVB
for the treatment of centre-involved DME. In summary, our
‘real world’ long-term visual acuity outcomes do not match the
results obtained in clinical trials. Early gains in BCVA were not
maintained at 5 years of follow-up.
Author afﬁliations
1Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine,
Baltimore, Maryland, USA
2Retina and Vitreous Service, Clínica Privada de Ojos, Mar del Plata, Argentina
3Retina Service, Instituto de Cirugia Ocular, San Jose, Costa Rica
4Retina Division, Retina Division, Department of Ophthalmology and Visual Sciences,
Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil
5Department of Ophthalmology, Consorcio Hospital, General Universitario de
Valencia, Valencia, Spain
6Facultad de Medicina, OFTALMOS, Universidad de Buenos Aires, Buenos Aires,
Argentina
7Department of Ophthalmology, University of Colorado School of Medicine, Denver,
Colorado, USA
8Retina Service, Clinica Oftalmologica Centro Caracas and the Arevalo-Coutinho
Foundation for Research in Ophthalmology, Caracas, Venezuela
9Retina Service, Fundación Hospital Nuestra Señora de la Luz, Mexico City, Mexico
Acknowledgements Dr Arevalo is a PhD student at Faculty of Health Sciences,
Stellenbosch University, Stellenbosch, South Africa. This article is part of his PhD
thesis on ‘Intravitreal Bevacizumab as Anti-Vascular Endothelial Growth Factor in the
Management of Complications of Diabetic Retinopathy’.
Collaborators For a complete listing of the participating members of Pan-American
Collaborative Retina Study, see the online supplementary appendix.
Contributors All authors have given ﬁnal approval of this version to be published.
JFA, AFL, DA, MM and SR participated in drafting the manuscript, study design,
data collection and screening, data-analysis and evidence synthesis, and revising the
manuscript. LW, MEF, RG-P, AAA, VF, HQ-M, GS-V, MM and MS participated in
literature search, data collection, data-analysis and evidence synthesis and drafting
the manuscript. JFA, LW and AFL participated in hypothesis generation, evidence
synthesis and revising the manuscript. JFA, AFL, DA, MEF, RG-P, AAA, VF, HQ-M,
GS-V, MM, MS and SR participated in study design, data collection, screening and
revising the manuscript.
Competing interests JFA is a consultant to Second Sight LLC, Alcon Laboratories,
Engineering, DORC International BV and Bayer AG.
Ethics approval Each participating centre’s institutional ethics committee approved
this study.
Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES
1 Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic
population. Ophthalmology 1998;105:998–1003.
2 Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic
retinopathy. XV. The long-term incidence of macular edema. Ophthalmology
1995;102:7–16.
3 Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor
is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006;142:
961–9.
4 Hutton D, Newman-Casey PA, Tavag M, et al. Switching to less expensive blindness
drug could save medicare part B $18 billion over a ten-year period. Health Aff
(Millwood) 2014;33:931–9.
5 Anothaisintawee T, Leelahavarong P, Ratanapakorn T, et al. The use of comparative
effectiveness research to inform policy decisions on the inclusion of bevacizumab for
the treatment of macular diseases in Thailand’s pharmaceutical beneﬁt package.
Clinicoecon Outcomes Res 2012;4:361–74.
6 Soheilian M, Garfami KH, Ramezani A, et al. Two-year results of a randomized trial
of intravitreal bevacizumab alone or combined with triamcinolone versus laser in
diabetic macular edema. Retina 2012;32:314–21.
7 Solaiman KA, Diab MM, Dabour SA. Repeated intravitreal bevacizumab injection
with and without macular grid photocoagulation for treatment of diffuse diabetic
macular edema. Retina 2013;33:1623–9.
8 Arevalo JF, Sanchez JG, Wu L, et al. Primary intravitreal bevacizumab for diffuse
diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24
months. Ophthalmology 2009;116:1488–97, 1497.e1.
9 Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized
controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the
management of diabetic macular edema: 24-month data: report 3.
Arch Ophthalmol 2012;130:972–9.
10 Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab
therapy for diabetic macular edema: the 36-month results from two phase III trials:
RISE and RIDE. Ophthalmology 2013;120:2013–22.
11 Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aﬂibercept for diabetic
macular edema. Ophthalmology 2014;121:2247–54.
12 Elman MJ, Qin H, Aiello LP, et al. Diabetic Retinopathy Clinical Research Network.
Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred
laser treatment: three-year randomized trial results. Ophthalmology
2012;119:2312–18.
13 Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-year outcomes of individualized
ranibizumab treatment in patients with diabetic macular edema: the RESTORE
extension study. Ophthalmology 2014;121:1045–53.
14 Arevalo JF, Lasave AF, Wu L, et al. Intravitreal bevacizumab plus grid laser
photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for
diffuse diabetic macular edema: results of the Pan-American Collaborative Retina
Study Group at 24 months. Retina 2013;33:403–13.
15 Goyal S, Lavalley M, Subramanian ML. Meta-analysis and review on the effect of
bevacizumab in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol
2011;249:15–27.
16 Mehta S, Blinder KJ, Shah GK, et al. Intravitreal bevacizumab for the treatment of
refractory diabetic macular edema. Ophthalmic Surg Lasers Imaging
2010;41:323–9.
17 Stefanini FR, Arevalo JF, Maia M. Bevacizumab for the management of diabetic
macular edema. World J Diabetes 2013;4:19–26.
18 Forooghian F, Cukras C, Meyerle CB, et al. Tachyphylaxis after intravitreal
bevacizumab for exudative age-related macular degeneration. Retina
2009;29:723–31.
19 Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular
endothelial growth factor pharmacotherapy in age-related macular degeneration?
Ophthalmology 2008;115:2199–205.
20 Stewart MW. Corticosteroid use for diabetic macular edema: old fad or new trend?
Curr Diab Rep 2012;12:364–75.
21 Funk M, Schmidinger G, Maar N, et al. Angiogenic and inﬂammatory markers in
the intraocular ﬂuid of eyes with diabetic macular edema and inﬂuence of therapy
with bevacizumab. Retina 2010;30:1412–9.
22 Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery ﬂuocinolone
acetonide vitreous inserts provide beneﬁt for at least 3 years in patients with
diabetic macular edema. Ophthalmology 2012;119:2125–32.
23 Gabai A, Veritti D, Lanzetta P. One-year outcome of ranibizumab for neovascular
age-related macular degeneration: a thorough analysis in a real-world clinical
setting. Eur J Ophthalmol 2014;24:396–401.
24 Marques IP, Fonseca P, Luz Cachulo M, et al. Treatment of exudative age-related
macular degeneration with intravitreal ranibizumab in clinical practice: a 3-year
follow-up. Ophthalmologica 2013;229:158–67.
25 Pagliarini S, Beatty S, Lipkova B, et al. A 2-Year, phase IV, multicentre,
observational study of Ranibizumab 0.5 mg in patients with Neovascular
age-related macular degeneration in routine clinical practice: the EPICOHORT study.
J Ophthalmol 2014;2014:857148.
Table 5 Person-time incidence rates of complications of IVB for
DDME during 60 months of follow-up*
Number (%) Incidence rate Annual incidence
Ocular complications
TRD 5 case per 1000
Glaucoma 4 cases per 1000
Uveitis 3 case per 1000
RRD 2 cases per 1000
VH 1 case per 1000
Endophthalmitis 7 cases per 1000
Systemic complications
Stroke 6 cases per 1000
Death 6 cases per 1000
Myocardial infarction 5 (1.7) 0.003 3 cases per 1000
*Values represent number and percentages.
DDME, diffuse diabetic macular oedema; IVB, intravitreal bevacizumab; RRD,
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Chapter 7: Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy at 6 months of 
follow up  
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Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye 






Hypothesis 3: IVB may decrease retinal neovascularization in patients with PDR at 6 months of 
follow up. However, the effect may decrease at 24 months of follow up due to tachyphylaxis, and 
pan-retinal photocoagulation and/or vitrectomy will be necessary.  
 
AIMS: To study the effects of intravitreal bevacizumab (Avastin) on retinal neovascularization (RN) 
in patients with proliferative diabetic retinopathy (PDR). 
 
METHODS: Retrospective study of patients with RN due to PDR who were treated with at least 
one intravitreal injection of 1.25 or 2.5 mg of bevacizumab. Patients underwent ETDRS best-
corrected visual acuity (BCVA) testing, ophthalmoscopic examination, optical coherence tomography 
(OCT), and fluorescein angiography (FA) at baseline and follow-up visits. 
 
RESULTS: Forty-four eyes of 33 patients with PDR and a mean age of 57.2-years (range: 23-82 
years) participated in the study. Thirty-three eyes (75%) had previous panretinal photocoagulation 
(PRP). Twenty-seven eyes (61.4%) showed total regression of RN on fundus examination with 
absence of fluorescein leakage, 15 eyes (34.1%) demonstrated partial regression of RN on fundus 
examination and FA. Follow-up had a mean of 28.4 weeks (range from 24 to 40 weeks). BCVA and 
OCT demonstrated improvement (P<0.0001). Three eyes without previous PRP ('naive' eyes) and 
with vitreous haemorrhage have avoided vitreo-retinal surgery. One eye (2.2%) had PDR progression 
to tractional retinal detachment requiring vitrectomy, and one eye (2.2%) had vitreous haemorrhage 
with increased intraocular pressure (ghost cell glaucoma). No systemic adverse events were observed. 
 
CONCLUSIONS: Intravitreal bevacizumab resulted in marked regression of RN in patients with PDR 
and previous PRP, and rapid resolution of vitreous haemorrhage in three naive eyes. Six-months 
results of intravitreal bevacizumab at doses of 1.25 or 2.5 mg in patients with PDR do not reveal any 
safety concerns. 
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Abstract
Aims To study the effects of intravitreal
bevacizumab (Avastin) on retinal
neovascularization (RN) in patients with
proliferative diabetic retinopathy (PDR).
Methods Retrospective study of patients with
RN due to PDR who were treated with at least
one intravitreal injection of 1.25 or 2.5mg of
bevacizumab. Patients underwent ETDRS
best-corrected visual acuity (BCVA) testing,
ophthalmoscopic examination, optical
coherence tomography (OCT), and fluorescein
angiography (FA) at baseline and follow-up
visits.
Results Forty-four eyes of 33 patients with
PDR and a mean age of 57.2-years (range: 23–
82 years) participated in the study. Thirty-three
eyes (75%) had previous panretinal
photocoagulation (PRP). Twenty-seven eyes
(61.4%) showed total regression of RN on
fundus examination with absence of
fluorescein leakage, 15 eyes (34.1%)
demonstrated partial regression of RN on
fundus examination and FA. Follow-up had a
mean of 28.4 weeks (range from 24 to 40
weeks). BCVA and OCT demonstrated
improvement (Po0.0001). Three eyes without
previous PRP (‘naive’ eyes) and with vitreous
haemorrhage have avoided vitreo-retinal
surgery. One eye (2.2%) had PDR progression
to tractional retinal detachment requiring
vitrectomy, and one eye (2.2%) had vitreous
haemorrhage with increased intraocular
pressure (ghost cell glaucoma). No systemic
adverse events were observed.
Conclusions Intravitreal bevacizumab
resulted in marked regression of RN in
patients with PDR and previous PRP, and
rapid resolution of vitreous haemorrhage in
three naive eyes. Six-months results of
intravitreal bevacizumab at doses of 1.25 or
2.5mg in patients with PDR do not reveal any
safety concerns.
Eye (2009) 23, 117–123; doi:10.1038/sj.eye.6702980;
published online 21 September 2007
Keywords: avastin; bevacizumab; diabetic
retinopathy; intravitreal injections; proliferative;
retinal neovascularization
Introduction
Diabetic retinopathy remains a major threat to
sight in the working age population in the
developed world. Furthermore, it is increasing
as a major cause of blindness in other parts of
the world especially in developing countries.1
Proliferative diabetic retinopathy (PDR) is a
major cause of visual loss in diabetic patients. In
PDR, the growth of new vessels from the retina
or optic nerve, is thought to occur as a result of
vascular endothelial grow factor (VEGF) release
into the vitreous cavity as a response to
ischaemia.2–4 Because VEGF has been shown to
play a major role in retinal neovascularization
(RN),2,3 although other factors may be involved
as well,5,6 anti-VEGF treatments have been
hypothesized as an alternative adjunctive
treatment for RN.7,8
Bevacizumab (AvastinTM Genentech Inc., San
Francisco, CA, USA) is a complete full-length
humanized antibody that binds to all subtypes
of VEGF and is successfully used in tumour
therapy as a systemic drug.9 Recent studies
have demonstrated the usefulness of
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an intravitreal injection of bevacizumab in the reduction
of vascular permeability and fibrovascular proliferation
in macular oedema secondary to central vein occlusion,
RN secondary to PDR, and choroidal neovascularization
secondary to age macular degeneration.8,10–14 The
amount of human retinal penetration for a complete
full-length anti-VEGF antibody is not known at present.
However, full thickness retinal penetration of intravitreal
bevacizumab was observed in an animal model.15,16
Additionally, intravitreal bevacizumab does not appear
to be toxic to the albino rabbit retina at a concentration
up to 2.5mg.17
Panretinal photocoagulation (PRP) currently is the
principal therapy for PDR, unless the patient already has
extensive vitreous haemorrhage, which would preclude
the possibility of laser photocoagulation.
Neovascularization on and around the optic disc
(NVD) and vitreous haemorrhage were found to be
more frequently associated with severe visual loss
despite PRP in the Diabetic Retinopathy Study (DRS) and
Early Treatment Diabetic Retinopathy Study
(ETDRS).18,19 Long intervals between PRP sessions and
the variable amount of time required for a favourable
response may increase the incidence of complications
due to the progression of PDR.18,20 In fact, a single
episode of PRP or shorter intervals between PRP
episodes, although desirable in severe PDR and when the
patient must travel long distances for treatment, are often
associated with acute visual disturbances due to
exudative choroidal detachment, retinal detachment, and
macular oedema.21–24
The purpose of this retrospective study was to evaluate
the effectiveness of intravitreal bevacizumab on RN in
patients with PDR as a base for future studies in which
bevacizumab may be used as an adjuvant treatment to
PRP for PDR.
Patients and methods
We conducted a retrospective study in 44 eyes of 33
patients with RN in patients with PDR, who were treated
with off-label intravitreal bevacizumab between
September 2005 and August 2006 at five institutions in
Venezuela, Costa Rica, Brazil, Argentina, and Peru.
Institutional Review Board/Ethics Committee approval
and patients’ informed consent were obtained for this
study at all five institutions. The off-label use of the drug
and its potential risks and benefits were discussed
extensively with all patients. Eyes that were previously
treated with scatter photocoagulation, had prior focal/
grid laser photocoagulation, and previous intravitreal
triamcinolone injection were included if any of those
therapies had been performed at least 6 months before
intravitreal bevacizumab. An injection of 1.25mg
(0.05ml) or 2.5mg (0.1ml) of bevacizumab was given
according to the discretion of the treating physician.
Baseline data included age, sex, type, and duration of
diabetes mellitus. Patients also underwent clinical
examination including best-corrected visual acuity
(BCVA) measurement with ETDRS chart, applanation
tonometry, fundus examination, fluorescein angiography
(FA), and optical coherence tomography (OCT). In
patients with clinical significant macular oedema,
baseline central retinal characteristics was observed by
OCT (Stratus III OCT, Carl Zeiss, Dublin, CA, USA) using
six diagonal slow 6-mm radial line scans, with software
versions 3.0 and 4.0, through a dilated pupil by a retina
specialist.
A 0.18-ml aliquot of commercially available
bevacizumab was prepared for each patient and placed
in a tuberculin syringe using aseptic techniques.
Bevacizumab was stored for up to 3 weeks under
refrigeration at 41C under sterile conditions, and the
syringes were capped with a needle. After the eye had
been prepared in a standard manner using 5%
povidone/iodine, an eyelid speculum was used to
stabilize the eyelids, and the injection of 1.25mg (0.05ml)
or 2.5mg (0.1ml) of bevacizumab was given 3.5–4mm
posterior to the limbus, through the infero-temporal pars
plana with a 30-gauge needle under topical anaesthesia
or subconjunctival lidocaine. After the injection,
intraocular pressure and retinal artery perfusion were
checked, and patients were instructed to administer
topical antibiotics for 7 days.
Patients were examined at 1, 2 weeks, and 1 month
after the first injection and monthly thereafter. One, three
and six months after initial injection, patient evaluation
was performed using ophthalmic examination with slit-
lamp biomicroscopy, OCT, and FA. Patients were
included in this consecutive series if there was a
minimum of 6-months follow-up. The main outcome
measure was the change in RN defined as the change in
the area of vitreous leakage from NVD and new vessels
elsewhere (NVE) in the late phase of FA. Patients
received reinjections only if RN was not totally resolved
on ophthalmic examination or FA. Data was analysed by
a paired Student’s t-test and a Fisher’s exact test when
appropriate.
Monitored systemic conditions included myocardial
infarction, stroke, systemic hypertension,
thromboembolic diseases, and death. Blood pressure was
measured prior to bevacizumab injection and at 1 and 2
weeks following each injection. Other systemic
conditions were assessed by a thorough review of
systems. If the patients were unable to attend a particular
visit, a telephone interview was conducted to assess for
possible systemic complications, and a new appointment
was scheduled. We certify that all applicable institutional
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and governmental regulations concerning the ethical use
of human volunteers were followed during this research.
Results
We reviewed the clinical records of 33 consecutive
patients (44 eyes) with PDR injected with intravitreal
bevacizumab between September 2005 and August 2006.
Patients had a mean follow-up of 28.4 weeks (range from
24 to 40 weeks). Our patients had a mean age of 57.2
years (range from 23 to 82 years), and 51.5% were female
(16 men and 17 women). Twenty-three diabetic patients
(69.7%) were insulin-dependent. The mean duration of
diabetes was 17 years (range from 1 to 30 years). Thirty-
five eyes (79.5%) were treated with an intravitreal
injection of 2.5mg of bevacizumab, and nine eyes (20.5%)
with 1.25mg of bevacizumab. Of the 33 eyes (75%) that
were previously treated with scatter photocoagulation
(Figure 1), 19 had prior focal/grid laser photocoagulation
(Figure 2), and two patients had a previous intravitreal
triamcinolone injection (Table 1). Seventeen eyes had
clinical significant macular oedema (CSME) at
biomicroscopic non-contact fundus examination with a
66- or a 78-D lens.
The mean baseline BCVA was logMAR¼ 1.21 and the
final mean BCVA was logMAR¼ 0.70 (Po0.0001). Final
BCVA analysis by subgroups demonstrated that 12 eyes
(27.3%) remained stable, 29 eyes (65.9%) improved two
or more ETDRS lines of BCVA, and three eyes (6.8%)
decreased two or more ETDRS lines of BCVA. OCT
results were available for all 18 patients with CSME, the
mean central macular thickness was 487.4 mm (range
from 284 to 1082 mm), and decreased to a mean of
260.6mm (range from 178 to 475mm) at the end of follow-
up (Po0.0001). Final BCVA analysis by subgroups of
patients with CSME demonstrated that 14 eyes (82.4%)
improved two or more ETDRS lines of BCVA (Table 2).
Twenty-seven eyes (61.4%) showed total regression of
RN on fundus examination with absence of fluorescein
leakage (Figures 1 and 2), 15 eyes (34.1%) demonstrated
partial regression of RN on fundus examination and FA,
and two eyes (4.5%) of two patients showed no
regression of RN. The first of those two patients who did
not respond was treated with 1.25mg of bevacizumab
and had PDR progression to tractional retinal
detachment requiring vitrectomy resulting in a poor final
visual acuity (VA) (counting fingers) due to ischaemic
optic neuropathy. The second patient was treated with
2.5mg of bevacizumab and developed vitreous
haemorrhage with increased intraocular pressure
(ghost cell glaucoma). In addition, these two patients had
previous PRP (Table 3).
Twenty-one eyes (47.7%) needed a second injection
due to recurrence of neovascularization at a mean of
Figure 1 A 53-year-old man had a 2-month history of visual
loss to 20/60 in his right eye. We had performed panretinal
photocoagulation in his right eye 2 years previously. Fundus
examination revealed a mild vitreous haemorrhage. (a) Fluor-
escein leakage from neovascularization of the disc (NVD) at
baseline (arrow) between retinal vessels crossing the optic disc at
9 O’clock and 10 O’clock was demonstrated. In addition, FA
showed magnification of retinal neovascularization elsewhere
(NVE) in the superonasal retina (arrowheads). (b) At week 1
after intravitreal bevacizumab, total resolution of leakage from
NVD and NVE are shown. His VA returned to 20/32 1 month
later. He has not needed a reinjection at 5 months of follow-up.
Figure 2 (a) Late-phase fluorescein angiogram demonstrating
retinal neovascularization at the optic disc (NVD) (arrows) and
neovascularization elsewhere (NVE) (arrowheads) in an 80-year-
old man with proliferative diabetic retinopathy. He received a
complete panretinal photocoagulation 2 years previously. (b) A
fluorescein angiogram obtained 2 weeks after intravitreal
bevacizumab injection demonstrated total regression of leakage
from NVE and NVD in the late phase of the study.
Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy
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12.4 weeks (range from 4 to 34 weeks), and seven eyes
(15.9%) needed a third injection due to recurrence of
neovascularization at a mean of 17.3 weeks (range from
11 to 22 weeks). Three eyes without previous PRP (‘naive’
eyes) and with vitreous haemorrhage have avoided
vitreo-retinal surgery. There were no episodes of
inflammation or severe decrease of vision immediately
after an injection.
At 6 months, no systemic adverse events such as
thromboembolic events (cerebrovascular accidents,
transient ischaemic attacks, myocardial infarctions, or
peripheral vascular disease) were reported.
Discussion
Although RN actually may be due to more than one
cytokine, VEGF is an important, if not the most important
cytokine involved.25 Activation of the VEGF receptor
pathway triggers a network of signalling processes that
promotes endothelial cell growth, migration, survival from
pre-existing vessels, differentiation, and mobilization of
endothelial progenitor cells from the bone marrow into the
peripheral circulation.9,26,27 Furthermore, VEGF increases
vessel permeability leading to deposition of proteins in the
interstitium that facilitate the process of angiogenesis.28
There are several reports published on the intravitreal
administration of anti-VEGF compounds for RN in diabetic
retinopathy.7,13 In addition, there are five case reports on
the use of intravitreal bevacizumab in RN in diabetic
retinopathy demonstrating regression of RN in PDR.14,29–32
Our study demonstrated that intravitreal bevacizumab
resulted in marked regression of RN on fundus
examination and FA in patients with PDR and previous
PRP. Furthermore, a rapid resolution of vitreous
haemorrhage in three naive eyes was also seen. In
addition, intravitreal bevacizumab demonstrated a
similar beneficial response on macular thickness in eyes
with PDR, and probably bevacizumab prevents
exacerbation of macular oedema in patients with
concomitant CSME and PDR. To determine the effect of
an intravitreal injection of bevacizumab on actively
growing new vessels, we chose the change in vitreous
leakage from RN as our primary outcome. The detection
of NVD and NVE on FA allowed the use of a systematic
anatomical approach to monitor the area of leaking new
vessels over time. Finally, to determine the effect of an
intravitreal injection of bevacizumab on macular oedema,
we measured the change of retinal thickening with OCT.
Regression of neovascularization and decrease of
retinal thickening occurred in some injected eyes as soon
as 7–15 days after the intravitreal injection of
bevacizumab. Twenty-one eyes (47.7%) needed a second
injection due to recurrence of neovascularization at a
mean of 12.4 weeks, and seven eyes (15.9%) needed a









PRP 12 2 14
PRPþgrid 11 4 15
PRPþ focal 2 2 4
Total of eyes 25 8 33
IVT, intravitreal; PRP, panretinal photocoagulation.
Table 2 Characteristics of patients with macular oedema associated to RN
Patient no. Prior treatment Baseline VA logMar Baseline macular
thickness by OCT
(mm)
Final VA LogMar Final macular
thickness by OCT
(mm)
1 PRP 0.3 284 0.1 244
4 No 1.0 1082 0.5 357
5 No 2.0 404 1.3 369
6 No 2.0 267 0.7 178
7 PRPþ focal 1.3 559 1.2 178
9 PRPþ grid 1.0 471 1.9 475
10 PRP 1.0 589 0.3 215
11 No 2.0 381 2.0 219
12 PRPþ grid 1.8 615 0.2 209
13 PRPþ grid 1.0 481 0.2 269
14 PRPþ grid 1.0 481 0.3 263
15 PRPþ grid 1.8 383 0.5 192
16 PRPþ grid 1.3 355 0.5 213
17 PRPþ grid 1.3 862 0.6 324
18 PRPþ grid 1.0 362 0.5 203
19 (RE) PRP 1.8 367 1.3 270
19 (LE) No 2.0 343 1.3 252
CF, counting fingers; LE, left eye; OCT, optical coherence tomography; PRP, panretinal photocoagulation; RE, right eye; RN, retinal neovascularization;
VA, visual acuity.
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third injection due to recurrence of neovascularization at
a mean of 17.3 weeks. Interestingly, we found that the
2.5mg seems to be more effective than the 1.25mg dose
to induce complete regression of RN in naive eyes
(P¼ 0.01; Table 3). The reason for this dose-dependant
response on RN in naive eyes in unknown. In addition,
the optimum dose and dosing sequence for intravitreal
bevacizumab is still undetermined. We elected to defer
reinjection only when there was a recurrence. Our clinical
impression is that the effect of intravitreal bevacizumab
on RN may be more lasting than in eyes with other
pathologies such as choroidal neovascularization or
macular oedema; however, the cause is not known.
Our results suggest an overall VA gain as well as a
reduced risk of VA loss in eyes with diabetic macular
oedema (as recognized on OCT) treated with intravitreal
bevacizumab. We did not find any differences in the
effectiveness between the doses of 1.25 and 2.5mg for
CSME, both of them demonstrated improvement with
respect to VA and decrease in retinal thickness. Avery
et al13 reported similar results to the present study in
45 eyes of 32 patients with retinal and/or iris
neovascularization secondary to diabetes mellitus who
had received intravitreal injections of 6.2 mg–1.25mg of
bevacizumab. They demonstrated that all patients with
neovascularization had complete or at least partial
reduction in leakage of the neovascularization within
1 week after the injection. Additionally, they found in
two cases, a subtle decrease in leakage of retinal or iris
neovascularization in the fellow uninjected eye. We could
not confirm their observation as in our study, utilizing
higher doses (1.25–2.5mg) of bevacizumab, all of our
patients with bilateral RN underwent bilateral
intravitreal injections.
Panretinal photocoagulation has been the mainstay for
the treatment of PDR, and its suppressive effect on RN
has been well documented.20,21,33,34 However, substantial
regression of new vessels may take weeks after
completion of PRP, and in up to one-third of cases, new
vessels continue to grow despite initial PRP.21,34 In these
cases, vitreous haemorrhage may induce visual loss and
prevent complete laser. Moreover, macular oedema may
increase after PRP and cause transient or persistent
visual loss.35,36 Our study demonstrates multiple benefits
of intravitreal bevacizumab on PDR and in the future this
new option could be an adjuvant agent to PRP so that
more selective therapy may be applied. In addition,
bevacizumab may allow long intervals between PRP
sessions to avoid the development of macular oedema
and other complications.21–24
The current study has several limitations, including a
relatively small sample size and a relatively short
duration of follow-up. In addition, this study included
patients from five different centres and patients were
treated according to the discretion of the treating
physician. However, the large difference in the
quantitative morphologic outcomes and the trend
towards improvement in BCVA in injected eyes found at
6 months confirms our hypothesis that at least some eyes
with PDR, such as those with pre-existing macular
oedema or rapidly growing new vessels, may truly
benefit from intravitreal bevacizumab. In addition, we
can safely assume with a 95% confidence, that the true
rate of systemic complications is o9% in our study.37
In summary, intravitreal bevacizumab seems to be a
promising treatment for PDR, minimizing the risk for
exudative complications, progression of RN, vitreous
haemorrhage, and decreased vision caused by macular
oedema. Intravitreal bevacizumab may potentially be
used as an adjuvant agent to PRP for PDR. Although no
serious complications of intravitreal injection of
bevacizumab occurred in our series, further studies are
needed to assess the efficacy and safety of intravitreal
bevacizumab in the management of PDR.
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Chapter 8: Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy at 2 years of follow up  
 
Arevalo JF, Lasave AF, Wu L, Maia M, Diaz-Llopis M, Alezzandrini AA, Brito M; Pan-American 
Collaborative Retina Study Group (PACORES). 
INTRAVITREAL BEVACIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Results 
From the Pan-American Collaborative Retina Study Group (PACORES) at 24 Months of Follow-up. 




Hypothesis 3: IVB may decrease retinal neovascularization in patients with PDR at 6 months of 
follow up. However, the effect may decrease at 24 months of follow up due to tachyphylaxis, and pan-
retinal photocoagulation and/or vitrectomy will be necessary.  
 
PURPOSE: To evaluate the effects of intravitreal bevacizumab (IVB) on retinal neovascularization in 
patients with proliferative diabetic retinopathy (PDR). 
 
METHODS: Retrospective multicenter interventional case series. A chart review was performed of 
81 consecutive patients (97 eyes) with retinal neovascularization due to PDR, who received at least 1 
IVB injection. 
 
RESULTS: The mean age of the patients was 55.6 ± 11.6 years. The mean number of IVB injections 
was 4 ± 2.5 injections (range, 1-8 injections) per eye. The mean interval between IVB applications 
was 3 ± 7 months. The mean duration of follow-up was 29.6 ± 2 months (range, 24-30 months). Best-
corrected visual acuity and optical coherence tomography improved statistically significantly (P < 
0.0001, both comparisons). Three eyes without previous pan-retinal photocoagulation ("naive" eyes) 
and with vitreous hemorrhage did not require vitreoretinal surgery. Five (5.2%) eyes with PDR 
progressed to tractional retinal detachment requiring vitrectomy. No systemic adverse events were 
noted. 
 
CONCLUSION: Intravitreal bevacizumab resulted in marked regression of retinal neovascularization 
in patients with PDR and previous pan-retinal photocoagulation. Intravitreal bevacizumab in naive 
eyes resulted in control or regression of 42.1% of eyes without adjunctive laser or vitrectomy 
during 24 months of follow-up. There were no safety concerns during the 2 years of follow-up of IVB 
for PDR. 
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INTRAVITREAL BEVACIZUMAB FOR
PROLIFERATIVE DIABETIC RETINOPATHY
Results From the Pan-American Collaborative
Retina Study Group (PACORES) at 24 Months of
Follow-up
J. FERNANDO AREVALO, MD, FACS,* ANDRES F. LASAVE, MD,† LIHTEH WU, MD,‡
MAURICIO MAIA, MD,§ MANUEL DIAZ-LLOPIS, MD,¶ ARTURO A. ALEZZANDRINI, MD,**
MIGUEL BRITO, MD†† FOR THE PAN-AMERICAN COLLABORATIVE RETINA STUDY GROUP (PACORES)
Purpose: To evaluate the effects of intravitreal bevacizumab (IVB) on retinal neo-
vascularization in patients with proliferative diabetic retinopathy (PDR).
Methods: Retrospective multicenter interventional case series. A chart review was
performed of 81 consecutive patients (97 eyes) with retinal neovascularization due to PDR,
who received at least 1 IVB injection.
Results: The mean age of the patients was 55.6 ± 11.6 years. The mean number of IVB
injections was 4 ± 2.5 injections (range, 1–8 injections) per eye. The mean interval between
IVB applications was 3 ± 7 months. The mean duration of follow-up was 29.6 ± 2 months
(range, 24–30 months). Best-corrected visual acuity and optical coherence tomography
improved statistically signiﬁcantly (P , 0.0001, both comparisons). Three eyes without
previous panretinal photocoagulation (“naive” eyes) and with vitreous hemorrhage did
not require vitreoretinal surgery. Five (5.2%) eyes with PDR progressed to tractional retinal
detachment requiring vitrectomy. No systemic adverse events were noted.
Conclusion: Intravitreal bevacizumab resulted in marked regression of retinal neo-
vascularization in patients with PDR and previous panretinal photocoagulation. Intravitreal
bevacizumab in naive eyes resulted in control or regression of 42.1% of eyes without
adjunctive laser or vitrectomy during 24 months of follow-up. There were no safety
concerns during the 2 years of follow-up of IVB for PDR.
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Diabetic retinopathy remains a major sight-threatening disease of the working population
in developed and developing countries.1 Proliferative
diabetic retinopathy (PDR) is a major cause of visual
loss in patients with diabetes. Proliferative diabetic
retinopathy is characterized by retinal neovasculari-
zation (RN), retinal capillary leakage, hemorrhage,
and ﬁbrovascular proliferation in the vitreous retinal
interface, which results in vitreous hemorrhage (VH)
and tractional retinal detachment (TRD).2 Prolifera-
tive diabetic retinopathy is rapidly becoming a major
cause of blindness in many countries. Approxi-
mately, 1.5% of adults with diabetes have PDR.3
Current evidence indicates that the growth of new
vessels from the retina or optic nerve is likely a result
of the release of vascular endothelial growth factor
(VEGF) into the vitreous cavity as a response to
ischemia.4–6 Studies have demonstrated a correlation
of VEGF levels to the severity of PDR and a reduc-
tion in VEGF levels after successful laser treatment
of PDR.3 Currently, panretinal photocoagulation
(PRP) is the only successful evidence-based treat-
ment for PDR. Panretinal photocoagulation reduces
the risk of severe visual loss by 50% to 60% with
regression of the majority of new vessels over
a period of 3 months.7 Despite this evidence, several
attempts have been made to modify PRP laser tech-
niques to reduce side effects such as decreased visual
acuity, peripheral ﬁeld loss, and macular edema.8
Despite adequate PRP, many patients still require
supplemental laser treatment and nearly 4.5% show
disease progression that eventually requires pars
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plana vitrectomy.9 Additionally, most patients
require at least 2 PRP treatments and several patients
return for multiple additional sessions for persistent
neovascularization. Consequently, long intervals
between PRP sessions and the variable amount of
time required for a favorable response may increase
the incidence of complications due to the progression
of PDR.10,11 A single episode of PRP or shorter in-
tervals between PRP episodes is desirable for severe
PDR or when the patient must travel long distances
for treatment. However, shorter intervals between
PRP sessions are often associated with acute visual
disturbances due to exudative choroidal detachment,
retinal detachment, and macular edema.12–14
These difﬁculties and complications have spurred
a search of new therapies for treating PDR, such as
anti-VEGF compounds. Our group previously re-
ported on the efﬁcacy of intravitreal bevacizumab
(IVB) for RN in patients with PDR at 6 months of
follow-up.15 This previous study indicated a marked
regression of RN, especially in patients with PDR and
with a history of PRP.15
Several randomized non–placebo-controlled trials
of IVB for the treatment of PDR have been recently
published.16–18 This retrospective study evaluated the
effectiveness of IVB on RN in patients with PDR at
24 months of follow-up as a basis for future studies
of bevacizumab, as an adjuvant treatment to PRP
for PDR.
Patients and Methods
A retrospective study was performed of 97 eyes (81
patients) with RN secondary to PDR, who were
treated with off-label IVB between September 2009
and August 2011 at 5 institutions in Venezuela, Costa
Rica, Brazil, Argentina, and Spain. Institutional
review board/ethics committee approval and informed
consent was obtained for this study at all 5 institu-
tions. The off-label use of the drug and its potential
risks and beneﬁts were discussed extensively with all
patients. This study adhered to the 1964 Declaration
of Helsinki for research involving human subjects.
Eyes that were previously treated with scatter photo-
coagulation, had prior focal/grid laser photocoagula-
tion, and had previous intravitreal triamcinolone
injection were included if any of those therapies had
been performed at least 6 months before IVB. Eyes
treated previously with any anti-VEGF drugs were
excluded from this study. An injection of 1.25 mg of
bevacizumab was delivered at the discretion of the
treating physician. Baseline data were collected on
age, sex, type, and duration of diabetes mellitus.
Patients underwent clinical examination including
best-corrected Snellen visual acuity testing, ophthal-
moscopic examination, applanation tonometry, ﬂuo-
rescein angiography (FA), and optical coherence
tomography (OCT) at baseline and follow-up visits.
In patients with clinically signiﬁcant macular edema,
baseline central retinal characteristics were observed
by time-domain OCT using 6 diagonal slow 6-mm
radial line scans through a dilated pupil. The retinal
thickness of the 1-mm central retina was obtained
using the macular thickness map for the calculations in
all cases. When spectral-domain OCT became avail-
able, a volume scan centered on the fovea was
performed. The equivalence between the Stratus
OCT (Zeiss GmBh, Jena, Germany) and Cirrus
spectral-domain OCT (Zeiss GmBh) values was
resolved by adding 50 microns to each central macular
thickness (CMT) measured by Stratus OCT. The scans
were reviewed, and manual measurements were used
in cases of segmentation errors.
A 0.10-mL aliquot of commercially available bev-
acizumab was prepared for each patient and placed in
a tuberculin syringe using aseptic techniques. After the
eye had been prepared in a standard manner using 5%
povidone/iodine, an eyelid speculum was used to
stabilize the eyelids, and the injection of 1.25 mg
(0.05 mL) of bevacizumab was delivered 3.5 mm to
4 mm posterior to the limbus, through the pars plana,
with a 30-gauge needle under topical anesthesia. After
the injection, intraocular pressure and retinal artery
perfusion were checked.
To determine the effect of an intravitreal injection of
bevacizumab on actively growing new vessels, we
chose the change in vitreous leakage from RN on FA
as our primary outcome. Retinal neovascularization
was divided into two groups based on location: new
vessels on the disk (NVD) and new vessels elsewhere.
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Fluorescein angiography allowed the use of a system-
atic anatomical approach to monitor the area of leaking
new vessels over time.
Patients were examined at 1 week, 2 weeks, and
1 month after the ﬁrst injection and monthly thereaf-
ter. One, 3, 6, 12, and 24 months after the initial
injection, ophthalmic examination included OCT and
FA. Fluorescein angiography was performed at the
discretion of the examiner and not at every post-
injection evaluation, usually every 6 weeks. An
assessment for retreatment with IVB, retreatment with
laser, or initiation of laser treatment occurred at each
visit. Patients received reinjections if RN was not
totally resolved on ophthalmic examination or FA. In
addition, patients received retreatment whenever there
was a recurrence of neovascular activity. Recurrence
was deﬁned as an increased size of the neovascular
area associated with increased and diffuse ﬂuorescein
leakage on FA, after complete or partial resolution in
previous follow-up visits.
In this study, the term “immediate PRP” denoted
a case with PDR treated with primary IVB who was
subsequently treated with PRP within 3 months after
the ﬁrst IVB therapy. The term “deferred PRP” de-
noted a case where PRP was performed 3 months after
the beginning IVB therapy. Laser augmentation was
deﬁned as “additional laser” performed due to either
active residual neovascularization or new large
ischemic areas in eyes previously treated with PRP
(6 months or more before IVB therapy). The treating
physician decided if laser augmentation was required.
Best-corrected visual acuity (BCVA) was converted
from Snellen chart values to logarithm of minimum
angle of resolution (logMAR) equivalent units for
statistical calculations. All data were collected in
a Microsoft Ofﬁce Excel 2007 spreadsheet (Microsoft
Corporation, Redmond, WA) and were statistically
analyzed by MedCalc Software for Windows 8.2.0.3
(MedCalc, Mariakerke, Belgium). The paired t-test
was used to compare the mean values to analyze mean
logMAR visual acuity. A P value ,0.05 was consid-
ered statistically signiﬁcant.
Interval data were analyzed at the 1-, 3-, 6-, 12-, and
24-month follow-up time points. Repeated measures of
the analysis of variance were used to compare mean
values of retinal thickness and logMAR visual acuity. A
signiﬁcant increase or decrease in BCVA was deﬁned
as a change of two or more Snellen lines. The main
outcome measures included change in RN deﬁned as
the change in the area size of vitreous leakage from new
vessels (NV) in the late phase of FA and changes in
BCVA with assessment of CMT measured by OCT.
Patients were included in this consecutive series if there
was a minimum of 24 months of follow-up.
Monitored systemic conditions included myocardial
infarction, stroke, systemic hypertension, thromboem-
bolic diseases, and death. Other systemic conditions were
assessed by a thorough review of systems. If the patients
were unable to attend a particular visit, a telephone
interview was conducted to assess for possible systemic
complications, and a new appointment was scheduled.
Results
A review of clinical records was performed of 81
consecutive patients (97 eyes) with PDR who under-
went at least 1 injection of IVB. Sixty-eight (84%)
patients were Hispanic, 11 (13.6%) were white, and 2
(2.5%) were African American. Patients had a mean
follow-up of 29.6 ± 2 months (range: 24–30 months).
The mean age of patients was 54.9 ± 11 years (range:
25–79 years). Forty-four (54.3%) patients were male.
Thirty (30.9%) patients were insulin dependent, 23
(23.7%) patients were being treated with oral hypogly-
cemic agents, and 44 (45.3%) patients were being
treated with combined therapy (insulin dependent plus
oral hypoglycemic agents) at the time of PDR diagno-
sis. The mean duration of diabetes was 19.1 ± 9 years
(range: 1–40 years). The mean glycosylated hemoglo-
bin (HbA1c) was 9 ± 2% (range: 5.9–13.6%). Demo-
graphic data of all patients are presented in Table 1.
There was a statistically signiﬁcant change in mean
BCVA from 20/125 (0.8 ± 0.4 logMAR) at baseline
to 20/60 (0.5 ± 0.4 logMAR) at last follow-up visit
Table 1. Demographics Data of 81 patients (97 eyes) With
PDR Treated With IVB*
Variable Patients, n (%)
Eyes 97
Age, years 54.9







African American 2 (2.5)






Insulin plus OHA 44 (45.4)
HbA1c, % mean 9
±1 SD 2
*Values represent number and percentages.
HbA1c, glycosylated hemoglobin; n, number of eyes; OHA,
oral hypoglycemic agents; SD, standard deviation.
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(P , 0.0005). Best-corrected visual acuity improved
from 20/125 (0.8 ± 0.4 logMAR) at baseline to 20/80
(0.6 ± 0.4 logMAR) (P = 0.018) at 1 month and re-
mained stable during the 3 months and 6 months of
follow-up, with a BCVA mean of 20/80 (0.6 ± 0.4
logMAR) (P = 0.038) and 20/80 (0.6 ± 0.4 logMAR)
(P = 0.022), respectively. The mean BCVA was 20/60,
(0.5 ± 0.4 logMAR) (P = 0.001) at 12 months of
follow-up. At month 24, the mean BCVA was 20/60
(0.5 ± 0.4 logMAR) (P , 0.0005) (Figure 1).
Final BCVA remained stable in 49 (50.5%) eyes,
improved by 2 or more Snellen lines in 42 (43.3%)
eyes, and decreased by 2 or more Snellen lines in 6
(6.2%) eyes (Table 2).
Optical coherence tomography results were avail-
able for all cases at 1, 3, 6, 12, and 24 months. At 1
month, the mean CMT decreased from 359.9 ± 152.5
mm to 348.4 ± 120.5 mm (P = 0.441). At 3 months
and 6 months, the mean CMT measurements were
359.7 ± 159.9 mm (P = 0.821) and 351.5 ± 103.9
mm (P = 0.322), respectively. At 12 months and 24
months, the mean CMT measurements were 325.2 ±
102.5 mm (P = 0.016) and 311.7 ± 93.7 mm
(P , 0.0001), respectively (Figure 2).
The mean number of IVB injections per eye was
4 ± 2.5 (range: 1–8 injections) (Figure 3). The mean
interval between IVB applications was 3 ± 7 months
(range 1–12 months) (Table 3). Regression of neo-
vascularization occurred in some eyes within 7 days
to 15 days after the intravitreal injection.
Retinal neovascularization lesions were divided into
2 groups according to the area affected by NV at
presentation. We observed 54 (55.6%) eyes with
NVD. Of these eyes, complete regression of neo-
vascularization occurred in 22 (40.7%) eyes, 14
(25.4%) eyes had partial regression, and 18 (32.6%)
eyes had no regression after IVB therapy. New vessels
elsewhere on the retina occurred in 71 (73.1%) eyes,
which had total neovascular regression in 42 (59.1%)
eyes, partial regression in 22 (30.9%) eyes, and no
regression in 7 (9.8%) eyes. Including all RN cases,
complete NV regression occurred in 58 (59.7%) eyes
at the end of follow-up, partial resolution in 17
(17.7%) eyes, and no regression in 22 (22.6%) eyes
(Table 4).
Data were subdivided into eyes treated with PRP
before IVB therapy and untreated eyes (naive eyes)
before IVB therapy. All cases treated previously with
PRP were performed at least 6 months before the IVB
treatment. Sixty (61.9%) eyes had been treated pre-
viously with PRP. Of these, 41 (68.3%) eyes showed
good response to IVB therapy alone, 10 (16.6%) eyes
underwent laser augmentation immediately after the
ﬁrst IVB due to the presence of large ischemic areas
on FA, and 9 (15%) eyes needed at least one session of
laser augmentation during follow-up (Table 5). This
subgroup of 60 eyes with prior PRP showed a complete
regression of NV in 44 (73.3%) eyes at the end of
follow-up, partial resolution (with reduction of NV
present) in 9 (15.1%) eyes, and no regression in 7
(11.6%) eyes at 2 years of follow-up (Table 4). Of
the 37 (38.1%) eyes that had no history of previous
PRP, 18 (48.6%) eyes were treated with IVB plus
immediate PRP after IVB and 19 (51.4%) eyes were
treated with IVB therapy only. However, of these 19
(100%) eyes, 11 (57.8%) eyes required either PRP
therapy or surgery to improve the diabetic retinopathy
during follow-up, whereas the other 8 (42.1%) eyes
that underwent only IVB achieved a complete regres-
sion of PDR during the 24 months of follow-up. This
subgroup of 37 naive eyes with PDR treated ﬁrstly
with IVB showed a complete regression of NV in 14
(37.9%) eyes at the end of follow-up, partial resolution
(with reduction of NV present) in 8 (21.6%) eyes, and
no regression in 15 (40.5%) eyes at 2 years of follow-
up (Table 4).
Ocular complications associated with either pro-
gression or the lack of response to treatment were
observed in 12 (12.3%) eyes including 1 (1.0%) case
of epiretinal membrane, 2 (2.1%) cases of neovascular
glaucoma, 4 (4.1%) cases of VH, and 5 (5.2%) cases
with TRD. Out of four VH cases, only two resolved
spontaneously. One case of neovascular glaucoma was
controlled with medical treatment. All cases of ocular
complications are presented in Table 6.
Over the study period, 9 (11.1%) patients (eyes)
underwent surgery. A total of 9 surgical procedures
Fig. 1. The changes in BCVA in eyes with RN after IVB are plotted
versus time. The mean BCVA improved at 1 month from the baseline
(BL) value of logMAR = 0.8 ± 0.4 (Snellen equivalent 20/125) to log-
MAR = 0.6 ± 0.4 (Snellen equivalent 20/80, P = 0.018). At 3 months, the
mean BCVA was stable at logMAR = 0.6 ± 0.8 (Snellen equivalent 20/80,
P = 0.038). At 6 months, the average BCVA was logMAR = 0.6 ± 0.4
(Snellen equivalent 20/80, P = 0.022). At 12 months, the mean BCVA
decreased to logMAR = 0.5 ± 0.4 (Snellen equivalent 20/60, P = 0.001).
The mean BCVA at 24 months was logMAR = 0.5 ± 0.4 (Snellen
equivalent 20/60, (P , 0.0005)). *Statistically signiﬁcant changes (P ,
0.05) with respect to the baseline mean BCVA with baseline.
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were performed, of which 8 (8.2%) eyes underwent
pars plana vitrectomy and 1 (1.0%) eye underwent
trabeculectomy and a valve implant due to neovascular
glaucoma. Pars plana vitrectomy was performed
because 1 (1.0%) eye had an epiretinal membrane, 2
(2.1%) eyes presented with VH, and 5 (5.2%) eyes
developed TRD.
Local adverse events that may be associated with
IVB therapy included 1 (1.0%) eye with anterior
uveitis, 1 (1.0%) eye with ocular hypertension which
was controlled with antiglaucoma medications, and 1
(1.0%) eye with VH only 2 days after IVB injection,
which resolved a few days later. Systemic adverse
events included 1 (1.0%) case of stroke, and 1 (1.0%)
patient died during follow-up.
Discussion
This retrospective multicenter study included 81
patients (97 eyes) with PDR who were treated with at
least 1 primary IVB injection or treated with IVB for
reactivated PDR after PRP over a 2-year period. We
observed that 58 (59.7%) eyes had complete regres-
sion of RN on fundus examination with the absence of
ﬂuorescein leakage, 17 (17.7%) eyes demonstrated
partial regression of RN, and 22 (22.6%) eyes had
active NV on fundus examination and FA at the end of
follow-up.
Panretinal photocoagulation has been the mainstay
for the treatment of PDR, and its suppressive effect on
RN has been well documented.11,19–21 However, sub-
stantial regression of new vessels may take weeks after
completion of PRP, and in up to one third of cases,
new vessels continue to grow despite initial PRP.14,20
In these cases, VH may induce visual loss and prevent
complete laser.22 Sinawat et al23 evaluated the efﬁcacy
and safety of IVB for the treatment of PDR with new
dense VH after previous full panretinal photocoagula-
tion. Out of 18 eyes, VH cleared completely in 7
(38.8%), 9 (50%), and 13 (72.2%) eyes after 6 weeks,
6 months, and 12 months, respectively. We observed
that 60 (61.9%) eyes had been treated previously with
photocoagulation. Of these, 41 (68.3%) eyes showed
good response to IVB therapy alone, including 4
(9.1%) eyes that presented with VH. In addition, we
observed 3 eyes without previous PRP (“naive” eyes)
and with VH to have avoided vitreoretinal surgery.
Many studies have evaluated the efﬁcacy of com-
bined IVB injection and PRP for treatment of high-risk
PDR but most were not large-scale trials.15–18,24,25
Table 2. Analysis of BCVA by Subgroups in 97 Eyes With PDR Treated With IVB Therapy*
Month 1 Month 3 Month 6 Month 12 Month 24
Improved 2 or more Snellen lines of
BCVA
29 (29.9) 33 (34.1) 30 (30.9) 38 (39.2) 41 (42.2)
Remained stable 63 (64.5) 55 (56.7) 56 (57.7) 48 (49.5) 49 (50.5)
Decreased 2 or more Snellen lines of
BCVA
5 (5.2) 9 (9.3) 11 (11.3) 11 (11.3) 7 (7.2)
*Values represent number and percentages.
n, number of eyes.
Fig. 2. Changes in CMT with OCT after IVB in eyes with RN along 24
months of follow-up. CMT at baseline had a mean of 359.9 ± 152.5 mm
which was reduced to a mean of 348.4 ± 120.5 mm (P = 0.441) at the
ﬁrst month of follow-up. At 3 and 6 months, the mean CMT meas-
urements were 359.7 ± 159.9 mm (P = 0.821) and 351.5 ± 103.9 mm
(P = 0.322), respectively. At 12 months and 24 months, the mean CMT
was 325.2 ± 102.5 mm (P = 0.016) and 311.7 ± 93.7 mm (P , 0.0001),
respectively. *Statistically signiﬁcant change (P , 0.05) compared with
baseline.
Fig. 3. The number of intravitreal injections of bevacizumab in 97 eyes
with PDR divided by prior PRP versus treatment naive eyes. The mean
number of intravitreal injections of bevacizumab (IVB) per eye was 4 ±
2.5 (range: 1–8 injections). The mean interval between IVB applications
was 3 ± 7 months (range 1–12 months).
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Tonello et al17 evaluated the effects of PRP compared
with PRP plus IVB on BCVA and total area of ﬂuo-
rescein leakage from active new vessels in 30 eyes
with high-risk PDR.
The authors17 suggested that in the short term (16
weeks), the combination of IVB with PRP may be
associated with a higher rate of regression of active
leaking NV than PRP alone in patients with high-risk
PDR. Additionally, Jorge et al26 evaluated the effect of
IVB injection in eyes with persistent, active PDR in
a noncomparative study. The authors26 administered 1
injection of bevacizumab to 15 eyes at 12 weeks of
follow-up. As a result, BCVA improved signiﬁcantly
from baseline at all time points (1, 6, and 12 weeks),
from 20/160 at baseline to 20/125 at 12 weeks.23 The
mean area of ﬂuorescein leakage also improved signif-
icantly at all time points.23
Recently, investigators from the Diabetic Retinop-
athy Clinical Research Network27 (DRCR.net) pre-
sented the results of a clinical trial comparing PRP
and intravitreal ranibizumab (IVR) among patients
with PDR. Patients in the IVR group (n = 191 eyes)
received IVR (0.5 mg) (and PRP if treatment failed)
and received ranibizumab as needed for diabetic mac-
ular edema, whereas patients in the PRP group
(n = 203 eyes) received PRP and ranibizumab as
needed for diabetic macular edema. In this random-
ized clinical trial, IVR met the primary noninferiority
outcome of visual acuity change at 2 years. There was
no statistically signiﬁcant difference in visual acuity
between the ranibizumab and PRP groups at 2 years;
however, notably, 53% of the PRP group received
ranibizumab injections for diabetic macular edema
(DME). Greater peripheral visual ﬁeld loss occurred
(95% conﬁdence interval for difference, 213–531 dB)
and more vitrectomies were performed in the PRP
group than in the ranibizumab group (95% conﬁdence
interval for difference, 4–15%). Among eyes without
center-involved DME at baseline, development of
DME with vision impairment was substantially more
frequent in the PRP group (95% conﬁdence interval
for difference, 10–28%). Only 12 eyes (6%) in the
ranibizumab group received PRP; more than half of
the eyes in the PRP group received ranibizumab for
DME; thus, the protocol essentially tested ranibizu-
mab for PDR versus PRP plus ranibizumab as needed
for DME treatment.
In another study, Mirshahi et al16 evaluated 40 pa-
tients with Type 2 diabetes and bilateral PDR with
a high-risk proﬁle who underwent scatter laser treat-
ment after the Early Treatment Diabetic Retinopathy
Study protocol and a single bevacizumab injection in 1
eye, and sham injection in the contralateral eye.
They16 demonstrated that at Week 6, 87.5% of the
eyes treated with bevacizumab presented with com-
plete regression of neovascularization versus 25%
in the sham-treated group (P , 0.005).16
Alternately, small nonrandomized pilot studies
have reported successful short-term results with IVB
in iris neovascularization and RN demonstrating
regression of RN in PDR.28–30 An interventional con-
secutive retrospective case series28 reported that 100%
of 44 eyes (32 patients) demonstrated some degree of
regression of leakage on FA secondary to PDR within
1 week of IVB, even with doses as low as 6.2 mg. The
authors28 also noted a complete resolution of new
vessels elsewhere in 59% of eyes, NVD in 73% of
eyes, and iris neo-vascularization in 82% of eyes. In
the current study, evaluating the topographic location
of RN, we found a complete resolution of new vessels
Table 3. Mean Number of IVB Injections in 97 Eyes With PDR*
Number IVB Eyes, n (%) Mean Interval, weeks Range, weeks Prior PRP TN
1 10 (10.3) — — 9 (90) 1 (10)
2 17 (17.5) 22.7 ± 15.1 4–54 15 (88) 2 (12%)
3 20 (18.5) 17.5 ± 13.9 4–50 15 (75) 5 (25)
4 7 (7.2) 16.4 ± 10.6 4–42 6 (86) 1 (14)
5 20 (20.6) 7.5 ± 6.3 4–28 7 (35) 13 (65)
6 10 (10.3) 9.3 ± 6.2 5–20 3 (30) 7 (70)
7 6 (6.2) 12 ± 5.6 8–16 3 (50) 3 (50)
8 7 (7.2) 5 ± 2.0 4–6 2 (29) 5 (71)
*Values represent number and percentages.
n, number of eyes; prior PRP, prior PRP; TN, treatment naive.
Table 4. Retinal Neovascularization Regression in 97
Eyes With IVB Therapy for PDR at 2 Years Follow-up*
NV Localization RN Prior PRP TN
RN Regression
Complete 58 (59.7) 44 (73.3) 14 (37.9)
Partial 17 (17.7) 9 (15.1) 8 (21.6)
No 22 (22.6) 7 (11.6) 15 (40.5)
Total 97 (100) 60 (100) 37 (100)
*Values represent number and percentages.
n, Number of eyes; prior PRP, prior PRP; TN, treatment naive.
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elsewhere in 42 (59.1%) eyes and in 22 (40.7%) eyes
with NVD. Additionally, we observed complete
regression of RN in 58 (59.7%) eyes at 2 years of
follow-up, of which 44 (73.3%) eyes were previously
treated with PRP 6 months or more before IVB ther-
apy and 14 (37.9%) eyes were treatment-naive eyes.
Avery et al28 also noted, however, that recurrence of
RN began as early as 2 weeks after intravitreal injec-
tions of bevacizumab, which could be its major short-
coming compared with PRP. In contrast to these
results, in our study, the mean interval between IVB
applications was 3 ± 7 months. This observation in-
dicates that the mean recurrence of NV in our patients
was longer than those described by Avery et al.24
However, a retrospective analysis by Adamis et al31
demonstrated a persistent beneﬁcial effect of intravi-
treal pegaptanib in patients with PDR, with 62% of
the treated eyes showing regression or absence of neo-
vascularization 6 months after injection. In addition,
Mendrinos et al21 reported complete regression of
neovascularization 1 year after a single injection of
pegaptanib in a patient with previous PRP. In concor-
dance with our study, Minnella et al32 reported that
the effects of bevacizumab were maintained at 3
months in 15 treated eyes with PDR.32 Additionally,
Schmidinger et al33 showed that 62% (8 of 13) of the
treated eyes required retreatment with bevacizumab 3
months after baseline injection because of the appear-
ance of new vessels. Therefore, a major limitation of
anti-VEGF therapy for PDR seems to be the recur-
rence of RN from 2 weeks28 to 12 months after
injection.21,34,35
Our study concurs with Chung et al36 who suggest
that repeated injections, panretinal photocoagulation,
and/or pars plana vitrectomy may be necessary after
IVB to reinforce the anti-VEGF effect of the drug.
The authors36 demonstrated that a single IVB injec-
tion might not be sufﬁcient in inducing complete
blockage of VEGF and pathologic neovascularization
in active patients with PDR. In our series, the mean
number of IVB injections per eye was 4 ± 2.5 (range:
1–8 injections) at 24 months of follow-up, with a mean
interval of 3 ± 7 months. We found that out of 37
(38.1%) eyes that had not received previously PRP
(naive eyes), 18 (48.6%) eyes were treated with
PRP immediately (within the third month) after the
ﬁrst IVB, and 19 (51.4%) eyes were treated with
IVB therapy only. However, 11 (57.8%) of the eyes
treated only with IVB underwent PRP therapy or
surgery during follow-up.
Alternately, we observed that .60% of the eyes
included in the current study had been previously trea-
ted with PRP. Therefore, we compared the general
results based on the presence or absence of previous
PRP before IVB therapy. We found that almost 75%
of eyes that had been treated with prior PRP had a good
response to IVB therapy alone. These ﬁndings suggest
that most patients (73%) with active PDR who had
previously undergone PRP may be treated with IVB
alone. However, in patients with PDR treated with
IVB therapy only (19 eyes) (PRP naive), a complete
regression of the NV was seen in 42.1% of the treated
eyes. The remaining 11 eyes needed additional laser
therapy to improve the retinopathy during the moni-
toring period. DRCR.net reported that there were 58%
of eyes in the ranibizumab group, and 54% in the PRP
group without signs of PDR, with complete regression
of neovascularization at the disk or elsewhere (on fun-
dus photographs) at 2 years. The difference in favor-
able responses in our IVB-only group (42.1%) and the
ranibizumab group (58%) from DRCR.net is likely
due to the lower frequency of IVB in our study. In
our study, patients treated only with IVB were treated
Table 5. Eyes With PDR Treated With IVB Therapy According to the Presence of PRP Before Intravitreal Therapy*
Prior PRP TN Total P
Eyes 60 (61.8) 37 (38.1) 97 (100)
Modality therapy
IVB Alone 41 (68.3) 8 (32.4) 52 (53.6) 0.0002†
IVB + Immediate LA or PRP 10 (16.6) 18 (48.6) 25 (25.7) 0.0001†
IVB + Deferred LA or PRP 9 (15) 11 (18.9) 20 (20.6) 0.825
*Values represent number and percentages.
†Statistically signiﬁcant.
LA, laser augmentation; n, number of eyes; TN, treatment naive.
Table 6. Ocular Complications to PDR Observed in 97







Total OC 12 (12.3)
*Values represent number and percentages.
ERM, epirretinal membrane; n, number of eyes; NVG, neo-
vascular glaucoma; OC, ocular complications.
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at a mean interval of 3 months between doses, with
a mean of 4 injections with 2 years of follow-up,
whereas most patients in the ranibizumab group from
DRCR.net received 6 monthly injections initially and
many had additional visits and injections throughout
the 2 years of follow-up. Another important difference
was that our sample size was smaller than the DRCR.
net sample (19 eyes in our IVB-only therapy group
versus 142 eyes in the ranibizumab group from
DRCR.net). Hence, the administration of a loading
series of injections to completely suppress the effects
of VEGF in eyes with PDR could be more effective
than the application of IVB every 3 months. Moradian
et al37 reported the use of IVB for cases with PDR that
were not responsive to PRP therapy. The authors37
observed 2 cases of TRD (5.3% of study eyes) at the
end of follow-up. We have previously reported 11
eyes (patients) out of 211 eyes that development or
had progression of TRD with decreased BCVA after
IVB before vitrectomy for the management of PDR for
an incidence of 5.2%.38 Sinawat et al23 published
a case series of 18 eyes with PDR and VH treated with
IVB. The authors23 observed that 2 (11%) eyes had
severe visual loss because of the TRD. In a previous
study, we found 25 eyes (patients) (3.5%) out of 698
patients who underwent IVB and developed or had
progression of TRD after the injection.39 Risk factors
for TRD after IVB identiﬁed in our previous study
were long-standing diabetes mellitus of more than 15
years, greater than 13 days from injection to vitrec-
tomy, and the use of a higher dose (2.5 mg) of bev-
acizumab.39 In the current study, we included eyes
treated with a dose of 1.25 mg/mL of IVB. We
observed that 5 (5.2%) cases presented with TRD after
IVB therapy. Our study demonstrates that IVB can
generate marked regression of RN on fundus exami-
nation and FA in patients with PDR, especially in
patients with previous PRP. In addition, IVB could
be preventing exacerbation of macular edema in pa-
tients with concomitant clinically signiﬁcant macular
edema and PDR.
The mean interval between IVB applications was
3 ± 7 months. Therefore, bevacizumab may allow
long intervals between PRP sessions to avoid the
development of macular edema and other complica-
tions.12–14,40 In addition, bevacizumab could subse-
quently play a role in the treatment of actively
leaking new vessels elsewhere or NVD refractory to
laser treatment in patients with PDR.41 Our ﬁndings
suggest that IVB might be the ﬁrst line of treatment in
patients with previous PRP and recurrence of neovas-
cular activity. Intravitreal bevacizumab therapy seems
to have some advantages over PRP, including better
average BCVA, due to either a lower rate of develop-
ment of DME or a more controlled clinically
signiﬁcant diabetic macular edema, preservation of
peripheral visual ﬁeld sensitivity, and lower rates of
vitrectomy.27 However, regular follow-up is critical to
managing patients treated with intravitreal anti-VEGF
therapy. Treatment-naive patients who have under-
gone several IVB treatments but do not regularly
present for follow-up may develop recurrent neovas-
cularization leading to vision loss. Similarly, the
DRCR.net27 concluded that among eyes with PDR,
treatment with IVR resulted in visual acuity that
was noninferior to (not worse than) PRP at 2 years
of follow-up.
Limitations of our study include that it is non-
randomized, uncontrolled, and retrospective. In addi-
tion, this study included patients from ﬁve different
centers, and patients were treated according to the
discretion of the treating physician. However, the
large difference in the quantitative morphologic out-
comes and the trend toward improvement in BCVA in
injected eyes found at 24 months conﬁrms our
hypothesis that at least some eyes with PDR, such
as those with previous PRP or preexisting macular
edema, may truly beneﬁt from IVB. We also observed
that in 42.1% of naive eyes, PDR was controlled or
PDR regressed with IVB injections during 24 months
of follow-up without requiring additional laser or
vitrectomy. This percentage is lower than the results
of the IVR group from DRCR.net which reported that
58% of the treated eyes had no signs of PDR or the
neovascularization regressed at the end of follow-up.
However, in the same study, the percentage of eyes
with active neovascularization was 42% in the ranibi-
zumab group and 46% in the PRP group at the end of
follow-up, which is similar to the 15 (40.5%) naive
eyes treated only with IVB in our study.
In summary, IVB seems to be a promising treatment
for PDR, minimizing the risk for exudative complica-
tions, progression of RN, VH, and decreased vision
caused by macular edema. Intravitreal bevacizumab is
a potential adjuvant to PRP for PDR. Although no
serious complications of intravitreal injection of
bevacizumab occurred in our series, further studies
are needed to assess the efﬁcacy and safety of IVB in
the management of PDR.
Key words: bevacizumab, diabetic retinopathy, in-
travitreal injections, proliferative, retinal neovasculari-
zation.
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Chapter 9: Intravitreal Bevacizumab as an Adjuvant to Vitrectomy in Tractional Retinal 
Detachment at 2 years of follow up 
Arevalo JF, Serrano MA, Arias JD. Perfluorocarbon in vitreoretinal surgery and 
preoperative bevacizumab in diabetic tractional retinal detachment. World J Diabetes. 2014 Oct 
15;5(5):724-9. doi: 10.4239/wjd.v5.i5.724. 
DOI: 10.4239/wjd.v5.i5.724 
Hypothesis 4: Preoperative IVB may be beneficial for membrane dissection in diabetic tractional 
retinal detachment with minimally invasive vitreoretinal surgery (23-gauge transconjunctival 
sutureless vitrectomy [TSV]). In addition, post-operative rebleeding may be decreased. 
AIM: To describe the en bloc perfluorodissection (EBPD) technique and to demonstrate the 
applicability of using preoperative intravitreal bevacizumab during small-
gauge vitreoretinal surgery (23-gauge transconjunctival sutureless vitrectomy) in eyes with advanced 
proliferative diabetic retinopathy (PDR) with tractional retinal detachment (TRD). 
METHODS: This is a prospective, interventional case series. Participants included 114 (eyes) with 
advanced proliferative diabetic retinopathy and TRD. EBPD was performed in 114 eyes (consecutive 
patients) during 23-gauge vitrectomy with the utilization of preoperative bevacizumab (1.25 mg/0.05 
mL). Patients mean age was 45 years (range, 21-85 years). Surgical time had a mean of 55 min 
(Range, 25-85 min). Mean follow up of this group of patients was 24 mo (range, 12-32 mo). Main 
outcome measures included best-corrected visual acuity (BCVA), retinal reattachment, and 
complications. 
RESULTS: Anatomic success occurred in 100% (114/114) of eyes. Significant visual improvement 
>≥ 2 Earl\ TreaWmenW Diabetic Retinopathy Study (ETDRS) lines] was obtained in 69.2% (79/114), in 
26 eyes (22.8%) BCVA remained stable, and in 8 e\es (%) BCVA decreased (≥ 2 ETDRS lines). 
Final BCVA was 20/50 or better in 24% of eyes, between 20/60 and 20/400 in 46% of eyes, and 
worse than 20/400 in 30% of eyes. Complications included cataract in 32 (28%) eyes, 
iatrogenic retinal breaks in 9 (7.8%) eyes, vitreous hemorrhage requiring another procedure in 7 
(6.1%) eyes, and phthisis bulbi in 1 (0.9%) eye. 
CONCLUSION: This study demonstrates the usefulness of 
using preoperative intravitreal bevacizumab and EBPD during small-gauge vitreoretinal surgery in 
eyes with TRD in PDR. 
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was 45 years (range, 21-85 years). Surgical time had 
a mean of 55 min (Range, 25-85 min). Mean follow up 
of this group of patients was 24 mo (range, 12-32 mo). 
Main outcome measures included best-corrected visual 
acuity (BCVA), retinal reattachment, and complications.
RESULTS: Anatomic success occurred in 100% (114/114) 
of eyes. Significant visual improvement [≥ 2 Early 
Treatment Diabetic Retinopathy Study (ETDRS) lines] 
was obtained in 69.2% (79/114), in 26 eyes (22.8%) 
BCVA remained stable, and in 8 eyes (7%) BCVA de-
creased (≥ 2 ETDRS lines). Final BCVA was 20/50 or 
better in 24% of eyes, between 20/60 and 20/400 in 
46% of eyes, and worse than 20/400 in 30% of eyes. 
Complications included cataract in 32 (28%) eyes, iat-
rogenic retinal breaks in 9 (7.8%) eyes, vitreous hem-
orrhage requiring another procedure in 7 (6.1%) eyes, 
and phthisis bulbi in 1 (0.9%) eye.
CONCLUSION: This study demonstrates the usefulne-
ss of using preoperative intravitreal bevacizumab and 
EBPD during small-gauge vitreoretinal surgery in eyes 
with TRD in PDR.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: En bloc  perfluorodissection and preoperative 
intravitreal bevacizumab use for small-gauge vitrec-
tomy in patients with proliferative diabetic retinopathy 
and tractional retinal detachment are very useful, the 
combination reduces complications and operative time. 
En bloc  perfluorodissection and preoperative intravit-
real bevacizumab use seems to have many advantages 
including that the retina remains stable during vitrec-
tomy, better visibility of the ocular structures in the 
vitreous cavity, immediate reattachment of the retina, 
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Abstract
AIM: To describe the en bloc perfluorodissection 
(EBPD) technique and to demonstrate the applicability 
of using preoperative intravitreal bevacizumab during 
small-gauge vitreoretinal surgery (23-gauge transcon-
junctival sutureless vitrectomy) in eyes with advanced 
proliferative diabetic retinopathy (PDR) with tractional 
retinal detachment (TRD).
METHODS: This is a prospective, interventional case 
series. Participants included 114 (eyes) with advanced 
proliferative diabetic retinopathy and TRD. EBPD was 
performed in 114 eyes (consecutive patients) during 
23-gauge vitrectomy with the utilization of preoperative 
bevacizumab (1.25 mg/0.05 mL). Patients mean age 
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bleeding control, subretinal fluid reabsorbsion and 
drainage, bleeding sites’ tamponade, and easier dissec-
tion of epiretinal tissues.
Arevalo JF, Serrano MA, Arias JD. Perfluorocarbon in vitreoreti-
nal surgery and preoperative bevacizumab in diabetic tractional 
retinal detachment. World J Diabetes 2014; 5(5): 724-729  Avail-
able from: URL: http://www.wjgnet.com/1948-9358/full/v5/
i5/724.htm  DOI: http://dx.doi.org/10.4239/wjd.v5.i5.724
INTRODUCTION
Pars plana vitrectomy is a successful surgical technique 
for the complications of  proliferative diabetic retinopathy 
(PDR)[1,2]. It is usually necessary within one year in up to 
10% of  patients presenting with PDR[3]. The commonest 
indication for surgery is non-clearing vitreous hemor-
rhage. Unfortunately[1,2], postoperative vitreous hemor-
rhage is a significant complication occurring in about 
20% to 30% of  cases[4-10].
Some advances in surgical techniques and instrumen-
tation, such as; en bloc dissection, delamination, segmen-
tation, and bimanual surgical techniques, have allowed 
better results in the treatment of  severe PDR[11-13]. Vis-
codissection, described by Stenkula and Tornquist[12], and 
the use of  perfluorocarbon liquids (PFCL), introduced as 
a surgical adjuvant in vitrectomy in 1987 by Chang et al[14], 
facilitate removal of  epiretinal membranes, the manage-
ment of  proliferative vitreoretinopathy (PVR) with retinal 
detachment, tractional retinal detachments in diabetics, 
and control of  intraoperative hemorrhage.
Quiroz-Mercado et al[15,16] published a technique called 
perfluorocarbon-perfused vitrectomy (PCPV). In their 
technique, PFCL is used in the infusion in a continuous 
way during vitrectomy. In selected cases PFCL may offer 
several advantages over saline solution, because of  their 
properties including gravitational forces, immiscibility 
with fluids, and ability to transport oxygen[15,16]. Regard-
less of  PFCL’s advantages, the use of  PCPV has not 
extended worldwide. In addition, PCPV utilizes a consid-
erable amount of  PFCL, and membranes may be pushed 
against the retina during PCPV.
We have previously described “En bloc perfluorodis-
section” (EBPD), which combines the advantages of  
viscodissection and PCPV. EBPD helps the surgeon 
during removal of  membranes over the retina and to cre-
ate a posterior vitreous detachment by injecting PFCL 
between the retina and the posterior hyaloid separating 
tissues over the retina[17,18]. In addition, identification 
and removal of  all posterior vitreoretinal traction is very 
important. Furthermore, vitreoschisis can also occur in 
patients with PDR, it is important to identify this feature 
and to perform dissection in the true vitreoretinal plane, 
to avoid recurrent traction and postoperative bleeding 
from retinal neovascularization[19].
Postoperative vitreous cavity hemorrhage is a signifi-
cant complication following vitrectomy for the treatment 
of  PDR. It has two main forms, “early” when hemor-
rhage (bleeding) is present in the first few postoperative 
days and “late”, when hemorrhage occurs a number of  
months after surgery. The presence of  postoperative 
vitreous hemorrhage delays visual recovery can lead to 
elevated pressure within the eye and can make further 
treatment for diabetic retinopathy difficult. Revision 
surgery is required in 10% of  patients, which has signifi-
cant implications for resources, time and cost. The use 
of  anti-vascular endothelial growth factor (anti-VEGF) 
before surgery (preoperatively) has been proposed as an 
intervention to reduce the incidence of  postoperative vit-
reous hemorrhage[20]. 
Recently, it has been reported that intravitreal beva-
cizumab in patients with vitreous hemorrhage and PDR 
resulted in regression of  retinal neovascularization and 
resolution of  vitreous hemorrhage[21]. Chen et al[22] and 
Avery et al[23], have reported that preoperative intravitreal 
bevacizumab (Avastin®, Genentech Inc., San Francisco, 
CA) reduce the risk of  bleeding during vitrectomy facili-
tating the removal of  fibrovascular tissues.
The aim of  this article is to describe the surgical tech-
nique and demonstrate the usefulness of  combining en 
bloc perfluorodissection and preoperative intravitreal be-
vacizumab use for membrane peeling in tractional retinal 
detachment in advanced diabetic retinopathy with small-
gauge vitreoretinal surgery (23-gauge transconjunctival 
sutureless vitrectomy).
MATERIALS AND METHODS
This is a prospective, interventional case series. One hun-
dred fourteen (eyes) with tractional retinal detachment 
(TRD) in PDR participated. The authors performed 
EBPD in 114 eyes (consecutive patients) during 23-gauge 
transconjunctival sutureless vitrectomy for tractional 
retinal detachment in severe PDR with the utilization of  
preoperative bevacizumab (1.25 mg/0.05 mL). Main out-
come measures were best-corrected visual acuity (BCVA), 
retinal status, and complications. This study has been 
performed in accordance with the ethical standards laid 
down in the 1964 declaration of  Helsinki and it was ap-
proved by the Institution’s Ethics Committee. 
An aliquot of  commercially available bevacizumab 
was prepared for each patient and placed in a tuberculin 
syringe using aseptic techniques. Four days before vitrec-
tomy, after preparation of  the eye using 5% povidone/
iodine, an eyelid speculum was used to open the eyelids, 
and the injection of  1.25 mg (0.05 mL) of  bevacizumab 
was performed 4 mm posterior to the limbus, through 
the superotemporal or inferotemporal pars plana with a 
30-gauge needle under topical anesthesia. After the injec-
tion, retinal artery perfusion was checked with the indi-
rect ophthalmoscope. In none of  our cases an anterior 
chamber paracenthesis was necessary. No topical antibi-
otics were administered preoperatively.
A 23-gauge transconjunctival sutureless vitrectomy 
was performed in all cases. A core vitrectomy is done first 
to clear any vitreous hemorrhage present. A hole is then 
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made in the mid-peripheral posterior hyaloid (Figures 1A 
and 2A) to inject the perfluorocarbon liquid (PFCL) [Per-
fluorooctane (C8F18)] and mechanically detach the poste-
rior hyaloid from the retina (Figures 1B, 1C and 2B). We 
726 October 15, 2014|Volume 5|Issue 5|WJD|www.wjgnet.com
Figure 1  Artist's representation of surgical technique. A: An opening is made with the vitrector in the mid-periphery of the posterior hyaloid; B and C: Perfluorocar-
bon liquid (PFCL) is injected to separate the posterior hyaloid from the retina. A dual bore cannula (for 23-gauge cases) attached to a 5 cc syringe filled with PFCL is 
used to separate membranes and posterior hyaloid from the underlying retina; D: Once all the tissues have been separated from the retina, vitrectomy can be contin-
ued up to the periphery; E: Endolaser is applied under PFCL; F: An air-fluid and an air-gas (C3F8) exchange exchange are performed to end the case.
Figure 2  En bloc perfluorodissection performed in a case of tractional retinal detachment in proliferative diabetic retinopathy. A: An opening is made with 
the vitrector in the mid-periphery of the posterior hyaloid; B: Perfluorocarbon liquid (PFCL) is injected to separate the posterior hyaloid from the retina (arrows). A dual 
bore cannula (for 23-gauge cases) attached to a 5 cc syringe filled with PFCL is used to separate membranes and posterior hyaloid from the underlying retina; C: 
Once all the tissues have been separated from the retina, vitrectomy can be continued up to the periphery; D: Endolaser is applied under PFCL (shown). An air-fluid 
and an air-gas (C3F8) exchange are performed to end the case (not shown).
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tomy in eyes with TRD in PDR and preoperative use of  
intravitreal bevacizumab, we can obtained an anatomic 
(100%) and functional success (69.2%). Other benefits 
of  this technique include that the retina remains stable 
during vitrectomy, less blood in the vitreous cavity, rapid 
retinal reattachment, better visualization of  vitreous and 
intraocular structures, blood confinement, and easier dis-
section of  epiretinal membranes.
In our study, the authors have not seen any difficul-
ties with the technique. However, in one case PFCL was 
injected within a vitreous schisis. After a short amount of  
instillation (1 mL) that situation was apparent, and PFCL 
was aspirated and a new hole in the posterior hyaloid was 
made at another location making sure that the proper 
plane was found between the posterior hyaloid and the 
retina this time. No complications rose from this event. 
In addition, there were 2 eyes (1.7%) with subretinal PCL 
that were solved with a peripheral retinotomy, aspiration 
with an extrusion cannulae, and the injection of  addition-
al PCL in the posterior pole. In our study the prevalence 
of  postoperative vitreous hemorrhage was lower (6.1%) 
than that reported in other studies (20% to 30%)[4-10] 
which can be explained by the use of  intravitreal bevaci-
zumab 4 d preoperatively.
Surgeons with extensive experience can manage com-
plex retinal detachments in patients with TRD using ei-
ther viscodissection or conventional techniques with pick 
and scissors. Thus, surgeons should deal with these cases 
selectively according to their level of  experience. An ideal 
case for EBPD might be one in which there is a TRD 
with no tears, with limited posterior vitreous detachment, 
and relatively loose attachment of  the posterior hyaloid 
to the retina. We use a combination of  several techniques 
in our cases including EBPFD, and the use of  picks and 
forceps with bimanual surgery. Currently, the use of  
small-gauge vitreoretinal surgery (23-gauge transconjunc-
tival sutureless vitrectomy) and preoperative intravitreal 
bevacizumab for TRD in diabetics have improved our 
surgical time and results.
In the future, MIVS with 23-gauge transconjunctival 
sutureless vitrectomy techniques will be increasingly per-
formed in diabetic patients due to the increased incidence 
of  diabetes and its complications. In the coming years we 
will use techniques that are less invasive in vitreoretinal 
surgery such as 25+, and 27-gauge. We will have available 
other anti-VEGF antibodies capable of  blocking all types 
of  VEGF isoforms before and after surgery, reducing in-
traoperative bleeding, and postoperative inflammation. It 
is likely that the use of  preoperative agents that promote 
the detachment of  the posterior hyaloid and facilitate 
the removal of  membranes will become routine. They 
will facilitate surgery of  complex cases such as PDR 
cases. Optical coherence tomography equipment will be 
available in the operating room and that will facilitate in-
traoperative tissue differentiation, and help us get better 
functional results. The advent of  new lasers will permit 
us faster retinal photocoagulation, and will minimize col-
lateral damage of  the retina.
use a 23-gauge Dual Bore cannula (Dual Bore cannula 0.6 
mm, MedOne, Sarasota, FL) attached to a 5 cc syringe 
filled with PFCL to separate the posterior hyaloid and 
membranes from the retina. After all the membranes and 
posterior hyaloid have been separated from the retina, 
vitrectomy is completed up to the periphery (Figures 1D 
and 2C), endolaser is applied (Figures 1E and 2D), an air-
fluid and air-gas [Perfluoropropane (C3F8), Escalon Medi-
cal Corporation, New Berlin, WI] exchange is performed 
to finish the case (Figure 1F).
Non-illuminated instrumentation was usually used 
in our cases[7] combined with a non-contact wide-angle 
viewing system (BIOM, Oculus, Wetzlar, Germany). An 
illuminated cannula was utilized (25ga, Awh chandelier, 
Synergetics Inc., O’Fallon, MO) in some cases for biman-
ual surgery.
RESULTS
Patients were prospectively enrolled from January 2006 
to January 2010 at Clinica Oftalmologica Centro Caracas 
in Caracas, Venezuela. Inclusion criteria included patients 
with TRD in advanced PDR and macular involvement or 
impending macular involvement with or without vitreous 
hemorrhage. EBPD was performed in 114 consecutive 
eyes (patients) during small-gauge vitrectomy for severe 
PDR with TRD. The mean age of  the patients was 45 
years (range, 21-85 years). Surgical time had a mean of  55 
min (Range, 25-85 min). Mean follow up of  our patients 
was 24 mo (range: 12-32 mo). 
Each patient underwent BCVA measurement with 
ETDRS. Patients were followed postoperatively on day 1, 
at one week, at three weeks, at 7 wk, and every 3 mo with 
complete eye examination at each visit, including BCVA, 
anterior segment examination, IOP determination, and 
fundus biomicroscopy. Patients were included only with 
a minimum 12 mo of  follow-up. An increase or decrease 
in BCVA was considered to have occurred if  there was a 
change of  two or more Early Treatment Diabetic Reti-
nopathy Study (ETDRS) lines. Main outcome measures 
were changes in BCVA, and retinal reattachment.
En bloc perfluorodissection was performed using a 
mean volume of  PFCL of  4 mL (range: 3 to 8 mL). No 
patients in our series have shown ocular hypertension 
or inflammation. Anatomic success occurred in 100% 
(114/114) of  eyes. Significant visual improvement (≥ 
2 ETDRS lines) was seen in 69.2% (79/114), in 26 eyes 
(22.8%) BCVA remained stable, and in 8 eyes (7%) BCVA 
decreased (≥ 2 ETDRS lines). Final BCVA was 20/50 or 
better in 24%, between 20/60 and 20/400 in 46%, and 
worse than 20/400 in 30%. Complications included cata-
ract in 32 (28%) eyes, iatrogenic retinal breaks in 9 (7.8%) 
eyes, vitreous hemorrhage requiring another procedure in 
7 (6.1%) eyes, and phthisis bulbi in 1 (0.9%) eye.
DISCUSSION
In selected cases en bloc perfluorodissection during vitrec-
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In summary, EBPD and preoperative intravitreal beva-
cizumab use for vitrectomy in eyes with TRD in PDR it is 
very useful. En bloc perfluorodissection and preoperative 
intravitreal bevacizumab use seems to have many advan-
tages including that the retina remains stable during vitrec-
tomy, better visibility of  intraocular structures, immediate 
reattachment of  the retina, bleeding control, reabsorbsion 
and drainage of  subretinal fluid, bleeding sites’ tampon-
ade, and easier dissection of  epiretinal tissues.
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Authors have previously described a new surgical dissection technique, namely 
“En bloc perfluorodissection” (EBPD), which combines the advantages of vis-
codissection and perfluorocarbon-perfused vitrectomy. EBPD helps the surgeon 
during removal of epiretinal membranes and to detach the posterior hyaloid by 
injecting perfluorocarbon liquid between the retina and the posterior hyaloid to 
separate the epiretinal tissues from the retina. 
Research frontiers
The objective of this article is to describe the surgical technique and demon-
strate the usefulness of combining en bloc perfluorodissection and preoperative 
intravitreal bevacizumab use for membrane peeling in tractional retinal detach-
ment in advanced diabetic retinopathy with small-gauge vitreoretinal surgery 
(23-gauge transconjunctival sutureless vitrectomy).
Innovations and breakthroughs
En bloc perfluorodissection and preoperative intravitreal bevacizumab use 
seems to have many advantages including that the retina remains stable dur-
ing vitrectomy, better visibility of vitreous and intraocular structures, immediate 
retinal reattachment, bleeding control in the vitreous cavity, subretinal fluid 
reabsorbsion and drainage, bleeding sites’ tamponade, and easier dissection of 
epiretinal tissues.
Applications
En bloc perfluorodissection and preoperative intravitreal bevacizumab use for 
vitrectomy in eyes with tractional retinal detachment in advanced proliferative 
diabetic retinopathy it is very useful technique, reduces complication and opera-
tive time. 
Peer review
The report is interesting, well documented, and the paper should be published. 
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Hypothesis 5: Tractional retinal detachment (TRD) may occur following IVB as an adjuvant to 
vitrectomy for the management of severe PDR.  
 
AIMS: The aim of this study was to report the development or progression 
of tractional retinal detachment (TRD) after the injection of intravitreal bevacizumab (Avastin) used 
as an adjuvant to vitrectomy for the management of severe proliferative diabetic retinopathy (PDR). 
 
METHODS: The clinical charts of patients who experienced the development or progression of TRD 
after an intravitreal injection of 1.25 mg bevacizumab before vitrectomy for the management of PDR 
were reviewed. 
 
RESULTS: Eleven eyes (patients) out of 211 intravitreal injections (5.2%) that developed or had 
progression of TRD were identified. All eyes had PDR refractory to panretinal photocoagulation 
(PRP). Nine patients had type 1 diabetes mellitus (DM), and two patients had type 2 DM. Patients 
had a mean age of 39.5 years (range 22-62 years). In the current study, all patients used insulin 
administration and had poor glycaemic control (mean HbA(1c) 10.6%). Time from injection to TRD 
was a mean of 13 days (range 3-31 days). Mean best correct visual acuity (BCVA) at TRD 
development or progression was logarithm of the minimal angle of resolution (LogMAR) 2.2 (range 
1.0-2.6) (mean Snellen equivalent hand motions; range 20/200 to light perception), a statistically 
significant worsening compared with baseline BCVA (p<0.0001). Eight eyes underwent vitrectomy 
and three patients refused or were unable to undergo surgery. The final mean BCVA 
after surgery was LogMAR 0.9 (range 0.2-2.0) (mean Snellen equivalent 20/160; range 20/32 to 
counting fingers), a statistically significant improvement compared with TRD BCVA (p = 0.002). 
 
CONCLUSIONS: TRD may occur or progress shortly following administration of 
intravitreal bevacizumab in patients with severe PDR. 
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Aims: The aim of this study was to report the
development or progression of tractional retinal detach-
ment (TRD) after the injection of intravitreal bevacizumab
(Avastin) used as an adjuvant to vitrectomy for the
management of severe proliferative diabetic retinopathy
(PDR).
Methods: The clinical charts of patients who experienced
the development or progression of TRD after an
intravitreal injection of 1.25 mg bevacizumab before
vitrectomy for the management of PDR were reviewed.
Results: Eleven eyes (patients) out of 211 intravitreal
injections (5.2%) that developed or had progression of
TRD were identified. All eyes had PDR refractory to
panretinal photocoagulation (PRP). Nine patients had type
1 diabetes mellitus (DM), and two patients had type 2
DM. Patients had a mean age of 39.5 years (range 22–62
years). In the current study, all patients used insulin
administration and had poor glycaemic control (mean
HbA1c 10.6%). Time from injection to TRD was a mean of
13 days (range 3–31 days). Mean best correct visual
acuity (BCVA) at TRD development or progression was
logarithm of the minimal angle of resolution (LogMAR) 2.2
(range 1.0–2.6) (mean Snellen equivalent hand motions;
range 20/200 to light perception), a statistically significant
worsening compared with baseline BCVA (p,0.0001).
Eight eyes underwent vitrectomy and three patients
refused or were unable to undergo surgery. The final
mean BCVA after surgery was LogMAR 0.9 (range 0.2–
2.0) (mean Snellen equivalent 20/160; range 20/32 to
counting fingers), a statistically significant improvement
compared with TRD BCVA (p= 0.002).
Conclusions: TRD may occur or progress shortly
following administration of intravitreal bevacizumab in
patients with severe PDR.
Proliferative diabetic retinopathy (PDR) is a major
cause of visual loss in patients with diabetes
mellitus.1–3 Studies have demonstrated not only a
correlation of vascular endothelial growth factor
(VEGF) levels with the severity of PDR, but also a
reduction in levels after successful laser treatment
of PDR.4 5 Thus a rational approach to treating
neovascularisation in these patients would include
the use of anti-VEGF agents.6–8
Bevacizumab (Avastin; Genentech Inc., San
Francisco, CA, USA) is a full length humanised
antibody that binds to all subtypes of VEGF and
has been approved by the US Food and Drug
Administration for the treatment of metastatic
colorectal cancer.9 Recent reports have suggested
that bevacizumab may be useful in the treatment
of choroidal neovascularisation, diabetic macular
oedema, PDR and macular oedema associated with
retinal venous occlusive disease.7 10–15
Panretinal photocoagulation (PRP) is currently
the mainstay of therapy for PDR, significantly
reducing the risk of blindness in these patients.16 17
However, there are instances when it is difficult or
impossible to administer PRP because of media
opacity, such as vitreous haemorrhage. There are
also cases that do not respond with complete
regression even after extensive PRP: in such cases
intravitreal bevacizumab could be considered as an
alternative salvage therapy.
Recently, it has been reported that intravitreal
injection of bevacizumab may be also useful for
early vitreous haemorrhage in PDR in order to
decrease the risk of new haemorrhages while
clearing occurs and to minimise the indications of
vitrectomy.18 In addition, Chen and Park19 and
Avery et al20 have suggested that preoperative
intravitreal bevacizumab might be helpful to
facilitate vitrectomy in severe PDR cases. In such
cases, the preoperative use of bevacizumab might
reduce the risk of intraoperative bleeding facilitat-
ing the removal of fibrovascular membranes,
particularly when preoperative PRP cannot be
placed.
The purpose of this retrospective case series is to
report the development or progression of tractional
retinal detachment (TRD) following intravitreal
bevacizumab as an adjuvant to vitrectomy for the
management of severe PDR.
PATIENTS AND METHODS
We reviewed the medical records and obtained
follow-up information on all patients in our files
with TRD who had undergone intravitreal injec-
tion of 1.25 mg bevacizumab before vitrectomy for
the management of PDR from September 2005 to
November 2006 at seven centres from Brazil,
Argentina, the USA, Costa Rica, Puerto Rico and
Venezuela. The ‘‘off-label’’ status of this medica-
tion, and possible systemic and ocular complica-
tions, were discussed in detail and informed
consent was obtained from all patients.
Institutional review board/ethics committee
approval was obtained for this study at all seven
institutions.
Pre-injection examination included Snellen or
Early Treatment Diabetic Retinopathy Study
(ETDRS) visual acuity measurement, slit-lamp
biomicroscopy and dilated fundus examination.
Although not a formal exclusion criterion, patients
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with a history of uncontrolled hypertension and recent
thomboembolic events were not usually injected with bevaci-
zumab; however, this decision was taken at the discretion of the
treating physician. Inclusion criteria for the use of intravitreal
bevacizumab before vitrectomy for the management of PDR
included TRD, persistent vitreous haemorrhage and incomplete
regression even after extensive PRP.
An aliquot of commercially available bevacizumab (0.18 ml)
was prepared for each patient and placed in a tuberculin syringe
using aseptic techniques. After the eye had been prepared in a
standard fashion using 5% povidone/iodine, an eyelid speculum
was used to stabilise the eyelids, and the injection of 1.25 mg
(0.05 ml) bevacizumab was performed 3.5–4 mm posterior to
the limbus, through the pars plana with a 30-gauge needle under
topical anaesthesia or subconjunctival lidocaine. Following the
injection, intraocular pressure and retinal artery perfusion were
confirmed, and patients were instructed to administer topical
antibiotics for 3–7 days.
Statistical analysis was performed using GraphPad Instat
Version 3.0 for Mac OSX (GraphPad Software, San Diego, CA,
USA). Patients’ BCVAs were transferred from their records and
converted to a logarithm of the minimal angle of resolution
(logMAR) scale for analysis. The paired t test was used to
compare mean values to analyse mean logMAR visual acuity
statistically. Correlation was considered significant if the p
value was (0.05.
RESULTS
Eleven eyes (patients) out of 211 intravitreal injections (5.2%)
that developed or had progression of TRD were identified. All
patients had had a PRP at least 2 months before intravitreal
bevacizumab. All eyes had PDR refractory to PRP. Eight (72.7%)
patients were white and 3 (27.3%) patients were Hispanic. The
mean age of the study group was 39.5 years (range 22–62 years),
and 54.5% were male (six men and five women). Nine patients
had type 1 diabetes mellitus (DM) with more than 15.5 years
from diagnosis (range 14–30 years), and two patients had type 2
DM with 1 year from diagnosis. In the current study, all
patients used insulin administration for glycaemic control and
had uncontrolled diabetes associated with elevated glycosylated
haemoglobin (mean HbA1c 10.6%). Seven eyes had local TRD
on indirect ophthalmoscopy, ultrasound, or biomicroscopic
non-contact fundus examination with a 66- or a 78-diopter
lens before intravitreal bevacizumab. The clinical findings of all
11 eyes with PDR and TRD after intravitreal bevacizumab are
presented in table 1.
Time from injection to TRD was a mean of 13 days (range 3–
31 days). The mean baseline (before intravitreal bevacizumab)
BCVA was LogMAR 0.8 (range 0.3–1.6) (mean Snellen
equivalent 20/125; range 20/40 to 5/200). At TRD development
or progression, the mean BCVA was LogMAR 2.2 (range 1.0–
2.6) (mean Snellen equivalent hand motions (HM); range 20/
200 to light perception (LP)), a statistically significant worsen-
ing compared with baseline BCVA (p,0.0001). One patient
(case 9) developed a retinal break as a result of the increased
traction, and a combined total tractional-rhegmatogenous
retinal detachment was apparent 3 weeks after intravitreal
bevacizumab.
Eight eyes underwent vitrectomy, two patients refused or
were unable to undergo surgery, and in one patient surgery was
not recommended. Vitrectomy was performed within 10 days
after the development or progression of TRD. Tractional retinal
detachments were managed with vitrectomy, membranectomy,
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in all patients that underwent surgery. Final mean BCVA after
surgery was LogMAR 0.9 (range 0.2–2.0) (mean Snellen
equivalent 20/160; range 20/32 to counting fingers (CF)), a
statistically significant improvement compared with TRD
BCVA (p=0.002). Sub-group analysis of final BCVA after
vitrectomy demonstrated that all eight (100%) eyes improved
two or more ETDRS lines of BCVA compared with TRD BCVA.
However, compared with baseline BCVA, final BCVA after
vitrectomy demonstrated that four (50%) eyes improved, two
(25%) eyes remained stable, and two (25%) eyes lost two or
more ETDRS lines of BCVA (table 1).
Selected case reports
Case 6
A 22-year-old woman with a history of poorly controlled type 1
DM since age 6 years presented with bilateral PDR. She had a
history of panretinal photocoagulation in her right eye. At
presentation, her BCVA was 20/200 and fundus examination
revealed NVD of 6 disc diameters emanating from the optic disc
into the vitreous cavity without any signs of bleeding (fig 1A).
Intravitreal bevacizumab at a dose of 1.25 mg was injected into
the vitreous cavity in preparation for a vitrectomy for
incomplete regression even after extensive PRP. Four days later
the patient returned complaining of a sudden visual loss in her
right eye. A dense vitreous haemorrhage was present. Extensive
fibrovascular proliferation extending from the optic nerve into
the vitreous cavity was causing a partial TRD (fig 1B). Pars
plana vitrectomy was performed 5 days later. Panretinal
photocoagulation was completed and 20% SF6 was left as
intraocular tamponade. The retina was successfully re-attached
and she recovered BCVA of 20/50 at her final follow-up
(20 weeks).
Case 7
A 45-year-old Hispanic man presented with a 1-month history
of visual loss in his left eye. He had poorly controlled type 2 DM
diagnosed 1 year earlier. His vision was 20/80 in his right eye
and HM in his left eye. He had severe PDR in the right eye with
a small localised TRD along the superior temporal arcade
(fig 2A). The left eye had dense vitreous haemorrhage without
evidence of retinal detachment by ultrasound. His right eye
received an intravitreal injection of 1.25 mg bevacizumab in
preparation for a vitrectomy. Three weeks later he complained
of sudden loss of vision in his right eye, and was noted to have
HM vision due to vitreous haemorrhage and a TRD (fig 2B).
Vitrectomy was performed the next day in his right eye. His
BCVA returned to 20/400 and has been stable for the past
8 months.
DISCUSSION
Recently, intravitreal bevacizumab has become popular as a
preoperative coadjuvant in cases of severe PDR.19 20 Preoperative
suppression of intraocular VEGF should reduce intraoperative
haemorrhaging during membrane dissection facilitating the
surgery. In our retrospective review, we identified 11 eyes
(patients) with development or progression of TRD with
decrease BCVA after intravitreal bevacizumab prior to vitrect-
omy for the management of PDR for an incidence of 5.2%.
The natural course of PDR is characterised by a cycle of
proliferation and regression typical of new vessels; proliferation
of fibrous tissue accompanying new vessels; formation of
adhesions between the fibrovascular proliferations and the
posterior vitreous surface; and contraction of the posterior
vitreous surface and associated proliferation. The development
or progression of TRD in PDR following intravitreal bevacizu-
mab in our patients could have happened by natural history or
rapid neovascular involution with accelerated fibrosis and
posterior hyaloidal contraction as a response to decreased levels
of VEGF.
It could be argued that TRD may develop soon after extensive
PRP in diabetes. In addition, all our patients were refractory to
extensive PRP. However, all patients had had a PRP at least
2 months before intravitreal bevacizumab. The short time
interval between the injection and TRD (mean 13 days; range
3–31 days) suggests a cause–effect relationship. It also suggests
that in cases at risk for progression of TRD that might involve
the central macular region, timely surgery should be anticipated
following intravitreal bevacizumab. Nine out of 11 (81.8%)
TRDs developed or progressed 5 days or more after the
injection. All patients who developed or had progression of
TRD in our study used insulin administration for glycaemic
control, and nine patients had elevated HbA1c (>9.5%; mean
10.6%).
Avery et al20 have reported that diabetic eyes may be very
sensitive to intravitreal bevacizumab. In their study, several
patients underwent intravitreal injection of lower doses of
bevacizumab: 6.2, 12.5, 62, 125 and 625 mg. Biological effects
were noted at all doses, sometimes at 24 h. The durability of
this effect is unknown, and larger doses may be shown to
produce a longer duration of effect, but to use lower doses seems
prudent in eyes with pre-existing significant traction.
Figure 1 Case 6. (A) Fluorescein angiogram before intravitreal
bevacizumab reveals marked hyperfluorescence resulting from leakage of
dye from new vessels and fibrous tissue on the disc (NVD). Notice
confluent scatter photocoagulation scars. The retina is attached and
BCVA is 20/100. (B) Fundus photograph 4 days after 1.25 mg intravitreal
bevacizumab demonstrating dense fibrous tissue contraction, vitreous
haemorrhage and tractional retinal detachment. BCVA is CF at 2 m.
Figure 2 Case 7. Fundus photograph before (A) and after (B)
intravitreal bevacizumab. (A) Fundus photograph demonstrates severe
proliferative diabetic retinopathy in the right eye with a small localised
TRD along the supero-temporal vascular arcade without macular
involvement. (B) Fundus photograph 3 weeks after 1.25 mg intravitreal
bevacizumab demonstrates progression of partial TRD along the supero-
temporal vascular arcade with decrease neovascularisation.
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In those eyes that underwent vitrectomy, we had the
impression that there was a reduced risk of intraoperative
bleeding facilitating the removal of fibrovascular membranes. A
bloodless field allows for better visibility and the surgeon may
be less likely to create an iatrogenic retinal break. In addition,
the chances of postoperative complications such as rebleeding or
fibrinoid syndrome may be decreased. All these advantages may
allow us to save more eyes by utilising preoperative intravitreal
bevacizumab regardless of increased traction on some severe
PDR cases. In addition, in our TRD cases that underwent
vitrectomy, final BCVA was significantly better than BCVA
before surgery and when TRD was present.
In summary, TRD in PDR may occur or progress after
intravitreal bevacizumab used as an adjuvant to vitrectomy.
Most patients had poorly controlled DM associated with
elevated HbA1c, insulin administration, PDR refractory to
panretinal photocoagulation, and a longer time interval
between intravitreal bevacizumab and vitrectomy.
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Chapter 11: Risk Factors for the Development of Tractional Retinal Detachment Following 
Intravitreal Bevacizumab in patients with Severe Proliferative Diabetic Retinopathy 
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Hypothesis 6: Risk factors for the progression or development of TRD following IVB as an adjuvant 
to vitrectomy in severe PDR may include age, time from diabetes mellitus (DM) diagnosis, glycemic 
control, cholesterol levels, triglycerides levels, hemoglobin A1c (HbA1C), dose of bevacizumab, and 
time from injection to vitrectomy.  
 
Twenty-five eyes (patients) (3.5%) out of 698 intravitreal injections (patients) developed or 
had progression to a TRD after intravitreal bevacizumab. Based on our data, we now believe that 
extreme care must be taken in using a dose of 2.5 mg or more of bevacizumab in patients with PDR. In 
addition, to have more than 15 years with a diagnosis of diabetes can increase the risk of TRD and that 
careful follow-up evaluation following injection is recommended. The timing of surgery after the 
injection is also important, as there are concerns that bevacizumab may cause progression of the TRD. 
It is important that surgery is performed once the anti-angiogenic effect of bevacizumab has fully 
developed, but before there is further fibrous proliferation; physicians must be prepared to perform the 
vitrectomy preferably before about 13 days after the application of bevacizumab and to perform a 
vitrectomy immediately on those patients in whom a TRD occurs.  
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Retinal Detachment after Bevacizumab
Dear Editor:
We have previously reported 11 eyes (patients) out of 211
intravitreal injections with development or progression of trac-
tional retinal detachment (TRD) with decrease best-corrected
visual acuity (BCVA) after intravitreal bevacizumab (Avastin;
Genentech Inc., San Francisco, CA) prior to vitrectomy for the
management of proliferative diabetic retinopathy (PDR) for an
incidence of 5.2%. Most patients had poorly controlled diabe-
tes mellitus associated with elevated HbA1c, insulin adminis-
tration, PDR refractory to pan-retinal photocoagulation (PRP),
and longer time between intravitreal bevacizumab and vitrec-
tomy.1 The purpose of this study was to determine risk factors
for the progression or development of tractional retinal detach-
ment following intravitreal bevacizumab (IVB) as an adjuvant
to vitrectomy in severe PDR.
We reviewed the clinical records of 698 intravitreal injections
and obtained follow-up information on all patients in our files with
TRD who had undergone IVB before vitrectomy for the manage-
ment of PDR from July 2006 to July 2009 at 6 centers. Clinical
parameters of patients previously identified as potential risk fac-
tors for TRD were obtained and analyzed and compared with the
clinical characteristics of those patients from the same cohort that
did not developed a TRD after IVB for PDR. These potential risk
factors included systemic and surgical background, age, time from
diabetes mellitus (DM) diagnosis, glycemic control, cholesterol
levels, triglycerides levels, hemoglobin A1c (HbA1C), dose of
bevacizumab, and time from injection to vitrectomy.
Twenty-five eyes (patients) (3.5%) out of 698 intravitreal
injections (patients) developed or had progression to a TRD
after intravitreal bevacizumab (Figure 1 and Table 1; avail-
able at http://aaojournal.org). Of these 698 intravitreal in-
jections, 626 applications were with 1.25 mg of bevaci-
zumab (of which 19 patients had TRD, 3%) and 72
injections with 2.5 mg of bevacizumab (of which 6 patients
had TRD, 8.3%). No systemic adverse events such as
thromboembolic events were reported. Before the initial
bevacizumab injection in patients with TRD, the mean
baseline BCVA was logMAR 1.25 (range, 1.046–1.454),
SD (0.45) – (mean Snellen equivalent 20/360; range, 20/223 –
20/570). At TRD development or progression, the mean
BCVA was logMAR 2.423 (range, 1.869– 2.971) (mean
Snellen equivalent Counting Fingers to light perception).
Final mean BCVA after bevacizumab and vitrectomy was
logMAR 1.029 (range, 0.736–1.322), SD (0.570) – (Snellen
equivalent 20/109 – 20/422), a statistically significant im-
provement (P!0.0001) compared with baseline BCVA. We
did not observe any statistically significant differences in
changes of BCVA between doses of 1.25 and 2.5 mg of
IVB. Risk factors for TRD after IVB identified in our study
included, more than 15 years from the diagnosis of diabetes
mellitus (DM) (P " 0.009), (OR " 0.30), (95% CI "
0.10–0.83), (RR " 0.35), more than 13 days from injection
to vitrectomy (P " 0.0001), (OR " 9.9), (95% CI "
3.4–29), (RR " 6.9) and the use of a higher dose (2.5 mg)
of bevacizumab (P " 0.022), (OR " 2.7), (95% CI "
1.05–7.18), (RR " 2.38). We did not find a statistical associ-
ations between others risk factors and TRD, such as macular
thickness (P " 0.123), or previous use of bevacizumab (P "
0.653). Fibrovascular proliferation was present in most patients
with TRD (95% CI " 73.9–99.8). However, no significant
correlation was found between TRD and fibrovascular prolif-
eration despite that 94.7% of the patients had this factor present
(P " 0.260) (Table 2; available at http://aaojournal.org).
Based on our data, we now believe that extreme care must be
taken in using a dose of 2.5 mg or more of bevacizumab in
patients with PDR. In addition, to have more than 15 years with a
diagnosis of diabetes can increase the risk of TRD and that careful
follow-up evaluation following injection is recommended. The
timing of surgery after the injection is also important, as there are
concerns that bevacizumab may cause progression of the TRD. It
is important that surgery is performed once the anti-angiogenic
effect of bevacizumab has fully developed, but before there is
further fibrous proliferation; physicians must be prepared to per-
form the vitrectomy preferably before about 13 days after the
application of bevacizumab and to perform a vitrectomy imme-
diately on those patients in whom a TRD occurs.
Limitations of our study include that it is nonrandomized,
uncontrolled, and retrospective, i.e., features which preclude any
estimation on the safety of bevacizumab. In addition, because no
control group is present we cannot rule out the possibility that
TRD is due to the natural history of disease. However, the results
suggest the need for further investigation to adequately elucidate
the risk factors that are associated with TRD after IVB in PDR.
J. FERNANDO AREVALO, MD, FACS
Riyadh, Saudi Arabia
JUAN G. SANCHEZ, MD
LUCAS SALDARRIAGA, MD
Medellin, Colombia
MARIA H. BERROCAL, MD





San Jose, Costa Rica
MAURICIO MAIA, MD
São Paulo, Brazil




for the Pan American Collaborative Retina Study
Group
*(Group members listed online in Appendix 1;
available at http://aaojournal.org).
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Appendix
The following investigators belong to the Pan-American Collaborative Retina Study Group (PACORES):
The Pan-American Collaborative Retina Study Group (PACORES)*-
L. Wu (PI), Instituto de Cirugia Ocular, San Jose, Costa Rica; J.F. Arevalo (PI), J.G. Sanchez, M.A. Serrano, J.D. Arias,
Clinica Oftalmologica Centro Caracas and the Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas,
Venezuela; M. Farah (PI), M. Maia, F.B. Aggio, Universidade Federal de São Paulo - Departamento de Oftalmologia -
Instituto da Visão - Sao Paulo, Brazil; V. Morales-Canton (PI), H. Quiroz-Mercado, J. Fromow-Guerra, J.L. Guerrero-
Naranjo, J. Dalma-Weiszhausz, Asociación para Evitar la Ceguera en México, Mexico City, Mexico; F.J. Rodriguez (PI),
R. Infante, D. Medina, Fundacion Oftalmologica Nacional, Universidad del Rosario, Bogota, Colombia; M.H. Berrocal (PI),
V. Cruz-Villegas, University of Puerto Rico, San Juan, Puerto Rico; F. Graue-Wiechers (PI), D. Lozano-Rechy, V. Robledo,
J.L. Rodriguez-Loaiza, Fundacion Conde Valenciana, Mexico City, Mexico; J.A. Roca (PI), Clı´nica Ricardo Palma, Lima,
Peru; M. J. Saravia (PI), M. Martinez-Cartier, Hospital Universitario Austral, Buenos Aires, Argentina; M. Avila (PI),
Universidade Federal de Goiás - Departamento de Oftalmologia - Goiânia, Brazil; J. Cardillo (PI), RA Costa, Hospital de
Olhos de Araraquara, and the Universidade de Sao Paulo, Sao Paulo, Brazil; J. Verdaguer T. (PI), C. Carpentier, J.I.
Verdaguer D., L. Filsecker, G. Sepúlveda, Fundacion Oftalmologica Los Andes, Santiago de Chile, Chile; A. Alezzandrini
(PI), F. Sanchez, C. Marini, B. Garcia, OFTALMOS, Catedra de Oftalmologia, Universidad de Buenos Aires, Buenos Aires,
Argentina; G. Alvira (PI), P. Flor, Hospital Metropolitano, Quito, Ecuador.
*PI " Principal Investigator.
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Figure 1. (A-C) Color photographs before intravitreal bevacizumab. Severe proliferative diabetic retinopathy with abundant fibrovascular tissue and
subhyaloid hemorrhage. The retina is attached and best-corrected visual acuity (BCVA) is 20/80. (D-F) Color photographs 10 days after 2.5 mg of
intravitreal bevacizumab demonstrating dense fibrous tissue contraction, and tractional retinal detachment with macular involvement; BCVA is hand
motions at 2 meters. (G-I) Same eye, 8 days after vitrectomy. The retina is re-attached and BCVA is 20/120 with silicone oil tamponade.
Ophthalmology Volume 118, Number 11, November 2011
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1 F 24 1 10 No Yes 9.06 Yes 450 Yes No No
2 M 44 1 11 No No 8.2 Yes 560 Yes No No
3 F 76 2 18 No No 7 Yes 566 Yes No No
4 F 46 2 10 No No 6.7 No 462 Yes No No
5 M 49 2 17 No No 9 No 670 Yes No No
6 F 56 2 18 No Yes 8.2 Yes 494 Yes No No
7 M 65 2 15 No No 9.28 Yes 848 Yes No Partial
8 M 52 2 10 No Yes 10.21 Yes 1244 Yes No Partial
9 M 42 2 10 No Yes 8.46 Yes 456 Yes No No
10 M 65 2 15 No Yes 7.83 Yes 638 Yes No Partial
11 M 58 2 23 No Yes 10.73 Yes 533 Yes No Total
12 F 45 1 30 No Yes 8.72 Yes 406 Yes No Partial
13 M 60 2 15 No Yes 9.56 Yes 600 Yes No No
14 F 41 1 22 No Yes 7.7 No 512 No No No
15 F 67 1 15 No Yes 7.1 Yes 435 No No No
16 M 65 1 19 Yes Yes 7.8 Yes 621 No No Total
17 F 61 1 7 Yes Yes 7.9 Yes 448 No No No
18 M 67 2 15 No Yes 14 Yes 459 Yes No Total
19 F 49 2 25 No Yes 14.3 Yes 288 No No No
20 F 59 2 15 No No 13.1 Yes 675 Yes No Partial
21 M 63 2 5 No Yes 6.8 Yes 551 Yes No Total
22 F 47 2 15 No No 8.2 No 587 Yes No Total
23 F 52 2 0 No No 13.7 Yes 532 Yes No No
24 F 52 1 13 No Yes 8.03 Yes 560 Yes No Partial
25 M 56 2 15 No No 10.53 No 573 No No No
*F " Female; M " male; DM " Diabetes Mellitus; HTA " Hypertension; HbA1c " Hemoglobin Glycosylated; PRP " Pan retinal Photocoagulation;
Less Bleeding; EMP " Easier Membrane Peeling; FS " Faster Surgery.
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2.5 6 No 20/63 20/400 20/200 TRD LB, EMP 16
2.5 31 Yes 20/32 20/320 20.63 TRD LB, EMP 56
2.5 32 No 20/500 HM 20/1250 TRD LB, EMP, FS 25
2.5 35 No 20/1250 HM 20/1250 TRD FS 12
2.5 28 No 20/400 LP 20/800 TRD LB, EMP, FS 11
2.5 6 No 20/1250 20/1250 TRD LB 12
1.25 35 No 20/1250 HM 20/400 TRD EMP, FS 2
1.25 37 Yes 20/400 HM HM TRD EMP, FS 0
1.25 15 Yes 20/400 HM 20/100 TRD EMP, FS 0
1.25 35 No 20/1250 HM 20/400 TRD EMP, FS 0
1.25 21 No 20/200 20/400 20/200 TRD EMP, FS 2
1.25 24 No 20/500 HM 20/32 TRD EMP, FS 0
1.25 20 No 20/500 HM 20/630 TRD LB 8
1.25 7 No 20/1250 LP HM TRD LB, EMP, FS 53
1.25 7 No 20/400 HM 20/63 TRD LB, EMP, FS 43
1.25 5 Yes 20/630 HM 20/40 TRD LB, EMP, FS 52
1.25 5 Yes 20/400 HM 20/32 TRD LB, EMP, FS 53
2.5 10 Yes 20/400 LP NLP TRD LB, FS 170
2.5 10 No 20/40 20/100 20/80 TRD EMP, FS 190
2.5 10 No 20/200 20/320 20/100 TRD LB, EMP, FS 60
1.25 14 No 20/200 HM LP TRD LB, EMP, FS 114
2.5 14 No 20/400 20/400 20/400 TRD LB, EMP, FS 110
2.5 16 Yes 20/200 LP NLP TRD LB, EMP, FS 136
1.25 17 No 20/400 HM 20/100 TRD LB 63
2.5 19 Yes 20/200 20/500 20/200 TRD FS,EMP 35
DME " Diabetic Macular Edema; RD " Retinal Detachment; TRD " Tractional Retinal Detachment; BCVA " Best Corrected Visual Acuity; LB "
Table 2. Risk factors for Tractional Retinal Detachment*
Risk Factor P CI 95%




More than 13 days from
injection to vitrectomy
0.0001‡ 3.4–29
Use of a higher dose (2.5
mg) of bevacizumab
0.022‡ 1.05–7.18
Diabetes Type 0.833 0.34–2.20
Fibrovascular proliferation 0.260 0.38–12.15
History of smoking 0.408 0.11–2.41
History of HTA 0.534 0.29–1.87




Total Cholesterol 0.895 0.16–4.53
Triglycerides 0.453 0.08–9.12
Hemoglobin A1C levels 0.796 0.07–4.40
Macular Thickness of DME 0.123 0.33–11.65
Prerretinal Hemorrhage 0.317 0.33–17.5
Vitreous Hemorrhage 0.292 0.24–1.47
Previous vitrectomy 0.632 0.49–24.97
Age # 60 years 0.521 0.30–13.7
Previous use of Bevacizumab 0.730 0.07–5.40
*DME " Diabetic Macular Edema; TRD " Tractional Retinal Detach-
ment; HTA " Hypertension.
‡Statistically significant.
Ophthalmology Volume 118, Number 11, November 2011
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Chapter 12: Prospective Unpublished Chapter: Pre-Operative Intravitreal Bevacizumab for 
Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy: Prospective 
Randomized Clinical Trial of the Pan-American Collaborative Retina Study (PACORES) Group 
 
Hypothesis 7 (prospective unpublished study): Intravitreal injection of 1.25 mg of bevacizumab as a 
pre-operative adjunct to PPV in eyes with TRD secondary to PDR will be safe and effective. IVB 
(compared to sham) will decrease intraoperative bleeding, total surgical time, post-operative vitreous 
hemorrhage, and visual acuity at 12 months. 
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Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to 
Proliferative Diabetic Retinopathy: Prospective Randomized Clinical Trial of the Pan-
American Collaborative Retina Study (PACORES) Group* 
 
J. Fernando Arevalo, MD FACS,1 Andres F. Lasave, MD,2 Igor Kozak, MD,3 Saba Al Rashaed MD,3 
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Purpose: To assess the effectiveness and safety of an intravitreal injection of 1.25 mg of 
bevacizumab (IVB) as a pre-operative adjunct to small-gauge pars plana vitrectomy (PPV) compared 
to PPV alone in eyes with tractional retinal detachment (TRD) secondary to proliferative diabetic 
retinopathy (PDR). 
Design: Randomized clinical trial.  
Methods: This prospective, double-masked, randomized, multicenter, active-controlled clinical trial 
enrolled 234 eyes among 234 patients between November 2013 and July 2015. All randomized eyes 
underwent a baseline exam included best corrected visual acuity (BCVA), color photos, optical 
coherence tomography (OCT) and fluorescein angiography (FA). Improved surgical visualization, 
reduced operative time, and intra-operative complications were the main outcome measures. Patients 
were followed for 12 months.  
Results: Two hundred and fourteen (214 eyes) patients were randomized with a 1:1 ratio to PPV plus 
IVB ([Study group] 102 eyes) or PPV plus sham ([control] 112 eyes). Iatrogenic retinal breaks were 
intraoperatively noted in 35 eyes (34.3%) in the study group, and 66 eyes (58.9%) in the control group 
(p=0.001). In the study group 32 (31.3%) eyes had grade 2 intraoperative bleeding, and 58 (51.7 %) 
eyes in the control group (p=0.001). Endodiathermy applications were necessary in 28 (27.4 %) eyes 
in the study group, compared with 75 (66.9 %) eyes in the control group (p=0.0001). Mean surgical 
time was 71.3 ± 32.1 minutes in the study group and 83.6 ± 38.7 minutes in the control group 
(p=0.061). 
Conclusion: Pre-operative IVB seems to reduce intraoperative bleeding, improving surgical field 
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Proliferative diabetic retinopathy (PDR), is an ocular disorder characterized by retinal 
ischemia, recurrent retinal neovascularization and fibrous proliferation, which can lead to blindness if 
not properly treated.1, 2 Patients with non-clearing vitreous hemorrhage, tractional retinal detachment 
(TRD) or extensive fibrovascular proliferations are candidates for pars plana vitrectomy (PPV). One 
of the most common intraoperative complications of PPV is bleeding. Intraoperative bleeding makes 
surgeons’ maneuvers very difficult due to poor visualization.  This difficult situation could prolong 
the total surgical time and hinder the surgical outcomes. Moreover, massive bleeding during surgery 
may even be uncontrollable and lead to surgical failure. 3 
The use of intravitreal injection of bevacizumab (Avastin; Genentech, South San Francisco, 
CA) has been effective to decrease vascular permeability and proliferation, improving diabetic 
macular edema and reducing the risk of intraocular bleeding in patients with PDR. 4 In addition, in 
eyes with advanced PDR characterized by, ample, active neovascularization and/or extensive or 
multiple layers of fibrovascular proliferation, an intravitreal bevacizumab (IVB) injection before 
surgery may potentially further decrease intraoperative hemorrhage, facilitate fibrovascular membrane 
dissection,5-14 and reduce intra- and post-operative ocular complications. 11,14-16 A meta-analysis 
supports the use of pre-operative bevacizumab in diabetic vitrectomies. 13 However, we have 
previously reported that TRD may occur or progress shortly following administration of intravitreal 
bevacizumab in patients with severe PDR. 17,18 In addition, other reports show that IVB may cause 
TRD in cases with PRD and pre-existing pre-retinal fibrosis.19 For that reason, there is no consensus 
in the retina community about the usefulness and risk/benefit ratio of IVB as an adjuvant to PPV in 
TRD in PDR. To provide more evidence to the literature, we decided to conduct a randomized trial 
evaluating the effectiveness and safety of an intravitreal injection of 1.25 mg of bevacizumab as a pre-
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Material and Methods 
 
 This prospective, double-masked, randomized, multicenter, active-controlled clinical trial 
(http://clinicaltrials.gov/show/NCT01976923) was conducted by the Pan-American Collaborative 
Retina Study (PACORES) Group at 13 clinical sites from 9 countries. Institutional Review 
Board/Ethics Committee approval and patients’ informed consent were obtained for this study at all 
institutions. The off-label use of the drug and its potential risks and benefits were discussed 
extensively with all patients. In addition, this study has been performed in accordance with the ethical 
standards laid down in the 1964 Declaration of Helsinki for research involving human subjects. 
Patients were randomized with a 1:1 ratio to small gauge PPV plus IVB (Study group) or small gauge 
PPV plus sham injection (Control group). Randomization was done by using the method of randomly 
permuted blocks by an internet-based randomization generator (http://www.randomization.com).  
 




 Patients (18 years or older) with type 1 or 2 diabetes mellitus if they had PDR and TRD 
threatening or involving the macula, with or without a rhegmatogenous component, and with or 
without vitreous hemorrhage (VH), were included in the analysis. Eyes with VH dense, enough to 
prevent visualization of the macula pre-pars plana vitrectomy (PPV), were included in the study if 
macular-involving TRD was seen with ultrasound. Eyes with or without DME were also eligible. 
Participants with both eyes enrolled had 1 eye assigned randomly to PPV with sham injection and the 
other eye to PPV with pre-operative IVB. The patients receiving intravitreal medication were 
explained the off-label use of the drug, the potential risks of thromboembolic events, endophthalmitis 
and uveitis. Written informed consent was obtained from all patients before the intravitreal injection 
as well as prior to small gauge PPV.  
Ocular Exclusion Criteria  
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 The following exclusions applied to the study eye only (i.e., they may have been present for 
the non-study eye): If TRD was considered to be due to a cause other than diabetes. An ocular 
condition such that, in the opinion of the investigator, visual acuity loss would not improve from 
resolution of TRD (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, non-
retinal condition, optic atrophy). An ocular condition (other than diabetes) that, in the opinion of the 
investigator, might affect retinal status or alter visual acuity during the course of the study (e.g., 
retinal vein occlusion, uveitis or other ocular inflammatory disease, glaucoma, etc.). History of 
treatment for diabetic macular edema or diabetic retinopathy at any time in the past 4 months with 
anti-VEGF drugs. History of major ocular surgery (including vitrectomy, scleral buckle, any 
intraocular surgery [except cataract surgery], etc.) within prior 4 months of randomization. History of 
neodymium-doped yttrium aluminium garnet (YAG) capsulotomy performed within 2 months prior to 
randomization. Intraocular pressure either equal or more than 25 mmHg. Exam evidence of external 
ocular infection, including conjunctivitis, chalazion, or significant blepharitis. 
  
Systemic Exclusion Criteria  
 Those patients who presented any of the following exclusion criteria were excluded: 
Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney 
transplant. A condition that, in the opinion of the investigator, would preclude participation in the 
study (e.g., unstable medical status including hypertension, cardiovascular disease, and glycemic 
control). Participation in an investigational trial within 30 days of randomization that involved 
treatment with any drug that has not received regulatory approval at the time of study entry. Known 
allergy to any component of the study drug. Blood pressure > 180/110 mmHg (systolic above 180 or 
diastolic above 110). Major surgery within 28 days prior to randomization or major surgery planned 
during the following 6 months to randomization. Myocardial infarction, other cardiac event requiring 
hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 
4 months prior to randomization. Systemic anti-VEGF treatment within 4 months prior to 
randomization. For women of child-bearing potential: pregnant or lactating or intending to become 
Stellenbosch University  https://scholar.sun.ac.za
                                       
 
 
pregnant within the next 12 months. Participant was expecting to move out of the area of the clinical 
center to an area not covered by another clinical center during the first 12 months of the study. 
History of blood diseases associated with abnormal coagulation. Anti-coagulant therapy. 
 Patients were enrolled and randomized with a 1:1 ratio to small gauge PPV plus sham 
(Control Arm) or small gauge PPV plus IVB (Study Arm). 
Control Arm:  
 A sham intravitreal injection was scheduled 3-5 days before surgery. The patient was 
prepared for intravitreal injection in the usual manner but only pressure with the hub of the syringe 
without the needle was applied 3.5 mm from the limbus under sterile conditions. PPV was scheduled 
3-5 days after the sham intravitreal injection. 
Study Arm:  
 An intravitreal injection of 1.25 mg/ 0.1 ml was scheduled and performed (3 to 5 days) before 
surgery. 
 
Anti-VEGF Injection Technique  
 The patients receiving IVB (or sham) were explained the off-label use of the drug, the 
potential risks of thromboembolic events, endophthalmitis and uveitis. Written informed consent was 
obtained from all patients before the IVB injection as well as prior to small gauge PPV.  
 A sterile lid speculum was used to separate the lids after topical anesthesia (proparacaine 
hydrochloride 4 %). A 5% povidone iodine solution is used to disinfect the entire conjunctival 
surface. 1.25 mg / 0.05 mL of bevacizumab was injected using a 30-gauge needle inserted through the 
inferotemporal pars plana 3.5 mm from the limbus. At baseline and at each follow-up visit, masked 
personnel measured best-corrected visual acuity (BCVA) using Early Treatment Diabetic Retinopathy 
Study (ETDRS) charts. 
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PPV Surgical Technique 
 Under local anesthesia and intravenous sedation or general anesthesia, the eye was prepped 
with a 5% povidone iodine solution and draped in the usual fashion. Standard three port 23-, 25- or 
27-small gauge PPV was performed in the usual fashion. Intraoperative maneuvers to deal with 
fibrovascular tissue dissection and retinal re-attachment was be left to each surgeon’s individual 
preference. Intraocular tamponade and the need for laser photocoagulation was also left to each 
surgeon’s discretion. During surgery intraoperative bleeding degree was registered as follows; grade 
0: None, grade 1: Minor bleeding stopping spontaneously or with transient bottle/pressure elevation, 
and grade 2: Moderate to severe bleeding requiring endodiathermy or with formation of broad sheets 
of clots. 20 Additionally, the total surgical time was also registered. 
 
Examination Schedule  
 
 Participants were examined at day 1, week 2, month 1, month 3, month 6, and moth 12. At 
each of these visits, each patient underwent BCVA measurement with ETDRS charts and ophthalmic 
examination, including slit-lamp biomicroscopy and applanation tonometry. Mean change in BCVA 
at 12 months were registered. Baseline central retinal thickness (CRT) were measured by optical 
coherence tomography (OCT) and fluorescein angiography (FA) were registered before surgery. 
Dilated color fundus images of the posterior pole, optic nerve and macula description was registered 
each visit. Ultrasound in the presence of vitreous hemorrhage was also performed to certify the 
presence of TRD if needed. 
 The following variables were used for primary outcome comparisons: Intraoperative 
bleeding, total surgical time, early (<1 month) post-operative vitreous hemorrhage (VH), and mean 
change in BCVA at 12 months. Secondary outcome comparisons: Number of endodiathermy 
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applications, intraoperative retinal breaks, change in central macular thickness, proportion of eyes 
gaining at least 2 lines (10 letters) of ETDRS BCVA were considered as secondary outcomes. 
 
Statistical analysis  
 Data were collected in an Excel 2011 spreadsheet (Microsoft, Redmond, Washington, USA). 
Statistical analysis was performed using MedCalc Software for Windows V.8.2.0.3 (MedCalc, 
Mariakerke, Belgium). To determine whether there is a significant difference in proportion of 
postoperative vitreous hemorrhage occurred between cases (6%) with injection of intravitreal 
bevacizumab and controls (19%) without injection as per Ahmadieh et al. 21 to achieve 80% power 
and 95% two-sided confidence level with equal ratio of controls to cases, at least 102 cases and 102 
controls were needed to study. The initial total sample required with 10% drop out has been 224 (112 
cases and 112 controls). ETDRS BCVA was converted to the logarithm of the minimum angle of 
resolution (logMAR) for statistical analysis. An increase or decrease in BCVA was defined as a 
change of ≥ 2 lines (10 letters) of ETDRS vision prior to logMAR conversion. The paired samples t 
test was performed to compare the CRT and BCVA with baseline values. Correlation was considered 







Stellenbosch University  https://scholar.sun.ac.za





Two hundred and thirty-four (234 eyes) patients were initially enrolled in this study. 
However, 20 participants (20 eyes) were not eligible for results because they did not meet the criteria 
for the study; 15 of them were lost before undergoing randomization, 3 patients requested to withdraw 
and 2 were withdrawn by the site. Two hundred and fourteen (214 eyes) patients were included and 
randomized with a 1:1 ratio to PPV plus sham injection (control group; 112) eyes or PPV plus IVB 
(Study group; 102 eyes). In the study group, 7 (6.8%) eyes underwent to 27-gauge PPV, 15 (14.7%) 
25-gauge PPV, and 80 (78.4%) 23-gauge PPV. In the control group, 6 (5.3%) eyes underwent 27-
gauge PPV, 12 (10.7%) 25-gauge PPV, and 94 (83.9%) eyes underwent to 23-gauge PPV. The gender 
distribution, age, and major systemic data between the study group and control group were not 
significantly different (Table 1). In the study group 96/102 eyes (94.12%) were reattached (figures 1 
to 4).  In the control group 98/112 eyes (87.5%) were reattached at the end of follow up with one 
procedure. This difference was not statistically significant (p=0.097). 
Intraoperative Complications  
 In the study group 69 (67.6%) eyes had some degree of intraoperative bleeding, while 100 
(89.2%) eyes had some intraoperative bleeding in the control group (p=0.0002). Of these eyes, 32 
(31.3%) eyes had grade 2 intraoperative bleeding in the study group, while 58 (51.7 %) eyes had that 
level in the control group (p=0.001). We observed a mean of 1.5 ± 2.2 (range from 0 to 7) 
endodiathermy applications in the IVB group, and 3.6 ± 3.1 (range from 0 to 10) in those eyes 
involved in the sham group. This difference was not statistically significant (p=0.062). However, the 
use of endodiathermy applications was necessary in 28 (27.4 %) eyes in the study group, compared 
with 75 (66.9 %) eyes involved in the control group, and this was statistically significant (p=0.0001).  
 At least one iatrogenic retinal break either along the TRD, or elsewhere was intraoperatively 
noted in 35 eyes (34.3%) in the study group, and 66 eyes (58.9 %) in the control group (p=0.001). 
Mean operating time was 71.3 ± 32.1 minutes (range 35 to 150) in the study group and 83.6 ± 38.7 
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minutes (range 35 to 185) in the control group. The study group had a shorter mean surgical time than 
the control group, but we did not observe a statistically significant difference (p=0.061). On the other 
hand, 24 (23.5%) eyes required silicone oil tamponade at the end of surgery in the study group, while 
48 (42.8%) eyes required silicone oil tamponade in the control group (p=0.003).  
 
Visual Acuity (VA) Outcomes  
 The BCVA mean was comparable in both groups at baseline (Table 1). In the study group, the 
mean baseline BCVA improved from 20/250, logMAR 1.1 ± 0.5 to 20/80, logMAR 0.6 ± 0.48 at the 
end of follow up (p<0.0001), whereas in the control group, baseline BCVA improved from 20/250, 
logMAR 1.1 ± 1.4 to 20/100, logMAR 0.7 ± 0.31 (p=0.034). These results represent a mean gain of 4 
lines of vision in the first month of follow up, and 5 lines of vision at the end of follow up in the study 
group. In the sham group a mean gain of 2 lines of vision was observed in the first postoperative 
month, and a mean of 4 lines of vision was observed at the end of follow up (Figure 5). Both groups 
significantly improved the mean of BCVA at the end of follow up. 
Each group was divided into two sub-groups according to the presence or not of VH before 
surgery to calculate in these sub groups of patients demonstrated variability in terms of both BCVA 
and central retinal thickness during the follow up. In the study group 55 (53%) eyes had some 
degree of vitreous hemorrhage before surgery with a mean of preoperative BCVA of 20/400, 
logMAR 1.3 ± 0.4 while in the control group 63 (56%) eyes presented VH at baseline with a mean 
of baseline BCVA of 20/500, logMAR 1.4 ±  2.1. Both groups presented a statistically significant 
visual improvement at the end of the follow-up, demonstrating a mean of BCVA 20/60, logMAR 
0.5 ±  2.1 (p< 0.0001) and 20/80, logMAR 0.6 ±  2.1 (p=0.032), respectively. 
 On the other hand, the study group included 47 patients (eyes) with TRD without VH before 
surgery. This subgroup had a mean of BCVA 20/100, logMAR 0.7  ± 1.9 at presentation, and the 
mean of BCVA improved to 20/60 logMAR 0.5  ±  2.9 (p=0.002) at 12 months of follow up. On the 
other hand, 49 patients (eyes) included in the control group presented TRD without VH at 
presentation registered a mean of BCVA 20/125, logMAR 0. 8 ± 1.3 improving to BCVA 20/60, 
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logMAR 0.6 ± 1.5 at the end of follow up (p=0.004). In both groups, there was a significant 
postoperative gain in vision but there was no significant difference between groups during the follow-
up visits. 
In the study group, the 12-month BCVA analysis by subgroups demonstrated that 75 (73%) 
eyes improved 2 or more ETDRS lines of BCVA, and that BCVA remained stable in 16 (15.6%) 
eyes at 12 months. In addition, 11 (10.7%) eyes decreased 2 or more ETDRS lines of BCVA at the 
end of follow-up. In the control group 76 (67.8%) eyes improved 2 or more ETDRS lines of BCVA, 
and BCVA remained stable in 20 (17.8%) eyes, and 16 (14.2%) eyes decreased 2 or more ETDRS 
lines of BCVA at the end of follow-up (Table 2). 
 
 
Postoperative Retinal Macular Thickness  
  
  Optical coherence tomography (OCT) results were available for all patients who had no 
dense vitreous hemorrhage at presentation. OCT results were available for 47 (46.1%) eyes in the 
study group, and 49 (43.7%) eyes in the control group. In the study group, mean CRT decreased from 
382.2 µm ± 116.2 µm to 334.5 µm ± 109.2 µm (p= 0.061) at the end of follow up, while in the 
control group the mean of CRT decreased from 409.4 ± 160.4 to 345.5 µm ±119.2 (p=0.089) at 12 
months of follow up. None of the groups had a significant difference between baseline mean CRT 
OCT and the mean final CRT OCT at the end of follow up. 
Postoperative Complications  
 Postoperatively, vitreous hemorrhage was observed in 29 (28.4 %) eyes in the study group, 
and 48 (42.8%) eyes in the control group had some grade of vitreous hemorrhage within the first 
month after surgery (p=0.028).  
 We registered 6 (5.8%) cases of tractional re-detachment in the study group. Four (66.6%) of 
these patients had been treated with intraocular gas (SF6 20%) as tamponade and 2 (33.3) eyes were 
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under silicone oil. In the control group we observed 14 (12.5%) cases of re-detachment of which 9 
(64.3%) cases had an intraocular gas (SF6 20%) and 5 (35.7%) eyes had silicone oil as tamponade. 
All cases required a second vitrectomy within first year of follow up. Number of re-interventions due 
to recurrence of tractional retinal detachment was lower in the IVB group, but we did not demonstrate 
a statistically significant difference between both groups (p=0.097). On the other hand, we observed 8 
(7.8%) cases of dense recurrent VH in the study group, of which 3 (37.5%) cases required a second 
vitrectomy. In the control group 26 (23.2%) cases presented with dense recurrent VH within first year 
of follow up, of which 14 (58.3%) patients required a second vitrectomy during the follow up period. 
Cases of dense recurrent VH were more frequent in the control group at one year of follow up, and the 
difference was statistically significant between both groups (p=0.002). Neovascular glaucoma 
occurred in 3 (2.9%) eyes in the study group and 7 (6.3 %) eyes in the control group (p=0.252) at the 
end of follow up. The only adverse event related to IVB injection was that there were 3/102 eyes 
(2.94%) of TRD progression 3 days after the injection. However, BCVA improved after PPV in those 
cases. This complication was not seen in the control group. 
 We found no statistical differences in our surgical results and complications among the cases 
operated on with 23-,25-, or 27-gauge PPV.  
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 This randomized study demonstrates that preoperative intravitreal injection of bevacizumab 
might be helpful to facilitate vitrectomy in cases of TRD secondary to advanced PDR.  Intravitreal 
bevacizumab as a preoperative adjunct in cases of severe PDR seems to be beneficial and to aid in 
rapid clearing of vitreous hemorrhage and reducing the surgical time by reducing intraoperative 
bleeding. 22 Tractional retinal detachment in PDR is challenging because of thin ischemic retina and 
extensive neovascularization. Intravitreal anti-angiogenic therapy is being widely used for 
neovascular complications of PDR. 23-26, 13 Surgical outcomes may limit visual prognosis of the 
disease and it could be compromised by intra and postoperative complications.  Perioperative vitreous 
hemorrhage resulting in formation of adherent fibrinous clots may necessitate frequent application of 
diathermy and exchange of instruments. Severe intraoperative hemorrhages represent the main 
obstacle in the surgical removal of pre-retinal tissue, and it may interfere with completion of the 
surgical procedure in nearly 4 % of cases.3 Conversely, a bloodless field allows for better visibility 
facilitating completion of surgery.  
In our study we observed that 32 (31.3%) eyes had grade 2 intraoperative bleeding in the 
study group, while 58 (51.7 %) eyes had that level in the control group (p=0.001).  This reduced risk 
of intraoperative bleeding may also decrease the use of endodiathermy applications that represent less 
trauma in a previously damaged and ischemic retina. In our study, the use of endodiathermy 
applications was necessary in 28 (27.4 %) eyes treated with pre-operative IVB, compared with 75 
(66.9 %) eyes involved in the control group (p=0.0001). In addition, the decrease of intraoperative 
bleeding may also facilitate removal of the fibrovascular membranes with less damage to subjacent 
retina. We also observed that the eyes in the study group had a lower incidence of intraoperatory 
iatrogenic retinal breaks than those eyes in the control group (sham). Previously, a lower incidence of 
intraoperative retinal tears had been observed in the IVB-PPV group than the conventional PPV 
group, possibly due to minimal intraoperative bleeding and improved retinal visualization during 
surgery. 27-30 Gupta et al 27 evaluated the effect of a single preoperative injection of IVB on visual 
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outcome in patients undergoing PPV for PDR. Intraoperatively, they described an incidence of 
iatrogenic retinal breaks comparable in the two groups [20 (21.3 %) vs. 15 (17.2 %) in groups A and 
B, respectively. However, the authors describe only a presence of TRD in 42 eyes in IVB group (44.7 
%) and 31 eyes (35.6 %) in control group. Recently Dong et al 31 investigated intravitreal injection of 
ranibizumab (IVR) on the surgical outcome for diabetic patients who had tractional retinal 
detachment but in cases that did not receive any preoperative retinal photocoagulation. They 
described results of ninety-seven patients (97 eyes) who had diabetic retinopathy with TRD enrolled 
to receive 23-gauge PPV. They were assigned to an experimental group (preoperative IVR plus PPV, 
n = 47 eyes) and a control group (VPP, n = 50 eyes). They describe that iatrogenic breaks were noted in 
5 eyes (11%) in the experimental group and 17 eyes (34%) in the control group; the difference was 
significant (p=0.006). In concordance with these results, we report at least one iatrogenic retinal break 
either along the TRD, or elsewhere intraoperatively in 35 eyes (34.3%) in the study group,  and 66 
eyes (58.9 %) in the control group (p=0.001). In addition, we observed that more than 70% of the 
retinal tears described in the control group were along the fibrovascular traction and that they 
probably occurred after fibrovascular membrane peeling. Therefore, iatrogenic retinal breaks may be 
strongly linked to the dissection maneuver of tractional fibrovascular tissue on the retina. This lower 
incidence of iatrogenic retinal breaks in study (IVB) group is an important finding that could be 
explained due to the significant regression of the vascular component after preoperative IVB, which 
could change the pathophysiology of the fibrovascular complex making it more prone to readily 
separate from the retina, and make it easier and faster to be dissected. These two findings, both the 
lower rate of intraoperative bleeding and the lower number of retinal breaks in the study group, 
suggest that preoperative IVB could make TRD surgery more efficacious and safe. This is 
concordance with the finding by Yeoh et al 28 that found that IVB was particularly useful in diabetic 
eyes with traction retinal detachments of short duration in which there was still active 
neovascularization. In our study, 72 (72.5%) eyes in the IVB group had some degree of vitreous 
hemorrhage before surgery which means that neovascularization was still active at the moment of 
IVB application. El-Sabagh et al 12 described a profibrotic switch in diabetic fibrovascular 
proliferation after IVB, and their results suggest that the vascular component of proliferation is 
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markedly reduced post-IVB. These findings are in concordance with our results, which suggest that 
PPV is safer and more complete when IVB is administered before surgery. Similar to our results, IVB 
has been previously used as a preoperative adjunct for TRD repair in severe PDR by Chen 11 and was 
also reported to make surgery more successful with significant regression of neovascularization in the 
fibrovascular proliferative membranes, consequently minimizing intraoperative bleeding during 
segmentation and delamination of membranes. On the other hand, we also observed that postoperative 
intravitreal hemorrhage was less markedly in the IVB group. 
In our study, there were 3/102 eyes (2.94%) that had a progression of TRD 3 days after IVB 
injection. However, BCVA improved after PPV. This complication was not seen in the control group. 
This rate is in concordance with previous reports.17, 18 We have previously reported that the majority 
of cases with progression or development of TRD after IVB occur 5 days or more after the injection. 
The low incidence in our study, and good visual outcomes confirm that IVB is safe and effective even 
in eyes that develop contraction and progression of TRD. 
In this study, we found that 75 (73%) eyes improved 2 or more ETDRS lines of BCVA in the 
study group, and 76 (67.8%) eyes improved 2 or more ETDRS lines of BCVA in the control group at 
the end of follow up. No significant difference we found between both groups. Our results show a 
significant improvement in BCVA in both groups. This, as others have suggested,
11 is most likely due 
to improved vitrectomy techniques. Similar improvement in visual acuity with the use of preoperative 
IVB has been reported previously in a number of series of patients after surgery. 13, 21, 28, 32 
Compared with the control group, patients who received preoperative IVB had lower use of 
silicone oil as internal tamponade suggesting that the surgical procedure was less complex. We 
reported that in the study group 24 (23.5%) eyes required silicone oil tamponade at the end of surgery 
while 48 (42.8%) eyes required silicone oil tamponade in the control group (0.003). Similar outcomes 
were showed by Dong et al who describe that silicone oil was used as internal tamponade agent in 22 
eyes (47%) of IVR group and 37 eyes (74%) of control group (p=0.006). Our results also 
demonstrated that the incidence of neovascular glaucoma following surgery was not significantly 
different between the study group and the control group.  
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 The strength of our study is that it is a prospective randomized clinical trial, however, its 
multicentric nature is a limitation as multiple surgeons from several centers participated with a non-
standardized surgical technique including all available gauges for minimally invasive vitrectomy. 
However, the number of patients is significant for a surgical trial, and shows the benefits of 
intravitreal bevacizumab to facilitate PPV in TRD in PDR. Another limitation of our study is that we 
changed our original proposed randomization scheme from 3:1 to 1:1. The protocol was amended to 
reflect this change. Originally, we had calculated that 374 patients (187 per group) would be needed 
to determine whether there is a significant difference in proportion of postoperative vitreous 
hemorrhage occurred between cases (6%) with injection of intravitreal bevacizumab and controls 
(19%) without injection as per Gupta et al. 27 to achieve 80% power and 95% two-sided confidence 
level. We realized that with the stringent inclusion and exclusion criteria it would be very difficult to 
achieve those numbers. Therefore, we recalculated our sample size to determine whether there is a 
significant difference in proportion of postoperative vitreous hemorrhage occurred between cases 
(6%) with injection of intravitreal bevacizumab and controls (19%) without injection as per 
Ahmadieh et al. 21 to achieve 80% power and 95% two-sided confidence level with equal ratio of 
controls to cases, we determined that at least 102 cases and 102 controls were needed to study. The 
initial total sample required with 10% drop out calculated was 224 (112 cases and 112 controls). We 
achived those numbers. 
 In summary, we demonstrated that pre-operative intravitreal bevacizumab as adjuvant to 
small-gauge pars plana vitrectomy may be helpful and beneficial for patients with TRD secondary to 
severe PDR. Pre-operative IVB seems to reduce intraoperative bleeding, improving surgical visual 
field visualization, and reducing intraoperative and postoperative complications including iatrogenic 
retinal tears and postoperative bleeding. However, retinal reattachment rates were also similar 
between both groups. In addition, neither the postoperative BCVA nor the proportion of eyes with 
BCVA improvement showed significant difference between groups at the end of follow up, which 
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Figure 1. (A) Color photograph of proliferative diabetic retinopathy (PDR) complicated by tractional 
retinal detachment (TRD) temporal to the macular area in the right eye in a 43-year-old type II 
diabetic man. (B) At 12 months after pars plana vitrectomy with preoperative bevacizumab, visual 
acuity (VA) had improved from 20/50 to 20/25. 
 
 
Figure 2. (A) A 39-year-old man with type II diabetes showing extensive tractional retinal detachment 
and fibrovascular proliferation in the left eye and visual acuity (VA) of 20/400. (B) 3 days after 
preoperative intravitreal bevacizumab and 1 day before surgery. Note significant vascular 
reabsorption on fibrovascular proliferations. (C) 12 months of follow up after 25-gauge pars plana 
vitrectomy with intraocular gas tamponade. His retina remained attached, and his postoperative VA 
was 20/70.     
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Figure 3. (A) A 54-year-old man with diagnosis of type II diabetes. His visual acuity (VA) was 
20/800. Note extensive neovascularization and fibrovascular traction along the vascular arcade with 
foveal involvement. (B) He received intravitreal bevacizumab 4 days before surgery. (C) One year 
after 25-gauge pars plana vitrectomy (PPV) and C3F8 14% gas as endo-tamponade, his retina 
remained attached, and his VA improved to 20/100.  
 
 
Figure 4. (A) A 27-year-old male with type II diabetes showing vitreous hemorrhage and tractional 
retinal detachment in the right eye and visual acuity of 20/400. (B) He received intravitreal 
bevacizumab 5 days before vitrectomy. (B) At 5 months of follow-up after surgery, her retina 
remained attached, and his visual acuity (VA) improved to 20/80.  
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Figure 5. A mean gain of 4 lines of vision in the first month of follow up, and 5 lines of vision at the 
end of follow up in the study group. In the sham group, a mean gain of 2 lines of vision was observed 
in the first postoperative month, and a mean of 4 lines of vision was observed at the end of follow up. 
In the study group, the mean baseline BCVA improved from 20/250, logMAR 1.1 ± 0.5 to 20/80, 
logMAR 0.6 ± 0.48 at the end of follow up (p<0.0001), whereas in the control group, baseline BCVA 
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Table 1. Patient’s Baseline Characteristics*     
     Study Group (n=102)       Control Group (n=112)   
Age (mean ± SD), years    59.5 ± 11   61.3 ± 10 
Gender (male/female)               62 % / 38 %   54 % / 46% 
Hypertension (%)      81%    94% 
Systemic glycemic control, n (%)  
 Insulin       9 (9%)    21 (19%) 
 Oral hypoglycemic   12 (12%)   17 (15%) 
 Combined therapy   81 (79%)   74 (66%) 
HbA1c at time of surgery     8.5  ±  2.1     8.9  ± 2.5  
Previous history of PRP     79 (77.4%)     92 (82.1%)  
VH at presentation (n/%)   
 Dense     55 (53%)   63 (56.2%)  
 Moderate      4 (3.9%)   5 (4.4%) 
 Mild      15 (14.7%)   5 (4.4%) 
 No     28 (27.4%)   39 (34.8%) 
 
Pre-operative BCVA (logMAR) 
 
 TRD with DVH     (n=55) 1.3  ±  0.4      (n=63) 1.4 ±  2.1  
 TRD without DVH    (n=47) 0.7  ±  2.1        (n=49) 0. 8 ± 1.3 
 Total TRD cases    1.1 ± 0.5                                 1.1 ± 0.3 
Mean OCT baseline (um)  
 TRD without DVH (n/%)   47 (46.1%)   49 (43.7%) 
 CRT (microns)             382.2 ± 116.2   409.4 ± 160.4 
Lens status  
  phakic     73 (71.6%)   85 (76%) 
 pseudophakic    29 (28.4%)   27 (24%) 
Stellenbosch University  https://scholar.sun.ac.za




* Values represent number and percentages, IVB= Intravitreal bevacizumab; logMAR = logarithm of the 
minimal angle of resolution; HbA1c= Glycosylated hemoglobin; n, number of patients; PRP= Pan-retinal 
photocoagulation; VH=vitreous hemorrhage; TRD=tractional retinal detachment; DVH= dense vitreous 
hemorrhage; OCT= optical coherence tomography; CRT=central retinal thickness. 
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Table 2. Variation of BCVA at 12 months of Pre-operative IVB versus Sham for TRD secondary 
to PDR (214 eyes)* 
 
 
                  Study Group  Control Group 
BCVA (logMAR) Results     (n / %)     (n / %)  p 
 
Improved 2 or more lines      75 (73%)  76 (67.8)              0.555     
 
Remained Stable                 16 (15.6%)  20 (17.8%)         0.672 
 
Decreased 2 or more lines      11 (10.7%)  16 (14.2%)         0.441 
 
 Total                    102 (100 %)              112 (100%) 
  
*Values represent number and percentages; IVB = Intravitreal bevacizumab; logMAR = logarithm of 
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The following investigators belong to the Pan-American Collaborative Retina Study Group 
(PACORES): 
 
The Pan-American Collaborative Retina Study Group (PACORES)*- 
J. F. Arevalo (PI), T. Y. A. Liu, The Wilmer Eye Institute, Johns Hopkins University, Baltimore, 
Maryland, USA; J. F. Arevalo (PI), Stellenbosch University, Stellenbosch, South Africa; L. Wu (PI), 
Asociados de Macula, Vitreo y Retina de Costa Rica, San Jose, Costa Rica; A. F. Lasave (PI), Clinica 
Oftalmologica Centro Caracas and the Arevalo-Coutinho Foundation for Research in Ophthalmology, 
Caracas, Venezuela; M. Farah (PI), M. Maia, F. M. Penha, E. B. Rodrigues, Universidade Federal de 
São Paulo - Departamento de Oftalmologia - Instituto da Visão - Sao Paulo, Brazil; V. Morales-
Canton (PI), J. Fromow-Guerra, J.L. Guerrero-Naranjo, J. Dalma-Weiszhausz, R Velez-Montoya, H. 
Quiroz-Mercado, Asociación para Evitar la Ceguera en México, Mexico City, Mexico; F. J. 
Rodriguez (PI), F. E. Gomez, A. C. Brieke, A. Goveto, Fundacion Oftalmologica Nacional, 
Universidad del Rosario, Bogota, Colombia; M.H. Berrocal (PI), V. Cruz-Villegas, University of 
Puerto Rico, San Juan, Puerto Rico; F. Graue-Wiechers (PI), D. Lozano-Rechy, E. Fulda-Graue, 
Fundacion Conde Valenciana, Mexico City, Mexico; J.A. Roca (PI), A. Hernández, Clínica Ricardo 
Palma, Lima, Peru; M. J. Saravia (PI), A. Schlaen, J. Rojas, M. Ingolotti, Hospital Universitario 
Austral, Buenos Aires, Argentina; M. Avila (PI), L. Carla, Universidade Federal de Goiás- 
Departamento de Oftalmologia - Goiânia, Brazil; J. Cardillo (PI), R. Jorge, Hospital de Olhos de 
Araraquara, and the Universidade de Sao Paulo, Sao Paulo, Brazil; C. Carpentier (PI), J. Verdaguer 
T., J.I. Verdaguer D., G. Sepúlveda, Fundacion Oftalmologica Los Andes, Santiago de Chile, Chile; 
A. Alezzandrini (PI), B. Garcia, M. Zas, OFTALMOS, Catedra de Oftalmologia, Universidad de 
Buenos Aires, Buenos Aires, Argentina; R. Gallego-Pinazo (PI), M. Diaz-Llopis, R.  Dolz-Marco, 
Hospital La Fe, Universidad de Valencia, Spain; M. Figueroa (PI), I. Contreras, D. Ruiz-Casas, 
Stellenbosch University  https://scholar.sun.ac.za
                                       
 
 
Hospital Universitario Ramón y Cajal, Departamento de Retina, and VISSUM Madrid, Madrid, 
Spain. 
 
*PI = Principal Investigator. 
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Chapter 13: Conclusions 
 
 
The advent of intravitreal anti-VEGF medications has revolutionized the treatment of diabetic 
eye diseases. Whereas ranibizumab and aflibercept are specifically formulated for intraocular uses, 
off-label use of bevacizumab remains popular and widespread in the world, especially in low-income 
and middle-income countries, given its lower cost, perceived effectiveness, and comparable safety 
profile.23-35 Based on our experience, we recognize intravitreal bevacizumab to be an important tool in 
our armamentarium for treating the complications of diabetic retinopathy. For center-involving DME, 
our real-world data suggests that there is a roughly 70% chance of stabilized or improved vision with 
intravitreal bevacizumab treatments over a time course of 5 years. Nevertheless, many patients so 
benefit from anti-VEGF injections long-term if a more frequent regime of injections is given specially 
during the first 2 years. It is possible that new molecules targeting different or combined cytokines 
and growth factors will lead to less frequent injections and the use of reservoirs for these agents that 
can be implanted surgical will reduce the burden of injections making the process and access easier 
although cost is always going to be an issue. 
For PDR, intravitreal bevacizumab is a good adjuvant therapy for patients who have already 
received prior PRP treatment, and unless frequent follow-up visits and treatments can be ensured, 
treatment-naive patients will likely have better control of retinal neovascularization with prompt PRP 
in conjunction with initiation of intravitreal treatments. I think we are going towards a change in 
treatment paradigm with combination therapy with a less aggressive PRP and anti-VEGF therapy. 
Lastly, preoperative intravitreal bevacizumab before vitrectomy is safe, with a low incidence (3.5%) 
of TRD development or progression. This risk can further be reduced by performing surgery within 4 
days of injection and by avoiding the usage of a higher dose (2.5 mg) of bevacizumab. In terms of 
future research directions, our group recently carried out a prospective study on the utility of 
preoperative intravitreal bevacizumab before diabetic TRD repair, and the data demonstrates that IVB 
as an adjuvant to vitrectomy can decrease surgical bleeding, facilitating surgical maneuvers, and 
techniques. In addition, postoperative complications such as iatrogenic retinal breaks and 
postoperative bleeding are reduced.  
 
Originality of the proposed research 
 
 At this point in time, many studies have looked at IVB for complications of DR. However, 
when we started our research (September 2005) we were one of the first groups to use it and 
demonstrate its efficacy in DME and PDR. Furthermore, our group was the first to describe tractional 
retinal detachment following IVB in patients with severe PDR. In addition, our collaborative work has 
changed the way research is performed in Latin-America.37 
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Contribution of the proposed research to existing knowledge 
Our central research question and purpose of our research is to determine if intravitreal bevacizumab 
as anti-vascular endothelial growth factor is helpful in the management of complications of diabetic 
retinopathy. We have proven that in several steps described in our chapters that have been able to 
respond to our several hypotheses: 
Hypothesis 1: Intravitreal bevacizumab (IVB) may have a beneficial anatomic (Optical Coherence 
Tomography [OCT]), and functional (visual acuity [VA]) effect on eyes with diffuse diabetic 
macular edema at 24 months of follow up. In addition, the lower dose (1.25 mg) may be as 
effective or more than the higher dose (2.5 mg) of IVB. 
We progressively reported over the years our experienced as we followed patients with DME treated 
with IVB at 6 months, 12 months, and 24 months of follow up. In addition, 5 year follow up data was 
added later on. We found that primary IVB at doses of 1.25 to 2.5 mg seem to provide stability or 
improvement in BCVA, OCT, and FA in DDME at 24 months. The results show no evident 
difference between IVB at doses of 1.25 or 2.5 mg. However, the early visual gains due to IVB were 
not maintained 5 years after treatment. Undertreatment seems to be the main reason for the loss of 
visual acuity over the years as patients did have at the end of follow up reduction in CMT measured 
with OCT, nevertheless between injections the increase in CMT chronically may lead to loss of vision 
gains at the end of follow up in many patients.  
Hypothesis 2: IVB combined with grid laser photocoagulation may have a beneficial anatomic 
(OCT), and functional (VA) effect on eyes with diffuse diabetic macular edema at 24 months of 
follow up as compared to monotherapy. In addition, IVB combined with grid laser photocoagulation 
(GLP) may decrease the number of injections if IVB necessary at 24 months. 
Our study provides evidence to support the use of primary IVB with or without GLP as treatment of 
diffuse diabetic macular edema. Primary IVB without GLP seems to be superior to GLP alone to 
provide stability or improvement in best-corrected visual acuity in patients with diffuse diabetic 
macular edema at 24 months. The best evidence continues to be for monotherapy, laser could only 
worsen visual acuity and does not reduce the number of injections. 
Hypothesis 3: IVB may decrease retinal neovascularization in patients with PDR at 6 months of 
follow up. However, the effect may decrease at 24 months of follow up due to tachyphylaxis, and 
pan-retinal photocoagulation and/or vitrectomy will be necessary.  
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We showed first that intravitreal bevacizumab resulted in marked regression of RN in patients with 
PDR and previous PRP, and rapid resolution of vitreous hemorrhage in three naive eyes. Six-months 
results of intravitreal bevacizumab at doses of 1.25 or 2.5 mg in patients with PDR did not reveal any 
safety concerns. Later, we published that IVB resulted in marked regression of retinal neo- 
vascularization in patients with PDR and previous pan-retinal photocoagulation at 2 years. Intravitreal 
bevacizumab in naive eyes resulted in control or regression of 42.1% of eyes without adjunctive laser 
or vitrectomy during 24 months of follow-up. Meaning that a large number of patients (almost 58%) 
needed PRP or vitrectomy. There were no safety concerns during the 2 years of follow-up of IVB for 
PDR. Again, I think we are going towards a change in treatment paradigm with combination therapy 
with a less aggressive PRP and anti-VEGF therapy. 
Hypothesis 4: Preoperative IVB may be beneficial for membrane dissection in diabetic tractional 
retinal detachment with minimally invasive vitreoretinal surgery (23-gauge transconjunctival 
sutureless vitrectomy [TSV]). In addition, post-operative rebleeding may be decreased. 
This study demonstrated the usefulness of using preoperative intravitreal bevacizumab during small-
gauge vitreoretinal surgery in eyes with TRD in PDR. This is was a prospective non-comparative 
study and patients had anatomic success in 100% (114/114) of eyes. Significant visual improvement 
[≥ 2 Early Treatment Diabetic Retinopathy Study (ETDRS) lines] was obtained in 69.2% (79/114). 
Complications decreased compared to previous studies. This study lays the ground for the need for a 
prospective randomized clinical trial comparing IVB before vitrectomy for TRD in PDR vs placebo.  
Hypothesis 5: Tractional retinal detachment (TRD) may occur following IVB as an adjuvant to 
vitrectomy for the management of severe PDR.  
We reported for the first time ever that TRD may occur or progress shortly following administration 
of intravitreal bevacizumab in patients with severe PDR (5.2%). The reduction of VEGF after IVB 
may lead to a relative increase in cytokines that can cause contraction and this is known as a fibrotic 
switch. Surgery should be performed before this contraction occurs. 
Hypothesis 6: Risk factors for the progression or development of TRD following IVB as an adjuvant 
to vitrectomy in severe PDR may include age, time from diabetes mellitus (DM) diagnosis, glycemic 
control, cholesterol levels, triglycerides levels, hemoglobin A1c (HbA1C), dose of bevacizumab, and 
time from injection to vitrectomy.  
TRD may occur or progress shortly following administration of intravitreal bevacizumab in patients 
with severe PDR (3.2%) in a larger number of patients. Based on our data, we now believe that 
extreme care must be taken in using a dose of 2.5 mg or more of bevacizumab in patients with PDR. 
In addition, to have more than 15 years with a diagnosis of diabetes can increase the risk of TRD and 
that careful follow-up evaluation following injection is recommended. The timing of surgery after the 
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injection is also important, as there are concerns that bevacizumab may cause progression of the TRD. 
It is important that surgery is performed once the anti-angiogenic effect of bevacizumab has fully 
developed, but before there is further fibrous proliferation; physicians must be prepared to perform 
the vitrectomy preferably before about 13 days after the application of bevacizumab and to perform a 
vitrectomy immediately on those patients in whom a TRD occurs. We recommend less than 5 days 
after injection as more than 80% of the retinal detachments developed after that period of time. 
Hypothesis 7 (prospective unpublished study): Intravitreal injection of 1.25 mg of bevacizumab as a 
pre-operative adjunct to PPV in eyes with TRD secondary to PDR will be safe and effective. IVB 
(compared to sham) will decrease intraoperative bleeding, total surgical time, post-operative vitreous 
hemorrhage, and visual acuity at 12 months. 
 
We demonstrated that pre-operative intravitreal bevacizumab as adjuvant to small-gauge pars plana 
vitrectomy may be helpful and beneficial for patients with TRD secondary to severe PDR. Pre-
operative IVB seems to reduce intraoperative bleeding, improving surgical visual field visualization, 
and reducing intraoperative and postoperative complications including iatrogenic retinal tears and 
postoperative bleeding. However, retinal reattachment rates were also similar between both groups. In 
addition, neither the postoperative BCVA nor the proportion of eyes with BCVA improvement 
showed significant difference between groups at the end of follow up, which means that preoperative 
IVB may not be a determinant factor for postoperative BCVA. 
 
 In summary, given the off-label nature of intravitreal bevacizumab, its effectiveness and 
safety have not been as thoroughly studied as other approved similar drugs. Our results have been 
important to determine that DME can be treated as effectively with monotherapy IVB rather than 
combined IVB plus grid/focal photocoagulation. However, undertreatment will lead in the long-term 
to loss of the visual acuity gains of the early years of follow up. In addition, we have been able to 
determine that IVB should be used as an adjuvant to PRP in patients with PDR, and that PRP and/or 
vitrectomy seem to be necessary to control PDR in the long-run in a large number of patients. 
Furthermore, we have determined that IVB can be used as an adjuvant to vitrectomy in patients with 
severe PDR and TRD, and that it decreases the chances of re-bleeding postoperatively as 
demonstrated in our unpublished data. In addition, we have been able to confirm that TRD do occur 
or progress after IVB in severe PDR, and determine the risk factors for this occurrence, and the best 
time to perform surgery after IVB. Finally, our prospective study shows that pre-operative intravitreal 
bevacizumab therapy as adjuvant to PPV may be helpful and beneficial for patients with TRD 
secondary to severe PDR. Pre-operative IVB seems to reduce intraoperative bleeding, improving 
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surgical visual field visualization, and reducing intraoperative and postoperative complications 
including iatrogenic retinal breaks and postoperative hemorrhage. 
 
Future Research Directions 
 
DME is multifactorial, anti-VEGF therapy does not seem to be the final answer to control DME over 
time. Other molecules need to be targeted and combined therapies will possibly be beneficial for long 
term control of the disease including regression of severity of DR. Combination therapy with new 
molecules and even steroids need to be studied. Reservoirs with anti-angiogenic agents inserted 
surgically and refilled in the clinic will reduce the number of injections. 
 
Data from our studies show that patients with PDR that had a previous PRP have a better response to 
anti-VEGF therapy monotherapy than treatment naïve eyes. This suggests that combined therapy may 
be more effective than PRP alone or anti-VEGF therapy alone. There are many advantages to both 
procedures and further studies should explore combination therapy. 
 
Anti-VEGF therapy as an adjuvant before vitrectomy for TRD in PDR as demonstrated in our 
prospective data, may be helpful and beneficial for patients with TRD secondary to severe PDR. Pre-
operative IVB seems to reduce intraoperative bleeding, improving surgical visual field visualization, 
and reducing intraoperative and postoperative complications including iatrogenic retinal breaks and 
postoperative hemorrhage. However, these complications do still occur and surgery is still a challenge 
to surgeons. There is a need for new pharmacologic agents to address the contraction component of 
the fibrovascular membranes.  
Finally, other advances in the future may include minimally invasive vitreoretinal surgery (MIVS) 
with 23-gauge transconjunctival suture-less vitrectomy techniques will be increasingly performed in 
diabetic patients due to the increased incidence of diabetes and its complications. In the coming years 
we will use techniques that are less invasive in vitreoretinal surgery such as 25+, and 27-gauge. We 
will have available other anti-VEGF antibodies capable of blocking all types of VEGF isoforms 
before and after surgery, reducing intraoperative bleeding, and postoperative inflammation. It is likely 
that the use of preoperative agents that promote the detachment of the posterior hyaloid and facilitate 
the removal of membranes will become routine. They will facilitate surgery of complex cases such as 
PDR cases. Optical coherence tomography equipment will be available in the operating room as 
routine and that will facilitate intraoperative tissue differentiation, and help us get better functional 
results. The advent of new lasers will permit us faster retinal photocoagulation, and will minimize 
collateral damage of the retina.  
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